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Aan de geïnteresseerde leek 
Een geneesmiddel neem je in, omdat je er een bepaalde werking van 
verwacht. Anders gezegd, een geneesmiddel wordt geacht wat met het 
(zieke) lichaam te doen, bi] voorkeur beter maken. Dit zal niemand 
onbekend in de oren klinken. Dat het lichaam ook wat met het geneesmid-
del doet, is mogelijk minder bekend. Toch is dit heel voor de hand lig-
gend. Iedereen die wel eens een 'aspirientje' heeft ingenomen, weet dat 
het even duurt voordat het effect merkbaar is en dat het na een paar 
uur weer is uitgewerkt. Hoe komt daf Het lichaam zorgt ervoor, dat 
een geneesmiddel met een bepaalde snelheid wordt opgenomen in het 
bloed, wordt vervoerd, o.a. naar de plaats van werking, en na enige 
tijd, al dan niet in zijn oorspronkelijke vorm, weer wordt uitgeschei 
den. Door het prikken van bloed en soms ook het verzamelen van urine en 
ander materiaal, bijvoorbeeld speeksel, probeert men erachter te komen 
wat er precies in de tijd met het geneesmiddel gebeurt. Dit nu is het 
werkterrein van de farmacokineticus. Veelal beslaat dit ook het ontwik 
kelen van de chemische analysemethodes die nodig zijn om de concentra-
tie aan geneesmiddel m het monstermatenaal te kunnen meten. 
De geneesmiddelen die in dit proefschrift worden beschreven, baclo-
fen en dantroleen, worden gebruikt door mensen van wie de spieren 
spastisch zijn ten gevolge van een aandoening in het centrale zenuw-
stelsel. Het zijn zogenaamde antispastische middelen. Baclofen is een 
eenvoudige chemische verbinding zoals is te zien in figuur 6 van het 
eerste hoofdstuk. Het is een afgeleide van gamma aminoboterzuur, een 
bepaald soort aminozuur dat normaal in het lichaam voorkomt. In verge-
lijking met de lichaamseigen voorraad aan aminozuren is de hoeveelheid 
baclofen die patiënten krijgen toegediend maar klein. Het trachten 
terug te vinden van dit kleine beetje baclofen in bloed-en urinemon-
sters heeft veel weg van het zoeken naar een speld in een hooiberg, 
of, erger, naar een onzichtbare speld in een onzichtbare hooiberg. 
Aminozuren, en daarmee ook de afgeleide verbinding baclofen, kunnen 
namelijk niet 'zomaar' worden gemeten. Ze moeten eerst op de een of 
andere manier zichtbaar worden gemaakt. In dit proefschrift is gekozen 
voor koppeling met het 'OPA'-reagens, waardoor verbindingen ontstaan 
die de eigenschap hebben fluorescentielicht uit te zenden. Zowel 
baclofen als de aminozuren kan men nu 'zien'. Om ze van elkaar te 
scheiden is een techniek gebruikt die kortweg HPLC wordt genoemd, 
oftewel hoge-drukvloeistofchromatografie (op zijn Engels afgekort). Bij 
deze techniek wordt in principe de onderkant van een stuk filtreerpa-
pier in een bodempje vloeistof gehangen. Zit er op het filtreerpapier 
een mengsel van stoffen, dan zal de vloeistof die door het filtreer-
papier wordt opgezogen het mengsel uit elkaar kunnen trekken, mits men 
de juiste vloeistof of vloeistoffen heeft gekozen. Door met hoge druk 
te werken gaat het allemaal wat sneller. 
Uit de proeven bij dieren en mensen kon worden geconcludeerd dat de 
nier een belangrijke rol speelt bij het verwijderen van baclofen uit 
het lichaam. Baclofen bleek echter toch een ingewikkelder verbinding 
dan aanvankelijk werd aangenomen. Baclofenmoleculen kunnen namelijk in 
twee vormen voorkomen, een linksdraaiende en een rechtsdraaiende vorm 
(vergelijkbaar met melkzuur in yoghurt). De linksdraaiende en rechts-
draaiende moleculen zijn eikaars spiegelbeeld en zijn weergegeven in 
figuur 1 van hoofdstuk 7. Slechts de linksdraaiende vorm is werkzaam 
als antispastisch middel, de andere vorm is overbodige ballast. Helaas 
is het zo dat alle patiënten worden behandeld met een mengsel van deze 
twee vormen, waarbij een tablet voor de helft uit de onwerkzame vorm 
bestaat. In het lichaam kan deze 50-50 verhouding echter veranderen, 
zoals de experimenten met proefdieren aannemelijk maken. Het is dus 
zaak om bij de chemische analyse beide vormen van elkaar te kunnen 
onderscheiden. Dit alles betekent dat in de eerder aangehaalde hooiberg 
in feite twee spelden, die eikaars spiegelbeeld zijn, zaten verborgen. 
Het gescheiden meten van 'spiegelbeeldmoleculen' is vrij gecompliceerd. 
In dit proefschrift wordt een methode beschreven die als basis kan 
dienen voor verder onderzoek. Het verschijnsel van 50% overbodige 
ballast is trouwens niet voorbehouden aan baclofen. Bij een kwart van 
alle geneesmiddelen zoals we die nu kennen, heeft men met deze proble-
matiek te maken. Pas de laatste jaren is hiervoor meer (publieke) 
belangstelling gekomen (De Volkskrant, zaterdag 27 januari 1990). 
Dantroleen is een heel ander soort antispastisch middel dan baclofen. 
Het valt in het lichaam uiteen in verschillende stoffen, metabolieten 
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genaamd. Een aantal van deze stoffen is te zien in figuur 5 van hoofd-
stuk l. Aangezien de hoeveelheid onveranderd dantroleen die door het 
lichaam wordt uitgescheiden minimaal is, kun je je bij farmacokinetisch 
onderzoek niet beperken tot het meten van alleen dantroleen, de zoge-
naamde moederverbinding. Dat is in feite farmacokinetiek op de 'vier-
kante millimeter' bedrijven. Gelukkig bracht ook hier de HPLC uitkomst. 
Uit de verschillende proeven kon worden geconcludeerd, dat de zogeheten 
hydroxy-metaboliet, waaraan ook enige antispastisehe activiteit wordt 
toegeschreven, in de urine (mens) of de gal (hond) terechtkomt. Het is 
echter zeer waarschijnlijk dat er nog meer metabolieten worden gevormd 
dan de eerder genoemde figuur suggereert. Wij vonden bijvoorbeeld een 
brokstuk van het in tweeen gesplitste molecuul in de urine. 
Om terug te keren naar het begin: als een geneesmiddel niet het 
effect heeft wat men ervan verwacht, dan kan dit komen doordat het 
onvoldoende door het lichaam wordt opgenomen. Als dat zo is, zal de 
bloedconcentratie van het geneesmiddel, de zogenaamde bloedspiegel, te 
laag zijn. De arts kan de dosis ophogen, waardoor het effect alsnog 
optreedt. De dosis aanpassen aan de hand van bloedspiegels gebeurt soms 
ook als het vaststellen van het gewenste effect niet zo eenvoudig is. 
Nu is het meten van spasticiteit erg moeilijk. Als het bepalen van 
bloedconcentraties van antispastische middelen inderdaad kan bijdragen 
aan het vinden van de juiste dosis, is in de praktijk al veel gewonnen. 
In dit proefschrift wordt beschreven hoe het effect van antispastisehe 
middelen bij een bepaalde groep van patiënten is te meten. Door tege-
lijkertijd bloedmonsters te nemen is in principe het verband tussen 
gewenst effect en bloedspiegel vast te stellen. 
Nijmegen, 15 januari 1991 Eveline W. Wuis 
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Preface 
The following clinical question underlies the work presented in this 
thesis: is it possible to guide dosage control of antispastic drugs in 
individual patients by measuring the drug plasma concentration7 When 
the clinical effect of a drug is hard to evaluate, this approach to 
chronic drug therapy has previously proved to be successful. A thesis 
describing this method of regulating drug therapy for epilepsy has been 
written by Schobben (1). Whereas the epilepsy study could build upon 
abundant pre-existing pharmacokinetic knowledge, therapeutic drug 
monitoring in spasticity appeared to be a terra incognita. 
The drugs most widely used for patients with spasticity are baclofen 
and dantrolene. For a meaningful interpretation of single-point plasma 
level determinations, which is usually one of the constraints of the 
clinical setting, knowledge of the pharmacokinetics of the drugs must 
be available. Although both baclofen and dantrolene have been in use 
since 1967, pharmacokinetic data are still scarce. The lack of 
sufficiently sensitive and specific analytical methods for 
pharmacokinetic purposes partially explains this. Moreover, the studies 
that are available have mainly focused on parent drug measurements in 
plasma, ignoring the information that can be obtained from metabolite 
and urine measurements. 
An important aspect of the present study was therefore to develop 
chemical analyses suitable for pharmacokinetic studies for the 
quantitative determination of these drugs and their metabolites in 
biological fluids. An investigation of an enantioselective assay for 
baclofen, which is marketed as the racemate, was also undertaken. 
The pharmacokinetics of racemic baclofen in man were studied both 
after a single oral dose and during chronic treatment. Because of the 
reported toxicity in patients with renal function impairment, influence 
of the renal function on the kinetics was anticipated. Lack of toxicity 
data on the enantiomers of baclofen prompted the use of the dog to 
study the pharmacokinetic behaviour of the isomers when individually 
administered. 
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The complexity of its disposition led to animal studies with dantro 
lene. Whole-body autoradiography in a small primate, the marmoset 
monkey, was chosen to detect regional presence of the ''•C-Jabelled 
compound. Parent drug and metabolite kinetics were studied in the dog 
following intravenous administration of dantrolene and 5-
hydroxydantrolene. Considering their physico-chemical properties, these 
compounds might undergo excretion in the bile. The pharmacokinetic 
behaviour of dantrolene in man was only briefly encountered 
A clinical pharmacokinetic study was undertaken in mentally retarded 
patients suffering from cerebral palsy. The particular patient 
population was chosen because they were being treated with antispastic 
drugs without adequate control of the clinical benefit. Since methods 
to measure response suited to the patients were not available, the 
development of simple tests became another aspect of this study. 
The aims of the present investigations can be summarised as follows: 
1. to develop analytical methods for the quantitative determination of 
baclofen, dantrolene, and their metabolites, and 
2. to apply these methods for the study of selected pharmacokinetic 
aspects of the drugs in animals, human volunteers, and patients. 
Reference 
1. Schobben AFAM. Pharmacokinetics and therapeutics in epilepsy. 
Nijmegen: Catholic University, 1979. Dissertation. 
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SECTION I 
LITERATURE REVIEW 

Chapter 1 
SPASTICITY AND DRUG THERAPY 
SPASTICITY AND DRUG THERAPY1 
E.W. Wuis 
Department of Clinical Pharmacy, St. Radboud University Hospital, Geert 
Grooteplein zuid 8, 6525 GA Nijmegen, the Netherlands. 
Abstract 
An overview is presented of pathophysiology, classification and 
measurement of spasticity and of its treatment, especially with 
dantrolene and baclofen. In spasticity, the balance between excitatory 
and inhibitory neurotransmitters in the central nervous system is 
impaired by mechanisms that are for the greater part unknown. 
Spasticity includes various disorders of motor control, and 
classification is needed for a meaningful evaluation of antispastic 
therapy. Cerebral palsy is a specific disorder, sometimes also called 
spasticity. Measurement of spasticity is complicated and should include 
signs characteristic of spasticity and parameters for clinical 
improvement. Dantrolene and baclofen have established their place in 
the treatment of spastic disorders, but a preference for either drug is 
hard to give. For tizanidine it is still too early to determine its 
place in therapy. Dantrolene is a direct acting muscle relaxant which 
should be avoided in patients with pre-existing liver damage. Its 
mechanism of metabolism and excretion is for the greater part unknown. 
The GABAB agonist baclofen is a centrally acting muscle relaxant. In 
patients with impaired renal function the dose should be reduced. 
Abrupt withdrawal carries the risk of unwanted reactions. The R(-)-
enantiomer has proved to be the active isomer. This means that human 
trials need reappraisal, especially those relating to the 
pharmacokinetics of the racemate. 
Key words: Baclofen; Cerebral palsy; Dantrolene; Drug therapy; Muscle 
relaxants; Spasticity; Tizanidine 
1
 Pharm Weekbl [Sci] 1987; 9: 249-60. 
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Introduction 
What is spasticity? Spasticity is not a disease but a disorder of mo-
tor control observed in a number of neurological conditions (Table I) 
(1). The word is derived from the Greek word 'GTTolOTlKoC t ^ ^ 
means 'he that draws or pulls· (patients with spasticity are often sub-
ject to sudden and violent muscular contractions). Depending upon the 
context, the term spasticity has several varieties of meaning. In the 
narrow sense, spasticity is a mere clinical sign referring to a specif-
ic type of increased muscle tone felt during passive movement. The in-
creased muscle tone of spasticity is a function of the velocity with 
which the muscle is stretched, differentiating it from the hypertonia 
of Parkinsonism and other forms of muscle hypertonia. 
The whole syndrome of spasticity, however, is much more complex and 
is characterized by a group of negative and positive signs, originally 
described by Jackson (Fig. 1) (2). Negative signs are weaJmess and loss 
of dexterity, while positive signs include increased muscle tone 
('spasticity'), hyperreflexia and flexor spasms. In this sense, spas-
ticity is nowadays defined according to Lance as 'a motor disorder 
characterized by a velocity-dependent increase in tonic stretch re-
flexes ('muscle tone') with exaggerated tendon jerks, resulting from 
TABLE I 
Most important neurological conditions in which spasticity may occur 
(reprinted with permission from ref. 1) 
Aetiology Incidence 
Trauma + + 
Cerebrovascular insult (apoplexy) + + + 
Autoimmune disease (multiple sclerosis) + + + 
Tumours + 
Infections, intoxications (Pb, Hg, Mg) + 
Dysontogenesis (cerebral palsy, Arnold-Chiari syndrome) + + 
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hyperexcitaJbility of the stretch reflex, as one component of the upper-
motor neuron syndrome' (2). In this definition not all signs are in-
cluded. The syndrome spasticity may develop following a lesion in de-
scending motor pathways in the spinal cord or at a supraspinal level. 
Depending upon the localization and the extent of the lesion, the clin-
mical appearance can be different. Sometimes, paralysis of one or more 
limbs is present. 
Of the neurological conditions given in Table I, cerebral palsy is 
also referred to as 'spasticity'. The striking presence of the signs of 
spasticity in the majority of cerebral palsy cases, has led to this 
confusing interchange of terms. Cerebral palsy or 'spasticity' in this 
specific sense is defined as 'a collection of nonprogressive neuromotor 
disorders of central origin that become manifest early in life and are 
not the result of a recognized cerebral malformation' (3). In the 
United States, cerebral palsy affects about one out of every fivehun-
dred school-age children, half of them with mental retardation, a quar-
ter with seizure disorders. In the Netherlands, the prevalence in the 
total population is about one per thousand (4). 
CNS LESION ^ Performance Deficit 
NEGATIVE 
SYMPTOMS 
V 
Abnormal Behavior: Abnormal Release of Function or 
Abnormal Spontaneous Discharge 
Activity 
FIGURE 1 
'JacJcsonian' negative and positive 'symptoms' observed in spasticity 
(reprinted with permission from ref. 2) 
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POSITIVE 
SYMPTOMS 
Pathophys i ology 
The stretch-reflex arc plays an important role in muscle control 
(Fig. 2) (5). Within skeletal muscles, muscle spindles are located 
which transmit information about changes in muscle length along la fi-
bres to the spinal cord. Via monosynaptic and polysynaptic connections 
impulses are transmitted back to the muscles through so-called extra-
fusal efferents of alpha motoneurons. Fusimotor efferents of gamma 
motoneurons adjust the sensitivity of the spindles. The most simple 
stretch reflex is the tendon jerk, which is monosynaptic. In normal 
hannonious movement, more complicated polysynaptic stretch reflexes and 
other spinal reflexes are involved, which are further controlled at 
spinal and supraspinal levels. 
Acetylcholine acts as an excitatory transmitter at all neuromuscular 
junctions. Within the spinal cord, a number of excitatory and inhibi-
tory neurotransmitters play a role. Glutamate and aspartate e.g., are 
responsible for excitation, glycine and gamma-amino butyric acid (GABA) 
FIGUHE 2 
The stretch-reflex arc (for explanation see text). E = excitatory 
presynaptic ending; I = inhibitory interneuron, « = alpha motoneuron, 
Y = gamma motoneuron (reprinted with permission from ref. 5) 
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TABLE II 
Several classificaticns cf spasticity 
Classification criteria Class nasie Brief characterization Major signs 
Site cf lesicn spinal spasticity lesicn within the spinal ccrd tendency tc flexien 
cerebral spasticity lesicn at a supraspinal level meter handicap ranges frcm 
purely spastic tc severely 
dyskinetic*, tendency tc 
weakness 
cryctest alpha spasticity 
gamma spasticity 
hyperactivity cf alpha 
metcneurens 
hyperactivity cf gamma 
metcneurens 
increased muscle tene en 
local ceding 
decreased muscle tone en 
local ceding 
¡Neurcphysiclcgical tests hyperactivity cf alpha 
metcneurens 
impaired GAEA-ergic 
presynaptic inhibition 
impaired (glycinergic) 
interneurcnal inhibition 
clinically similar patients 
may have different 
pathephyε i с1egy 
Invcluntary movement at rest with changing muscle tone. For further explanation see text. 
for inhibition, the latter selectively at presynaptic nerve endings. 
For increased muscle tone and hyperreflexia to develop, the stretch-
reflex arc must be intact. Several mechanisms underlying these positive 
signs of spasticity have recently been identified by neurophysiological 
testing of spinal cord functions (6). In patients with spasticity, the 
activity of alpha motoneurons is higher than in normal volunteers. Of 
the inhibitory mechanisms, GABA-mediated presynaptic inhibition on la 
fibres and a specific type of probably glycine-mediated interneuronal 
inhibition may be impaired, the preponderance of either varying consid-
erably between patients. Progress in clarifying other underlying mech-
anisms, especially on the supraspinal level, is being complicated by 
the lack of animal models resembling human spasticity. 
Classification 
As spasticity includes various disorders of motor control, a classi-
fication will contribute to a better understanding of prognosis and 
management. Considering the above, it will not come as a surprise that 
classification criteria are poor. A very simple clinical criterion can 
be the severity of the disorder. Pedersen gives a clear description of 
what he calls mild, moderately severe, and severe spasticity (7). Terms 
commonly found in the literature, are given in Table II. Depending upon 
the site of the lesion, a distinction is made between spinal and cere-
bral spasticity. This anatomical classification is clinically useful. 
In spinal spasticity following a period of shock, the response to all 
afferent inputs is exaggerated; patients tend to develop a flexed pos-
ture. In cerebral spasticity the generalized reflex hyperexcitability 
is usually less severe; besides increased muscle tone, weakness may 
present as a major problem. 
In Scandinavian literature, a simple test can be found to distinguish 
between hyperexcitability of alpha and gamma motoneurons (8). This so-
called cryotest, which is based upon the effect of local cooling on the 
spastic muscle, should differentiate between the two and has been used 
as a rough criterion to select a specific drug treatment. Findings with 
specialized interneuronal techniques, however, do not support the con-
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cept of hyperexcitability of the gamma system (6) If this is true, 
then the theory behind the cryotest needs reappraisal. 
The earlier indicated neurophysiological tests which distinguish be-
tween different spinal cord abnormalities, enable the development of a 
new type of pathophysiologically based classification (6). This classi-
fication will become of importance for drug therapy, the more so as 
clinically similar patients may have different pathophysiologies As 
long as this neurophysiologic testing is no current practice, at least 
a careful description of the disorder should be a prerequisite for a 
meaningful evaluation of an antispastic therapy. This applies also to 
the various motor forms of cerebral palsy, which can clinically be 
classified as spastic cerebral palsy, dyskinetic cerebral palsy (char-
acterized by involuntary movement at rest with changing muscle tone) 
and mixed forms (9). 
Measurement 
Measurement of spasticity is needed to be able to document its sever-
ity and to record changes in relation to a given treatment Quantita-
tive methods of measurement are especially important when the aim is a 
reduction in tone and not its total abolishment. This is as true for 
the individual patient who wants to benefit from his treatment, as for 
selected groups of patients undergoing clinical trials with new drugs. 
In the clinical evaluation of spasticity, resistance to passive move-
ment is still frequently recorded according to Ashworth (1964)· the ex-
aminer moves the spastic limb and expresses his subjective mpresssion 
m a simple five-grade scale (10). To obtain a less subjective and bet-
ter quantifiable measure of tone, many biochemical apparatus have been 
developed. An example is the relative equivalent damping (RED) appara-
tus of Kwee, used by Meyler to study the effectiveness of dantrolene 
(11). The RED-device measures the force required from the examiner to 
move the spastic limb against the pathological resistance. 
Measurement of tone is usually part of a more elaborate neurological 
rating system, of which many have been developed. In a comparison of 
five of these rating systems in the same group of patients with multi-
ple sclerosis, Grynderup gives some recommendations to achieve the max-
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imum benefit (12). He concluded that the effect of a therapy is best 
measured with a relatively large number of grades, which would favour 
the so-called Ry-system for this purpose. 
For information about the quality of life following a given treat­
ment, assessment of activities of daily living (ADD is better suited 
than a neurological examination. A still useful test is the Barthel 
Index: Ά simple index of independence to score the ability of a pa­
tient with a neuromuscular or musculoskeletal disorder to care for him­
self, and by repeating the test periodically, to assess his improve­
ment' (13). Compared with two other ADL indices in a group of stroke 
survivors, the Barthel Index had certain advantages: 'Completeness, 
sensitivity to change, amenability to statistical manipulation, and a 
greater familiarity due to more widespread use' (14). The Barthel Index 
has been used in a long-term study on baclofen in patients with multi­
ple sclerosis (2). 
A major function frequently used as a test parameter in spasticity, 
is gait. Methods of analysis range from clinical observation, prefera­
bly recorded on film or otherwise, to sophisticated electrophysiologi­
cal tests. A rating scale for gait analysis in children with spastic 
cerebral palsy was developed by Postema (15). Comparison of video re­
cordings before and after dantrolene treatment was part of his study 
on the effectiveness of this drug. He also developed the rapid repeti­
tive movement (RRM) test for quantitative measurement of voluntary mo­
tor control, which measures irregularity, slowness and limited freedom 
of movement. 
In the judgement of treatment programmes it is important to realize 
what is being measured: functional improvement does not necessarily 
mean treatment of spasticity. The latter preferably requires quantita­
tive electrophysiological analyses, the next step in the tests earlier 
referred to (6,16). As each test has its limitations, a combination of 
methods is usually necessary. For the measurement of the dyskinetic and 
mixed forms of cerebral palsy, hardly any test is available. The elec­
tronic measurement of limb movement and function, developed by Brown to 
construct feeding devices for patients with dyskinetic cerebral palsy, 
might also prove useful in testing the effectiveness of a given treat­
ment (17). Still other demands are made by cerebral palsy patients with 
mental retardation. In addition to the mental retardation, frequently 
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occurring disturbances in behaviour, consciousness, vision, hearing and 
speech further limit the possibilities of measurement. A simple func-
tional motor rehabilitation scale for moderately retarded children is 
given by Banham (18). 
Management 
Not all forms of spasticity require management. In mild cases, the 
discomfort may be so slight that the disadvantages of treatment become 
predominant. In patients with accompanying paralysis, treatment may 
lead to loss of their ability to remain in an upright position. A care-
ful consideration of the pros and cons should precede any management 
plan, especially in the case of destructive methods. 
Generally, treatment is started with physical therapy. Various pro-
grammes have been developed which are aimed at avoiding the shortening 
of tendons and muscles, preventing contractures, and improving volun-
tary power (7). For patients with cerebral palsy, specific training 
systems are available (17,19). Drug therapy with muscle relaxants is 
usually given in addition to exercise programmes. Only a very limited 
number of drugs has proved to be clinically useful in the management of 
spasticity (see below). For the dysJunetic form of cerebral palsy no 
specific drugs are available. 
Severe spasticity may require chemical destruction or surgical meas-
ures (7). Chemical destruction is performed with sclerosing agents such 
as alcohol and phenol in various dilutions. Injections at different 
sites along the stretch-reflex arc have given good results, but poor 
selectivity of action and recurrence of symptoms limit their use. In 
selected patients, improvement can be obtained with orthopedic surgical 
procedures, such as elongation or sectioning of tendons. Dissection of 
afferent or efferent fibres, stereotactic brain surgery and other neu-
rosurgical procedures are a last resort for patients not controllable 
by any other means and presently rarely used. 
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Muscle relaxants 
Pharmacologically, spasticity can be interfered with by interrupting 
the stretch-reflex arc at a number of sites (Fig. 2). Drugs have been 
developed which act at the neuromuscular junction (curare-like agents), 
at spinal or supraspinal levels (centrally acting muscle relaxants), or 
on the muscle itself (dantrolene). 
In Table III drugs with muscle relaxant properties are given in a 
chronological order. Curare paralyses skeletal muscles by blocking ace-
tylcholine receptors at the neuromuscular junction. But because of the 
elimination of voluntary power and the involvement of respiratory mus-
cles, curare-like agents are no longer employed outside the operating 
room or the intensive care unit (7). In 1910, with the discovery of 3-
phenoxy-l,2-propanediol, a substance was found which caused a reversi-
ble paralysis in animals (20). Its derivative 3-o-toloxY-l,2-propane-
diol, or mephenesin, became the prototype of a series of centrally ac-
ting muscle relaxants (21). The early compounds, however, were either 
too short-acting or lacking clinical effectiveness. The longer-acting 
carbamates meprobamate (2-methyl-2-propyl-l,3-propane-diol dicarbamate) 
and mephenoxalone (a cyclic carbamate) are clinically effective but too 
sedative to be of use in spasticity. 
All benzodiazepines have muscle relaxant properties. Traditionally, 
diazepam is the benzodiazepine most often used for muscle relaxation. 
Being a so-called classical GABAÄ-agonist it reinforces depressed pre-
synaptic inhibition in the spinal cord (5,16). For long-term adminis-
tration in spasticity, however, it is usually not the drug of choice, 
again because of sedation. For this purpose, baclofen has been the pre-
ferred centrally acting muscle relaxant over the past twenty years 
(see below). Recently, baclofen was joined by tizanidine Fig. 3). 
CI' |Jy^/ 
NH .HCl 
I FIGURE 3 
HN ^ N Structure of tizanidine, a new centrally 
\ ' acting muscle relaxant 
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TABLE III 
Historical review cf тіа:сг muscle relaxants 
Year cf First ccmpcund 
introduction 
Cne-nical class Seme currently 
available cempcunds 
Ref*-
ererce 
<1900 
1910 
1943 
1946 
1954 
1961 
1967 
1967 
1977 
curare 
3-phencxy-l,2-pr' 
benzimidazcle 
mephenesin 
meprcbamate 
chlordiazepcxide 
baclofen 
dantrolene 
tizamdine** 
curare-like agents 
benzazcle cempcunds 
tubecuranne (Curann1' 
chlcrzcxazcne (ParaflexH) 
tizaridine*'"(SirdaludH) 
(carbamates of) glycerol ethers 
(cyclic) carbanates cf glyccls mephencxalcne (Ecrsiflex14! 
benzodiazepines diazepam (Stesolid1*, 
Vallati1') 
САВА derivatives baclofen (IicresalB) 
imidazclidincres dantrolene (DantriumB) 
midazcline derivatives tizanidine**(SirdaludB; 
7 
20 
20 
21 
22 
23 
24 
28 
25 
* References on first compound. 
"* Can be classified either as benzazcle cr midazcline derivative 
Tizanidine can be classified as an imidazoline or as a new derivative 
of the benzazoles of which chlorzoxazone has been a rather ineffective 
example (20). Tizanidine interferes with polysynaptic reflexes in the 
spinal cord, possibly by inhibiting the release of the excitatory neu-
rotransmitter aspartate (26). Its effect was comparable to baclofen in 
a number of trials, but more studies are needed before its place in the 
management of spasticity can be determined (26,27). The only drug in-
terfering at the muscular level of the stretch-reflex arc, is dantro-
lene. 
Dantrolene 
Dantrolene, l-[[5-(p-nitrophenYl)-furfurylidene]-amino] imidazoli-
dine-2,4-dione (Fig. 4), was the most active compound of a series of 
substituted 2,4-imidazolidinones (=hydantoins) synthesized by Snyder et 
al. (28). Till today, it has remained the only clinically useful imid-
azolidinone derivative for muscle relaxation in spasticity. Of the oth 
er imidazolidinones given in Figure 4, Phenytoin has incidentally been 
used as co-medication in spastic disorders (29). The structural ana-
logue nitrofurantoin is not a muscle relaxant, but has resemblance to 
dantrolene in chemical stability and side effects. Both compounds are 
susceptible to acidic cleavage of the azomethine bond, and may cause a 
similar type of liver and lung injury on prolonged use (30,31). 
Clodanolene is an experimental compound in which the p-mtrophenyl 
group of dantrolene has been replaced by a 3,4-dichlorophenyl moiety. 
It has been tested in animal models of muscle relaxation and malignant 
hyperthermia (32,33). Malignant hyperthermia is a genetically deter-
mined disorder associated with a high mortality rate if left untreated. 
Dantrolene has been used very successfully in the treatment of this 
syndrome in addition to its use as an antispastic agent (34). Although 
clodanolene offered no clear advantage over dantrolene in the experi-
mental models, the lack of the mtro-group maJces it an interesting com-
pound as intermediates of nitro reduction have been associated with 
hepatotoxicity (35). The newest offspring of the imidazolidinone tree 
is the class of the oxazolyl-2,4-imidazolidinones, in which the furan 
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moiety has isosterically been replaced by oxazole (36). At present, 
these compounds are undergoing pharmacological evaluation. 
MODE OF ACTION 
Dantrolene is a direct acting muscle relaxant. It acts intracellular-
ly by affecting calcium flux across the sarcoplasmic reticulum of 
skeletal muscles. Its effect on muscle spindles is less clear (3/). 
Cardiac and smooth muscle are not as sensitive to dantrolene as skele-
9 
qKOXnHH=N-N NH 
dantrolene 
с\-<ГЫ ><:H=N-N NH 
cK 0 ^~Ъ 
02N-<ÇyCH=N-N NH 
nitrofurantoin 
Phenytoin 
FIGURE 4 
Substituted 2,4-imidazolidinones 
(=hydantoins) 
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tal muscle, probably because they are more dependent upon external cal-
cium which is influenced by calcium entry blockers like verapamil (38). 
Whether dantrolene also exhibits calcium entry blocking properties is 
still controversial (39,40). Farquhar et al. offer some explanations 
for the minimal effect of dantrolene on respiration (41). From their 
experiments with rats, they propose three compensatory mechanisms con-
tributing to maintenance of ventilation. Clinically, one should remain 
cautious, however, as two cases of depressed respiration following 
dantrolene administration have been reported in literature (42,43). 
BIOANALYSIS 
In 1968, Hollifield and Conklin developed a spectrophotofluonmetnc 
method for dantrolene in biological fluids, which was later modified to 
account for the presence of metabolites (44,45). For pharmacokinetic 
purposes the various high-pressure liquid chromatographic (HPLC) assays 
of a later date offer better specificity and sensitivity (46,47). 
Dantrolene plasma concentrations differ from concentrations in whole 
blood. This should be kept in mind when different studies are compared, 
e.g. effective 'levels' in malignant hyperthermia (48,49). Dantrolene 
and its metabolites are not stable under all conditions. The hydantoin 
ring can open in the presence of alkali, the azomethine bond is suscep-
tible to acid (30,50). In the presence of enteric bacteria dantrolene 
degrades to 7-aminodantrolene of which the acetylated form is light 
sensitive (47,51). 
PHARMACOKINETICS 
About the rate and extent of absorption of dantrolene little is yet 
known. No data on bioavailability have been reported. Mass balance 
studies are hampered by the aforementioned instability problems. Peak 
plasma concentrations have been reported to occur several hours after 
oral administration (11,46,52). In a group of cerebral palsy patients 
a poor correlation was found between daily oral dose and plasma concen-
tration (53). 
Distribution has been investigated with fluorescent techniques in 
mice. The highest concentrations were found in the intestine and in the 
liver (54). This agrees with an experiment with 1*C-dantrolene in a 
monkey (Wuis EW, unpublished observations). No fluorescence nor radio-
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activity was found in the brain in vitro binding of dantrolene to se­
rum albumin, red blood cells, sarcoplasmic reticulum and hepatic endo­
plasmic reticulum has been demonstrated, the latter also in vivo (55-
57). Binding to the cornea has been suggested to occur in a child and 
this is not contradictory to observations in the earlier mentioned mon­
key experiment (58). Dantrolene crosses the placenta as measured in two 
cases (59) 
The proposed metabolic scheme of dantrolene is given in Figure 5 
(60). It has been concluded from animal experiments that 5-hydroxy-
dantrolene contributes to some extent to the effect of dantrolene (60, 
61). Renal excretion in man accounts for 15 25% of an intravenous or o-
ral dose, mainly as the 5-hydroxy compound (52,62). As biliary and fae­
cal excretion were found to be negligible, the major route of elimi­
nation of dantrolene is still unknown (52,63). Elimination half-lives 
of dantrolene after oral administration show large interindividual var­
iations with extreme values of 3 and 22 hours (11,52). In several stud-
M) 
dantrolene 
nitro reduced 
dantrolene 
^"^^СЭ^С^^ 
nilro-reduced a cet y la led 
dantrolene (F490) 
HC 
5-OHdantrolene (F 563) 
FIGURE 5 
Proposed 
metabolism of 
dantrolene 
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íes a correlation was found between dantrolene plasma concentration and 
pharmacological effect, like depression of twitch tension. However, a 
correlation between plasma concentration and therapeutic effect m 
spasticity is less clear (11,15). As a minimum effective plasma concen-
tration 0.3 mg/1 has been suggested (11). 
THERAPEUTIC USE 
Many studies have been published on the use of dantrolene in spas-
ticity. How to determine the benefit of treatments has been the most 
difficult part of all studies (see above). The peripheral site of ac-
tion of dantrolene precludes electrophysiological testing of spinal 
cord functions to measure its effectiveness. The heterogeneity of the 
patients treated, even within a study, and the lack of objective 
quantitative methods of measurement, make the drawing of definite con-
clusions about its effectiveness for a specific type of spastic dis-
order a difficult task. In spasticity associated with multiple sclero-
sis dantrolene seems to be less effective than in other types of spas 
tic disorders. Nevertheless, its overall efficacy in patients with 
multiple sclerosis is comparable to that of baclofen (34). 
In Table IV a summary is given of the results of controlled double-
blind studies in children with cerebral palsy. In most studies subtle 
benefits were found, but these seldom warranted continuation of the 
drug after the trial period. In cerebral palsy, dantrolene has not been 
compared with baclofen. The results already obtained in 1973 by Chyatte 
et al. in patients with the dyskmetic form of cerebral palsy, ask for 
further studies (64). For an overview which also includes the use of 
dantrolene in malignant hyperthermia and related hypercatabolic dis-
orders, one is further referred to the article by Ward et al. (34). 
Hepatic injury has been the most feared side effect of dantrolene 
therapy. Fatal hepatitis has occurred in about 0.3% of patients. Since 
dosage recommendations for long-term treatment have been reduced to 
200 mg per day, the risk of liver damage appears to have decreased. In 
patients with pre-existing liver damage, dantrolene is still contrain-
dicated. Other side effects of dantrolene therapy are usually less se-
vere (34). 
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ω TABLE IV 
о 
Зшпшагу cf results cf ccntrclled, dcuble-blind trials cf dantrolene in patients with cerebral palsy 
DJumber Eos age 
cf regimen 
patients 
Euraticn Effect (nuniber cf 
cf ther- patients in brackets! 
ару* 
(weeks) 
Classificaticn Age cf Ref-
cf patients er-
cerebral palsy (years! enee 
Dantrolene 17 
versus 
placebo 
28 
23 
2C 
Dantrolene 22 
versus 
diazepam 
dantrolene 
2C-4C0 mg/day 
placebo 
dantrolene 
12 mg.kg^.d- 1 
placebo 
dantrolene 
1-10 mg.kg-1.d-i 
placebo 
dantrolene 
12 mg.kg-^d- 1 
placebo 
dantrolene 
1-15 mg.kg-1.d-i 
placebo 
dantrolene 
< 225 mg/day 
diazepam 
< 12 mg/day 
dantrolene > placebo (12! dyskinetic 
dantrolene = placebo (5) 
dantrolene > placebo (5 ) spastic 
dantrolene = placebc (23) 
1.5 dantrolene »• placebc spastic 
dantrolene > placebc spastic 
dantrclene = placebc spastic 
dantrclene > diazepam (9) spastic 
dantrclene < diazepam (7) 
dantrclene = diazepam (4) 
7 -38 64 
1.5-12 65 
9 -i·; 
4 -15 
66 
1.5-17 67 
68 
2 - 8 69 
" On maximum dose only. 
Baclofen 
Baclofen, 4-amino-3-(p-chlorophenyl(butyric acid (Fig. 6), is the 
product of research directed at the development of a drug with GABA-
ergic properties. Later it became known, after baclofen had already 
been introduced into therapy for spasticity, that it was not a true 
GABA agonist. Of the clinically administered racemate the R(-)-isomer 
(Fig. 7) is active at so-called GABAS receptors Other actions of 
baclofen, like its effect in tardive dyskinesia and schizophrenia, have 
been connected with the phenethylamine moiety of the molecule (Fig. 6) 
(70). At present, baclofen is the only drug m clinical use with GABAn 
agonistic properties. 
MODE OF ACTION 
An overwhelming amount of literature has been published on baclofen 
and its proposed mode of action. The results of early publications in 
which the racemate was tested for GABA-ergic activity, are rather con-
HoArV42 
phenethylamine 
FIGURE 6 
Structural formulae of GABA, baclofen, its 
V-hydroxy metabolite and phenethylamine 
CI<Q)»-Ç-CH2COOH 
сн2 
NH2 
RHbaclolen S(+)baclolen 
fusing. Some clearness was created when the enantiomers were tested 
separately in addition to the recognition of two types of GABA recep­
tors: the classical bicuculline-sensitive САВА
Л
 receptors linked to 
chloride channels, and the newly discovered GABAB receptors which are 
probably linked to calcium channels (71). The main site of action of 
baclofen seems to be on presynaptic GABAB sites within the spinal cord, 
where it stereospecifically depresses the release of excitatory ammo 
acids (72). 
GABAn receptors have not only been found in the spinal cord, but also 
at supraspinal levels and even extraneuronally in the rabbit uterus 
(73). Their localization is not restricted to presynaptic nerve termi­
nals; postsynaptic sites that are linked to potassium channels, may 
also be involved (74,75). Although benzodiazepine receptors have been 
linked with САВА
Л
 recognition sites, there is some evidence for the in­
volvement of baclofen with benzodiazepine receptors, possibly mediated 
by the postsynaptic GABAB sites (76). The implications of these find­
ings for the clinical effectiveness of baclofen are not yet clear. 
Terrence et al. found structural similarities between baclofen and 
carbamazepine (77). This last observation leads into the discussion 
about baclofen and epilepsy. Contradictory data have been published so 
far. Recently, R(-)-baclofen was found to act as a convulsant in vivo 
in the rat (78). In earlier studies anticonvulsant activity had been 
found, at least in some models of epilepsy (79). Another controversy is 
the analgesic action of baclofen which has been demonstrated m animal 
studies (80,81). In man, analgesia with baclofen seems to be restricted 
to trigeminal pain (82, 83). 
μ FIGURE 7 
CI©»*Ç-CH2NH2 
CH2 
С00Н 
Enantiomers of baclofen 
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BIOANALYSIS 
Baclofen can be determined in biological fluids either by gas chroma-
tography or by HPLC (84-86). In general, extraction and derivatization 
procedures are needed for detection of the GABA derivative baclofen in 
the presence of endogenous amino acids. The above-mentioned methods do 
not selectively measure the two enantiomers. Some preliminary results 
of enantioselective assays have been published, but chiral recognition 
in biological fluids has not yet been attained (87,88). For the pro-
posed metabolite of baclofen, 4-hydroxy-3-(p-chlorophenyl)butyric acid 
(Fig. 6), an HPLC assay was recently developed (86). 
PHARMACOKINETICS 
After intravenous and oral administration of '"C-labelled baclofen 
about 80% of radioactivity was recovered in the urine, mainly as un-
changed drug (?,89). Food did not significantly alter the rate and ex-
tent of absorption (2,90). The time to reach peak plasma concentrations 
after an oral dose was 1-2 hours (91). ^ C-labelled baclofen was used 
for distribution studies in the mouse and the rat. High concentrations 
were found in the liver and the kidneys, low concentrations in the 
brain and the spinal cord (2,89). In man, binding of baclofen to plas-
ma proteins is low, about 20-30% (2,90). Concentrations in the cerebro-
spinal fluid were usually ten times lower than their corresponding 
plasma values (92). Only 0.1% of a single oral dose of 20 mg was found 
in breast milk (93). 
About 701 of baclofen is excreted renally as unchanged drug. Dimin-
ished renal function requires dosage reduction (94). Ibuprofen-mduced 
renal insufficiency has led to baclofen toxicity (95). Whether dimin-
ished creatinine clearance in the elderly is also responsible for the 
greater incidence of side effects in this population, has not entirely 
been ruled out (96). One pharmacologically inactive metabolite has been 
found which accounts for only a very small fraction of the administered 
dose (Fig. 6) (2,89). Elimination half-lives range between 2 and 6 
hours (2,89). The prolonged elimination half-life (30-35 hours) after 
massive overdoses as found by Lipscomb et al. and Chose et al. was not 
confirmed in a later case (97-99). Very limited data are available on 
the relationship between plasma concentration and effect. Reduction in 
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spasticity has been observed with concentrations between 0.1 and 0 6 
mg/1 (92). 
All of the above-mentioned studies were carried out with the racemic 
drug without the possibility of enantioselective analysis. This means 
that not much weight can be attached to the pharmacokinetic data pres-
ented. An enantioselective assay is needed to enable measurement of the 
'true' parameters. 
THERAPEUTIC USE 
Like dantrolene, baclofen has established its place in the treatment 
of spasticity. Again, evaluation of the effect has been the most diffi-
cult part of all studies (?,17). In one study, the mode of action of 
baclofen was tested with electrophysiological analysis of spinal cord 
functions. However, this study, which also included tizanidine and di-
lazepam, did not yet assess the clinical benefit of treatment (16). An 
overview of the use of baclofen in cerebral palsy is given in Table V. 
In most studies baclofen had some effect, mainly in patients with the 
spastic form of cerebral palsy. The present data do not allow to choose 
for either baclofen or dantrolene in a specific type of spastic dis-
order. For more information on the use of baclofen, the proceedings of 
three symposia on baclofen and spasticity held in the past fifteen 
years are available (2,17,102). 
Intrathecal application of baclofen proved to be effective in a small 
number of patients with severe spasticity unresponsive to oral baclofen 
(103). A case of reversible coma following intrathecal baclofen, indi-
cates that this mode of administration warrants extreme caution (104). 
Long-term administration carries the risk of seizures, hallucinations, 
and dyskinesias on abrupt withdrawal (105,106). To circumvent these 
complications, a dosage reduction of 5-10 mg per week is recommended 
(107). 
Conclusions 
If one wants to treat spasticity, it is necessary to make clear what 
spasticity is. In recent literature, the definition of Lance is gener-
ally agreed upon (2). As spasticity is not a single entity, a classifi-
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TABLE V 
Sunraary cf results cf placebc-ccntrclled, dcuble-blind trials of baclcfen in patients with cerebral palsy 
Number Dosage regimen Euraticn cf Effect 
of therapy* 
patients (weeks) 
Classification cf cere- Age cf Reference 
bral palsy (пшіЬег cf patients 
patients in brackets! (years! 
35 
20 
18 
36 
45 mg/day 
30-60 mg/day 
2 Tng.kg-i.d-1 
30-70 mg/day 
2 
2 
1 
4 
baclofen > placebo 
baclcfen > placebo 
baclcfen = placebo 
baclcfen > placebo 
spastic 
spastic (17) 
mixed (3) 
spastic (12) 
mixed (6) 
spastic (21! 
mixed (15) 
3-61 
2-16 
7-16 
2-17 
2,pp41- 9 
17lppl6-22 
100 
101 
* Cn maximum dose only. 
cation will aid in the judgement of the different treatment pro-
grammes. A classification based upon the underlying pathophysiological 
mechanisms offers the best perspectives for treatment with drugs As 
long as the required electrophysiological tests are not universally a-
vailable, a careful description of the disorder is a prerequisite for 
meaningful comparisons. Which method should be selected or developed 
for the measurement of spasticity is dependent upon the primary aim of 
the treatment. A combination of methods is usually necessary as each 
method has its limitations. 
Muscle relaxants can be useful in the management of spasticity, but 
the advantages and disadvantages should be carefully considered. If 
drug therapy is decided upon, evaluation of the expected effect is of 
paramount importance in preventing unnecessary chronic drug consump-
tion. Of the many drugs that have been developed as muscle relaxants, 
only a few have survived as clinically useful. For the past twenty 
years only baclofen and dantrolene have been widely used, each with 
its own limitations. New developments are to be expected with the use 
of electrophysiological tests, which can discriminate between the vari-
ous pathophysiological abnormalities of spasticity. Matching the phar-
macological profile of muscle relaxants with the pathophysiological 
profile of spasticity may eventually lead to a better treatment. 
Cerebral palsy is not synonymous with spasticity, but it is a specif-
ic disorder, often with signs of spasticity. Little is known about the 
measurement and management of the dyskinetic and mixed forms of cere-
bral palsy. 
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SUMMARY 
A reversed phase high performance liquid chromatographic method for the determination 
of the skeletal muscle relaxant baclofen in human plasma and urine is described Cation-
exchange extraction, precolumn denvatization with o phthaldidldehyde, and on column con­
centration precede fluorimetrie detection (excitation at 340 nm, emission at 460 nm) 
The precision of the assay was always better than 6% Recoveries of standards added to 
plasma and urine were 92% and 93%, respectively With a sample size of 0 5 ml, a detection 
limit of a few nanograms, and the possibility of analysing up to four samples per hour, 
this method is suitable for pharmacokinetic studies An example is presented 
INTRODUCTION 
Baclofen, 4-amino-3-p-chlorophenylbutyric acid, is a skeletal muscle 
relaxant, which has been used in spastic disorders since its introduction for 
therapy in 1967 [1] . Several symposia have been dedicated to its 
pharmacological actions and clinical applications, but no conclusive evidence 
has yet been acquired for its mode of action [2—4]. Besides motor disorders 
other indications have also been proposed, such as schizophrenia [5—7], 
tardive dyskinesia [8, 9] , and trigeminal neuralgia, but only the latter shows 
promising results [10, 11]. 
Baclofen is a p-chlorophenyl analogue of 7-aminobutyric acid (GABA), 
with the substituent rendering it a centre of asymmetry (Fig. 1). The discus­
sion about its mode of action has been complicated by the different effects of 
the two enantiomers. The efficacy m spasticity has been attributed to (—)-
baclofen, a substance with GABAu-mimetic properties [12, 13] The com­
mercially available drug (Lioresal®) is the racemic mixture. 
0378 4347/85/$03 30 © 1985 Elsevier Science Publishers В V 
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Fig. 1. Structural formulae of 7-aminobutync acid (GABA), baclofen and its hydroxy 
metabolite. 
Baclofen is metabolized to only a minor extent. Deamination yields 3-(p-
chlorophenyl)-4-hydroxybutyric acid (Fig. 1), a metabolite which has been 
identified in the urine of rat, dog, and man. In man about 85% of a I4C-labelled 
oral dose was found to be excreted unchanged, primarily in the urine. Most of 
the remaining radioactivity was accounted for by the deaminated metabolite, 
which was inactive in animals [14, 15]. 
The development of a procedure to determine baclofen in body fluids 
encountered several analytical problems due to its amino acid structure. For 
the measurement of concentrations in the nanogram range, as needed for 
pharmacokinetic studies, it has to be separated from the endogenous amino 
acids. Degen and Riess [16] developed a gas—liquid chromatographic method 
with electron-capture detection, requiring lengthy derivatization reactions and 
resulting in only a 50% recovery. Geis chromatography in combination with 
mass spectrometry (GC—MS) has been described by Swahn et al. [17]. 
No high-performance liquid chromatographic (HPLC) method for the 
determination of baclofen has yet been published. One problem is that 
baclofen itself, like other amino acids, cannot be detected in low concen-
trations in biological material with ultraviolet spectrometry or fluorimetry. 
However, a considerable number of methods to assay endogenous amino 
acids, using reversed-phase HPLC in combination with fluorophore forma-
tion, have recently been published. Commonly used derivatization agents 
for pre- or postcolumn fluorescence detection of amino acids are Dns chloride, 
fluorescamine, and o-phthaldialdehyde (OPA) [18]. Derivatization with OPA 
is relatively simple and rapid. In the presence of alkylmercapto compounds 
highly fluorescent isoindoles are formed [19—21]. We developed an analytical 
assay for baclofen based upon precolumn derivatization with OPA. Separation 
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from the endogenous ammo acids was achieved by cation-exchange extraction 
prior to the denvatization. High sensitivty was obtained with an on-column 
concentration and cleaning procedure which allows for injection of large 
volumes [ 2 2 ] . 
MATERIALS AND METHODS 
Reagents and chemicals 
Solutions were made in distilled water. All glassware was rinsed with distilled 
water prior to use. Chemicals were of analytical grade and were used without 
further purification. A stock solution of baclofen (a gift from Ciba-Geigy, 
Amhem, The Netherlands) containing 100 mg/1 was diluted with water, urine, 
or plasma to produce concentrations in the range 0.02—2 mg/1 For the 
extraction procedure the following solvents and solutions were used hexane, 
methanol, saturated sodium chloride solution, citrate buffer pH 2.6 (0 1 M 
citric acid—0.2 M dibasic sodium phosphate, 89.1 10.9, v/v), and borate buffer 
pH 10.4 (0.1 M borax adjusted to pH 10.4 with sodium hydroxide) The 
denvatization reagent consisted of 250 mg of o-phthaldialdehyde dissolved in 
1.5 ml of methanol, 23 ml of borate buffer pH 10.4 (0.4 M boric acid adjusted 
to pH 10.4 with potassium hydroxide), and 0.5 ml of thioglycohc acid The pH 
was adjusted to 10.4 after mixing [ 2 3 ] . Two mobile phases were used eluent 
A, 0.9% (w/v) sodium chloride solution, eluent B, methanol—tetrahydrofuran— 
phosphate buffer pH 8.5 (0.067 M dibasic sodium phosphate adjusted to pH 
8.5 with monobasic potassium phosphate) (40.2 - 58, v/v/v). 
Apparatus 
Extraction was performed with the Baker-10 extraction system (Baker 
Chemicals, Cat. No. 70180, Deventer, The Netherlands), fitted with 3-ml 
disposable extraction columns packed with aromatic sulphonic acid bonded to 
sihca gel (Cat. No. 70903). 
The chromatographic system consisted of a double-head solvent pump 
(Orhta, DHP-1515, Bakker, Zwijndrecht, The Netherlands), two sampling 
valves (Valco, Houston, TX, U.S.A.), and a sampling loop of 1.0 ml. Complete 
pulse quenching was achieved with a pulsation dampener (Orhta, PDM 3 350 
M, Bakker) between pump and injection valve. The analytical column (25 cm X 
4.6 mm I.D.) was packed with reversed-phase matenal Cp-Spher C
e
, particle 
size 8 μτη (Chrompack, Cat. No. 28502, Middelburg, The Netherlands) The 
concentration column (5 cm X 3.0 mm I.D.) was filled with LiChrosorb RP-8, 
10 д т (Chrompack). A fluorescence detector (Perkin-Elmer, Model 3000, 
Delft, The Netherlands), equipped with a red sensitive photomultipher and a 
doubly mirrored flow cuvette, was used. The detector was connected to a 
10-mV recorder (Kipp & Zonen, BD 40, Delft, The Netherlands). 
Extraction and denvatization 
The extraction column was conditioned with two column volumes of 
hexane, two column volumes of methanol, two column volumes of water, and 
three column volumes of saturated sodium chloride solution. To 0.5 ml of 
plasma (low concentrations 1.0 ml) or 0.5 ml of urine (high concentrations 
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were diluted prior to use) an equal volume of citrate buffer pH 2 6 was added 
This mixture was loaded onto the column After five subsequent column 
washings, four with water and the last with saturated sodium chloride solution, 
the sample was eluted with four 0 5 ml ahquots of borate buffer pH 10 4 
To the collected eluent 0 4 ml of the denvatization reagent was added After 
mixing on a vortex mixer and subsequent centrifugation at 2000 g, a 1 0-ml 
sample was taken to be used for HPLC The time elapsed between the addition 
of the reagent until injection into the HPLC system was standardized at 150 
sec 
m 
cation 
exchange 
Fig 2 Schematic diagram of the assay of baclofen For further explanation, see text 
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HPLC and detection 
The sample loop was filled as shown in Fig 2b By turning the upper valve, 
solvent A (flow-rate 1.5 ml/mm, pressure approx. 5 MPa) transported the 
sample onto the concentration column (Fig. 2a) After 5 ml of solvent A had 
been used, the lower valve was turned and with 1.5 ml of solvent В (flow-rate 
1 0 ml/min, pressure approx. 10 MPa) the concentrated sample could be 
flushed onto the analytical column (Fig. 2b) With an excitation wavelength of 
340 nm and emission at 460 nm the fluorophore was detected quantitatively 
by measuring the peak height. The experiments were carried out at room tem­
perature. Between samples the concentration column was flushed with several 
1-ml methanol washings. 
Recovery 
The recoveries of the standards that had been added to water, plasma, and 
unne were measured in triplicate for three different concentrations in the range 
0.10—2.1 mg/1 and compared to a direct (i e. no extraction) assay in water. 
Experiment in a healthy volunteer 
A 35-year-old Caucasian woman (67 kg) was given a single oral dose of 20 
mg baclofen (Lioresal®, two tablets of 10 mg each) 2 h after breakfast. Blood 
samples of 1—2 ml were drawn at predetermined intervals by fingertip puncture 
for a total period of 14 h. Samples from spontaneously voided urine were 
collected for 50 h. All blood specimens were collected in hepannized tubes. 
Plasma and unne were stored at —20°С until analysis. 
RESULTS AND DISCUSSION 
Chromatograms of baclofen in plasma and urine are shown in Figs. 3 and 4. 
Blanks (Fig ЗА and 4A) did not show interfering substances. In Fig 3B a 
plasma sample obtained from a patient treated with a daily oral dose of 45 mg 
is shown. The detection limit in plasma at a signal-to-noise ratio of 3 was 
approx. 1 5 ng (Fig. 3C). An example of baclofen measured in the urine of a 
volunteer is given in Fig. 4B. The detection limit in urine was approx. 5 ng (Fig. 
4C). The capacity ratio (ft') was 3. Calibration curves showed good linearity 
between peak heights and concentrations (r2 always > 0 99). The precision of 
the determination in water, plasma, and urine was measured for three different 
concentrations in the range 0.10—2.1 mg/1 (n = 4). Coefficients of variation 
were always less than 6% Recovenes in a similar concentration range were 97% 
for extraction from water, 92% and 93% for extraction from plasma and urine, 
respectively. 
With the cation-exchange extraction procedure interfering endogenous 
amino acids could be effectively removed, owing to their low pKa>¡ values [24] 
as compared to baclofen (pKal = 3 87, pK^ = 9 62) [15]. Thus, based upon 
the pKa values of baclofen and the pH needed for the subsequent denvatization 
reaction, the different buffers were chosen. When the conditioning with sodium 
chlonde was omitted, baclofen was not reproducibly held on the column Prior 
to elution, another wash with sodium chlonde was necessary for complete 
recovery. Denvatization of baclofen with OPA was as simple and rapid as for 
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Fig. 3. Chromatograms of plasma samples: (A) plasma blank, (B) plasma of a patient on 
chronic oral therapy with 0.603 mg/1 baclofen, (C) plasma spiked with 0.021 mg/1 baclofen. 
b = baclofen. 
endogenous amino acids. The structure of the proposed reaction product is 
given in Fig. 5. As the stability of the fluorescent derivatives of OPA with 
amino acids can vary with time [19—21], the baclofen fluorophore was always 
measured at a fixed time, in this case 150 sec after starting the reaction. 
Although baclofen has been in clinical use for over fifteen years, hardly any 
pharmacokinetic data are available. Only a few studies have been published 
mentioning pharmacokinetic parameters, in volunteers [14,15] and in patients 
[25, 26]. This seems to be mainly due to the lack of analytical procedures 
suitable for routine measurements. 
To test the applicability of the presented HPLC method in pharmacokinetic 
studies a pilot experiment was done in a healthy volunteer. Fig. 6 shows the 
plasma concentration—time and renal excretion rate—time profiles of baclofen 
after a single oral dose of 20 mg. Some pharmacokinetic parameters are listed 
in Table I, calculated according to standard methods [27, 29]. The values of 
¿max a n d of Cm a x are similar to those reported by Swahn et al. [17] with the 
GC—MS method. After 50 h, 85% of the dose administered was recovered as 
unchanged drug in the urine. This is in agreement with data from experiments 
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Fig. 4. Chromatogr&ms of urine samples: (A) urine blank, (B) urine sample of a volunteer 
after a single oral dose of 2.51 mg/1 baclofen, (C) urine spiked with 0.205 mg/1 baclofen. 
b = baclofen. 
S_CH2-C00H 
'N-CH2-CH-CH,-C00H 
Fig. 5. Proposed reaction product of o-phthaldialdehyde and thioglycolic acid with baclofen. 
with radioactively labelled baclofen [14, 15]. Clearance values have not been 
reported earlier. A total plasma clearance (CI) of 0.16 1 h" 1 kg"1 was calculated. 
In this volunteer the renal clearance of baclofen (C/R) was equal to the 
creatinine clearance. Half-lives from plasma data have been reported to range 
from 2.5 to 6 h [14, 15]. After massive overdoses, however, half-lives of more 
than 30 h have been observed [30, 31]. We found a half-life of 5.4 h from 
terminal plasma data. When the combined plasma and urine data were fitted to 
a two-compartment open model using NONLIN [27], a higher terminal 
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Iplasma cone, pg/ml renal excr. rat« pg/min 
baclofen 
0.3 mg /kg po 
Fig. 6. Plasma concentration—time and renal excretion rate—time profiles of baclofen in a 
human volunteer following a single oral dose of 20 mg. % = percentage of the dose excreted 
unchanged in the urine. 
TABLE I 
SOME PHARMACOKINETIC PARAMETERS OF BACLOFEN IN MAN 
Single oral dose of 20 mg (π - 1). Abbreviations according to ref. 28, calculations according 
to refs. 27 and 29. 
Cjnax 
' m « 
'Их 
er C / R " 
А, ( - ) * * * 
0.24 mg/l 
2.0 h 
6.2 h 
0.16 I h " ' kg"1 
0.12 I h " · kg"1 
86% (of dose in urine) 
"Assumption F = 1. 
"Calculated from total plasma concentration data. 
***Extrapolated to infinity. 
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half-life of 6 2 h was found In a preliminary study in eighteen patients on 
chronic oral therapy with daily baclofen doses ranging from 0 26 to 1 2 mg/kg, 
we measured plasma concentrations varying from 0 078 to 0 60 mg/1, with a 
mean total plasma clearance of 0 21 ± 0 11 1 h" ' kg"1 Samples were drawn 3 h 
after the morning dose 
With the described reversed phase HPLC method, only the parent drug is 
measured The hydroxymetabohte lacks the ΝΗ2 group, which reacts with 
OPA Also no separation of the enantiomers is obtained These disadvantages 
also apply to the gas—liquid chromatographic methods From the results 
presented, the possibility of measuring up to four samples (plasma or urine) per 
hour, with a sample size of only 0 5 ml, and a detection limit of a few 
nanograms, it appears that baclofen can be measured with adequate sensitivity 
and selectivity for pharmacokinetic purposes 
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We have previously developed a method for the determination of the skeletal 
muscle relaxant baclofen (Fig 1 ) in plasma and urine by reversed-phase high-
performance liquid chromatography (HPLC) with fluorimetrie detection [1] 
This assay required cation-exchange extraction, pre-column derivatisation with 
o-phthaldialdehyde (OPA) and on-column concentration Although many sam­
ples have since been measured in this way, a simpler method was needed in order 
to speed up the analysis A rapid HPLC assay for baclofen in plasma was devel­
oped by Harrison et al [ 2 ]. This paper describes a rapid reversed-phase HPLC 
method with UV detection for the determination of baclofen in urine With this 
method it is also possible to measure the γ -hydroxy metabolite of baclofen (Fig 
1 ) No separation of the enantiomers is obtained, however Recently, we pub­
lished some preliminary results of an enantioselective assay [3] 
EXPERIMENTAL 
Chemicals 
Baclofen and its ^-hydroxy metabolite (sodium salt) were kindly supplied by 
Ciba-Geigy (Basle, Switzerland) ^-Glucuronidase was obtained from Sigma (St 
Louis, MO, U S A ) Hydrochloric acid, sodium hydroxide, sodium acetate, acetic 
acid, methanol and tetrahydrofuran were of analytical reagent grade (Merck, 
Darmstadt, F R G ) and were used without further purification 
0378 4347/87/$03 50 © 1987 Eisevier Science Publishers В V 
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^N-C^-CH-C^-COOH HO-CH2-ÇH-CH2-COOH 
ii-iiiilno-3-lM:Mciroc»Knylt«Jtyrlc odd З-іо-спіогоИкл ІJ^tohydrOTVbulvrlc ncia 
baclofen OH-metabolite 
Fig. 1. Structures of baclofen and its -/-hydroxy metabolite. 
Apparatus 
A Model 9208 liquid Chromatograph ( Kipp Analytica, Delft, The Netherlands ) 
with a variable-wavelength detector (Schoeffel SF 770 Spectroflow, GM 770 
Monochromator; Kratos, Rotterdam, The Netherlands ) was used. The analytical 
column (25 cm χ 4.6 mm I.D.) was packed with Cp=Spher C8 reversed-phase 
material, particle size 8μιη (Chrompack, Middelburg, The Netherlands). A guard 
column ( 7.5 cm X 2.1 mm I.D. ) ( Chrompack ) was filled with pellicular reversed-
phase material (Chrompack). 
Procedure 
Urine samples were diluted 1:3 with water and subsequently introduced into 
the HPLC system by means of a loop (50 μΐ). The mobile phase consisted of 
methanol-tetrahydrofuran-sodium acetate (0.02 M) (10:5:85, v/v/v). The flow-
rate was 1 ml/min on average (pressure approximately 10 MPa). The substances 
were detected at 220 nm, and the peak heights were measured. 
Deglucuronidation of urine samples was performed in three ways: enzymati-
cally with ^-glucuronidase and hydrolytic with hydrochloric acid or sodium 
hydroxide. In the enzymatic procedure, urine (0.3 ml) was incubated for 18 h at 
370C with 25 μΐ of ^-glucuronidase (5000 U/ml) and 0.3 ml of a 0.2 M acetate 
buffer (pH 5.0). In the hydrolytic procedure, (a) urine (0.3 ml) was incubated 
for 2 h with 0.1 ml of 1 M hydrochloric acid at 95 0 C, then neutralised with 1 M 
sodium hydroxide, or (b) urine (0.3 ml) was incubated for 1 h with 0.1 ml of 1 
M sodium hydroxide at 50 ^ C, then neutralised with 1 M hydrochloric acid. 
Urine samples 
Baclofen was administered to dogs and human volunteers in different dosages. 
Urine was collected and stored at —20° С until analysis. More detailed results 
will be published elswhere. 
Dog experiment with the metabolite 
A female beagle dog of 11 kg body weight was anaesthetised with "pentobarbi­
tone sodium (30 mg/kg) and subsequently given 2 mg/kg γ -hydroxy metabolite 
as an intravenous (i.v. ) infusion in 3 h. Urine samples were collected by means 
of a catheter for the first 7 h and subsequently spontaneously voided urine was 
used. 
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Fig. 2. Chromatograms of baclofen and its y-hydroxy metabolite in urine, (a) Urine blank; (b) urine 
sample from a dog administered the у-hydroxy metabolite i.V., containing 150 mg/l y-hydroxy metab­
olite; (c) urine sample from a dog administered baclofen i.v. containing 84 mg/l baclofen; (d) urine 
spiked with 10.5 mg/l y-hydroxy metabolite and 11.0 mg/l baclofen. Peaks: 1 = metabolite; 2 = baclofen. 
RESULTS AND DISCUSSION 
Typical chromatograms of baclofen and its y-hydroxy metabolite are shown in 
Fig. 2. A blank dog urine did not show interfering substances ( Fig. 2a ). However, 
depending on the nature of the samples, small day-to-day variations in the mobile 
phase and flow-rate may be necessary. Urine samples from a dog after i.v. admin­
istration of baclofen (Fig. 2c) and after i.v. administration of its y-hydroxy 
metabolite (Fig. 2b) are shown. The detection limit in spiked urine was approx­
imately 50 ng for both baclofen and its metabolite. The capacity ratios (k') were 
3.5 and 4.5 for the metabolite and baclofen, respectively. For both substances 
calibration graphs of blank urine, spiked with 4.0-100 mg/l and measured after 
diluting 1:3 with water, showed good linearity between peak height and concen­
tration ( r2 > 0.99 ). The precision of the determinations in water and in urine 
was measured for three different concentrations within the same range ( η — 4 ). 
The coefficients of variation were always less than 4% for both baclofen and its 
metabolite. Comparison of the direct UV method with the o-phthaldialdehyde 
(OPA) fluorimetrie determination for baclofen showed a good correlation (Fig. 
3 ). The correlation coefficient ( r2 ) based on fourteen samples was 0.99. 
According to Faigle et al. [4], following the administration of 14C-labelled 
baclofen 80-90% of the 14C dose was excreted in the urine in the dog and in man. 
In man 90% of the total radioactivity was accounted for by the unchanged drug 
and 7% by 3-(p-chlorophenyl)-4-hydroxybutyricacid, the y-hydroxy metabolite 
( Fig. 1 ). In the dog these values were 63 and 8%, respectively. In our experiments 
with unlabelled baclofen the recovery of the unchanged drug in the urine was 
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Fig 4 Renal excretion rate-time profile of the y-hydroxy metabolite of baclofen, administered as the 
parent compound to a dog Dose 2 mg/kg as ι ν infusion % = percentage of the dose excreted unchanged 
in the urine 
61 
variable both in man and in the dog, with values ranging from 40 to 90% of the 
dose administered 
With the direct UV method the urine samples could also be screened for the 
presence of the y-hydroxy metabolite The earlier described OPA fluorimetrie 
method could not be used as the metabolite lacks an NH2 group, which is needed 
for derivatisation As theoretically the metabolite ( and also baclofen itself) could 
have been present as the corresponding glucuronide, the samples were analysed 
prior to and after enzymatic and hydrolytic deglucuromdation 
In urine samples from both dogs and human volunteers following 1 ν admin­
istration of baclofen, however, no metabolite was found Given the detection limit 
of the method, this means that in 48 h, depending on the urinary flow-rate, 2-10% 
of a dose at the most could have been present as the y-hydroxy metabolite, with­
out having been detected No glucuromdes were found Because of the urinary 
pH values ( 5-9 ) it is unlikely that the y-hydroxy metabolite in the urine samples 
analysed would have been present as the corresponding lactone, which is not 
detected with this method. 
When the y-hydroxy metabolite was administered to a dog as the parent com­
pound, 70% was recovered unchanged in the urine in 30 h (Fig 4) This means 
that the described assay is suitable for the measurement of the y-hydroxy com­
pound if present in sufficiently high concentrations Apparently, the incomplete 
mass balance of baclofen is mainly due to other causes 
With this simple reversed-phase HPLC method, baclofen can be measured in 
urine samples For low concentrations ( less than 4 mg/1 ), the more lengthy OPA 
fluorimetrie method should be used. The y-hydroxy metabolite can also be mea­
sured in urine by the direct UV method if present at concentrations higher than 
4 mg/1 For separation of the enantiomers other methods are required. 
REFERENCES 
1 E W Wuis, R J M Dirks, Τ В Vree and E van der Kleyn, J Chromatogr , 337 (19Θ5) 341 
2 Ρ M Harrison, AM Tonkin and A J McLean,,! Chromatogr , 3 id (1985) 424 
3 E W Wins, E W J Beneken Kolmer, L E С Van Beijsterveldt, R С M Burgers, Τ В Vree and 
E van der Kleyn, J Chromatogr . 415 (1987) 419 
4 J W Faigle, Η Keberle and Ρ Η Degen in R G Feldman, R R Young and W Ρ Koella (Edi 
tors ), Spasticity-Disordered Motor Control, Year Book Medical Publishers, Chicago, IL, 1980, 
ρ 461 
6? 
Chapter 4 
ENANTIOSELECTIVE HIGH-PERFORMANCE LIQUID CHROMATOGRAPHIC 
DETERMINATION OF BACLOFEN AFTER DERIVATIZATION WITH A CHIRAL 
ADDUCT OF o-PHTHALDIALDEHYDE 
Journal of Chromatography, 415 (1987) 419-422 
Biomedical Applications 
Elsevier Science Publishers B.V., Amsterdam — Printed in The Netherlands 
CHROMBIO. 3509 
Note 
Enantioselective high-performance liquid chromatographic 
determination of baclofen after derivatization with a chiral adduct of 
o-phthaldialdehyde 
E.W. WUIS*, E.W.J. BENEKEN KOLMER, L E С. VAN BEIJSTERVELDT, R.C.M 
BURGERS, T.B. VREE and E. VAN DER KLEYN 
Department of Clinical Pharmacy, St Radboud University Hospital, Geert Grooteplein Zuid 8, 
6525 GA Nijmegen (The Netherlands) 
(First received September 1st, 1986; revised manuscript received November 5th, 1986) 
Baclofen (4-amino-3-p-chlorophenylbutyric acid), a skeletal muscle relaxant 
used in the treatment of spastic disorders, is administered clinically as a racemic 
mixture. In animals, R( — )-baclofen (Fig. 1) is the more potent isomer respon­
sible for the GABAB-mimetic action [1-5]. S( + )-Baclofen interferes with the 
binding of R ( — ) -baclofen, and has been proposed to act as an antagonist at the 
GABAfl-receptors [6,7]. Pharmacokinetic properties of the separate enantio-
mers have not yet been described. To be able to examine the optical purity of 
baclofen preparations, a reliable analytical method is required, for pharmacoki­
netic purposes to be extended to measurements in biological fluids. 
Stereoselective analysis of a mixture of enantiomers is difficult. In high-per­
formance liquid chromatography ( HPLC ), separation is possible through the use 
of chiral eluents or chiral stationary phases or through derivatization with chiral 
reagents [ 8,9 ]. For optical resolution of the baclofen enantiomers for preparative 
purposes, Weatherby et al. [ 10] used a chiral mobile phase. This paper describes 
the first results of a modification of our recently developed assay for racemic 
baclofen, based on derivatization with o-phthaldialdehyde (OPA) in the pres­
ence of thiol compounds [11]. The optically inactive thioglycolic acid was sub­
stituted for N-acetyl-L-cysteine (NAC), a method originally developed for the 
optical resolution of amino acids [12,13]. 
EXPERIMENTAL 
Chemicals 
o-Phthaldialdehyde and N-acetyl-L-cysteine were obtained from Merck 
(Darmstadt, F.R.G.) and R.S-, R(-)- and S( + )-baclofen were a gift from Ciba-
0378-4347/87/$03.50 © 1987 Elsevier Science Publishers B.V. 
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Fig 1 Enantiomers of baclofen 
Geigy ( Basle, Switzerland ). Solutions were prepared in distilled water. All glass-
ware was rinsed with distilled water prior to use. All other chemicals were of 
analytical-reagent grade and were used without further purification 
Chromatographic system 
The chromatographic system was similar to that described previously [ 11 ] a 
reversed-phase system with on-column concentration and fluorimetrie detection 
(excitation at 340 nm, emission at 460 nm) The only differences were the ana-
lytical column (Chrompack Cp-Spher C8, 25 cm, Cat No. 28310) and solvent В 
[43-50% (v/v) methanol, 2 5% (v/v) tetrahydrofuran and 54 5-47 5% (v/v) 
phosphate buffer (pH 8 5)] 
Pre-column derwahzation procedure 
For the preparation of the OPA-NAC reagent, bone acid (0 62 g) and NAC 
il 12 g) were dissolved in 20 ml of water and adjusted to pH 10 4 with sodium 
hydroxide OPA (250 mg) dissolved in 3 ml of methanol was added and diluted 
with water to a final volume of 25 ml This solution was kept at 4 0 С and prepared 
freshly every week 
To 0 9 ml of a sample solution of baclofen containing 5-500 ng was added 0 2 
ml of OPA-NAC reagent and the mixture was allowed to stand for 25 mm at 80 " С 
The solution was then cooled in ice for 1 mm and 25 μΐ of 60 mM sodium acetate 
solution were added After mixing, 1 0 ml was taken for direct injection into the 
HPLC system 
RESULTS AND DISCUSSION 
Fig 2 shows chromatograms of the OPA-NAC derivatives of R( — ) - and S ( + ) -
baclofen A blank run did not show interfering substances ( Fig 2a) The detec­
tion limit is approximately 2 ng ( Fig 2c ) The fluorescent derivatives of R ( — ' -
and S( + )-baclofen have capacity ratios of 2 7 and 3 1, respectively, and a reso 
lution of 1 0 The calibration graphs for both derivatives showed good hnearitv 
between peak heights and concentrations m the range 20-200 ng per injection 
( r 2 > 0 99) The precision of the determination was measured for three different 
concentrations of each enantiomer ( 35, 90 and 205 ng/ml ) ( η = 4 ) and the coef­
ficients of variation were less than 4% 
Denvatization of baclofen with the OPA-NAC reagent was not as simple and 
rapid as described for a series of amino acids [ 12,13 ] If the same reaction con­
ditions were chosen as for the amino acids, following injection of racemic baclofen 
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Fig. 2. Chromatograms of OPA-NAC derivatives of R( — )-andS( + )-baclofen. The injected sample 
contained (a) 0 ng (blank), (b) 410 ngand (c) 4.0 ngof fi,S-baclofen. Peaks: 1 = fi( - )-baclofen; 
2 — S ( + ) -baclofen; 0 = unresolved reaction product. 
Fig. 3. Example of the OPA-NAC derivatization with baclofen as a function of reaction time at 80° С 
The injected sample contained 40 ng of fi,S-baclofen; the fluorescence was measured as peak height. 
· , Ж - ) -Baclofen; O, S( + ) -baclofen. 
three peaks were observed on the chromatogram that were not present in the 
blank sample. Under these conditions (3 min at room temperature ), peak 0 (Fig. 
2b ) had the highest fluorescent response, its stability being comparable to that 
of the previously described OPA-NAC primary amine derivatives, i.e., a decom­
position half-life of about 3 h at room temperature [ 12]. The other two compo­
nents on the chromatogram, corresponding to derivatives of Ä- ( — ) - and S- ( + ) -
baclofen (Fig. 2, peaks 1 and 2) gave a maximum response beyond a reaction 
time of 7 h at room temperature. At 80° С this time could be reduced to 25 min 
(Fig. 3), with reproducible results. 
The reaction mechanism is not clearly understood. An explanation could be 
the formation of 1,3-dithio-substituted isoindoles, due to autoxidation [14]. As 
all ΟΡΑ-derived isoindoles have limited stability depending on parameters not 
yet fully known, the reaction time and temperature should be kept constant 
[15,16]. 
Additional studies in biological fluids are currently being carried out. 
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SUMMARY 
A reversed phase high-performance liquid chromatographic method is described for the 
simultaneous determination of the skeletal muscle relaxant dantrolene and its metabolites, 
ñ-hydroxydantrolene and mtro-reduced acetylated dantrolene (F 490), in plasma and urine 
of man and dog The substances are detected spectrophotometrically at 375 nm The detec 
tion limits are 0 02 mg/1 A preliminary extraction step into a chloroform—butano! 
mixture is required for the plasma samples The method is suitable for pharmacokinetic 
studies of dantrolene 
INTRODUCTION 
Dantrolene sodium, l-{[5-(p-mtrophenyl)-furfurylidene]-ammo}-imidazol-
idine-2,4-dione sodium salt hydrate, first reported by Snyder et al. [1], is used 
as a skeletal muscle relaxant which appears to act by blocking muscle con-
traction beyond the neuromuscular junction [2—5] It is used for the symp-
tomatic relief of clinical spasticity resulting from serious disorders such as 
cerebral palsy, stroke, spinal cord injury, and multiple sclerosis [6—13]. More 
recently, it has also been recommended for the prevention and treatment of 
malignant hyperthermia, a syndrome recognized as one of the causes of an-
aesthesia-related deaths [14—16]. 
Metabolism of dantrolene (see Fig 1) has been shown to proceed through 
both reductive and non-reductive pathways [17]. The nitro group of dantrol-
ene is reduced to the corresponding amine, and in man and some animals 
subsequently acetylated to yield mtro-reduced acetylated dantrolene (F 490). 
0378 4347/82/0000—0000/$02 75 © 1982 Elsevier Scientific Publishing Company 
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dankoiene 
ni iro reduced 
dantrolene 
n i l r o reduced ocetylaled 
dantrolene (F490] 
Fig 1 Proposed metabolic scheme of dantrolene [18] 
Of these reduced metabolites, which do not possess muscle relaxant properties 
[18], only F 490 has been detected in human blood [17,19] and unne [17,20]. 
Oxidation of dantrolene results in 5-hydroxydantrolene [21], a metabolite 
with muscle relaxant effects, the activity is less than dantrolene on an equi-
molar basis [18]. This 5-hydroxy metabolite has been identified in human 
blood [17,19,20,22,23] and unne [17,20]. 
Several analytical methods have been developed for the determination of 
dantrolene in blood and unne, including spectrophotofluonmetry [24,25], 
differential pulse polarography [17], high-performance liquid chromatogra-
phy (HPLC) [26,27], and a qualitative colorimetrie procedure [28]. The 
fluonmetnc and Polarographie methods require complicated differential 
analytical techniques to measure the drug in the presence of its metabolites. 
Meyler et al [22], who used the fiuonmetnc procedure for plasma concen-
tration measurements in volunteers and patients, encountered a discrepancy 
in the method which was not further investigated. They found that the total 
fluorescence of an extract from plasma containing dantrolene and 5-hydroxy-
dantrolene (direct method) was considerably less than the fluorescence mea-
sured after the extract had passed through a Sephadex column and the two 
fractions containing 5-hydroxydantrolene and dantrolene, respectively, had 
been combmed (indirect method). 
The first reported HPLC procedure for dantrolene has the disadvantage 
of using a non-aqueous mobile phase [19,26]. In a short communication 
Hackett and Dusci [27] reported a reversed-phase HPLC procedure with, 
however, limited sensitivity and selectivity. Only dantrolene itself was mea-
sured, in concentrations down to 0.25 mg/1. To investigate the pharmaco-
kinetics of dantrolene in volunteers and patients a new reversed-phase HPLC 
procedure was developed which allows the measurement of the drug and its 
metabolites at levels as low as 0.02 mg/1. 
5 OH dantrolene |F563I 
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MATERIALS AND METHODS 
Reagents and chemicals 
All chemicals were of analytical grade. Three separate standard solutions 
were prepared in Ν,Ν-dimethylformamide containing 0.5, 0.5 and 0.3 mg/ml 
dantrolene sodium, 5-hydroxydantrolene, and nitro-reduced acetylated dantrol­
ene (F 490), respectively, (a gift from Eaton Laboratories, Norwich, NY, 
U.S.A.). Ultrasonic treatment was used to increase the rate of dissolution of 
F 490. The extraction fluid was chloroform-1-butanol (95:5, v/v). Phosphate 
buffer (pH 6.8) was 50% (v/v) of dibasic sodium phosphate ·2H 2 О solution 
(11.88 g/1) and 50% (v/v) of monobasic potassium phosphate solution (9.08 
g/1). The mobile phase was acetonitnle—phosphate buffer (pH 6.8) (33.3:66.6, 
v/v). 
Apparatus and chromatographic conditions 
A liquid Chromatograph (Kipp Analytica No. 9208) with a variable-wave­
length detector (Schoeffel Instruments; SF 770 Spectroflow, GM 770 Mono­
chromator), and a column packed with CP-Spher C
e
 (Chrompack, Middelburg, 
The Netherlands; Cat. No. 28502, particle size 8 μ m, 25 cm X 4.6 mm I.D.) 
was used. The flow-rate was 1.5 ml/mm (pressure approx. 5 MPa). Samples 
were introduced by means of a 50-μ1 loop. The substances were detected at 
375 nm, and the peak heights were measured. 
Plasma 
Calibration curve A mixture of the standard solutions was diluted with 
blank plasma (concentrations 0 02—4 mg/1). To 1 0 ml of each solution were 
added 0 5 g of ammonium sulfate and 4.0 ml of the extraction fluid. The 
solutions were shaken for 10 min in a rotary mixer (Cenco Instruments, Cat. 
No. 23426). After centnfugation for 10 mm at 2000 g (Heraeus Christ, type 
UJ1S), an aliquot of the lower layer was collected and evaporated to dryness 
in a hot (50 o C) water bath under nitrogen. The residue was mixed with 1.0 ml 
of the mobile phase on a vortex mixer and injected onto the column. A control 
with Ν,Ν-dimethylformamide in blank plasma was treated in the same manner. 
Samples. To 1.0 ml of plasma were added 0.5 g of ammonium sulfate and 
4.0 ml of the extraction fluid; this mixture was further treated as described 
for the calibration curve. 
Urine 
Calibration curve. A mixture of the standard solutions was diluted with 
blank urine and diluted further 1 in 10 with the mobile phase to final concen­
trations of 0.02—4 mg/1. These solutions were directly injected onto the 
column. A control with Ν,Ν-dimethylformamide in blank unne was treated 
in the same manner. 
Samples Urine samples of 100 μΐ were diluted 1 in 10 with the mobile 
phase and directly injected. 
Dog experiment 
A male beagle dog of 12 kg body weight was anaesthetized with pento-
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barbitene and subsequently given 12 mg of dantrolene sodium (dantnum) 
intravenously. Blood samples were collected at scheduled intervals Urine 
samples were collected by means of a catheter for the first 7 h, thereafter 
spontaneously voided urine was used. 
Recovery 
Solutions in urine, prepared as described under the calibration curve for 
urine, and extracts from water and plasma, using the procedure as described 
under Calibration curve for plasma, were compared to a direct assay of stan­
dards in the mobile phase. The recoveries were determined for three differ­
ent concentrations. 
Stability 
The standard solutions, which were kept protected from light at 40C, were 
periodically measured spectrophotometrically (Beekman spectrophotom­
eter, Model 3600), and by the described HPLC procedure. 
RESULTS 
A chromatogram of a plasma sample obtained from a patient treated with a 
daily oral dose of 5 mg/kg body weight dantrolene sodium is given in Fig. 2. 
3 
2 
^лі 
-~J 
1 
^ 
Fig 2 Liquid chromatogram of patient plasma containing 0.705 mg/1 dantrolene (3), 
0.624 mg/1 5-hydroxydantrolene (2), and 0 055 mg/l F 490 (1) 
Calibration curves in plasma and unne showed good linearity between peak 
heights and concentrations from 0.02 to 4.0 mg/1 (r2 = 0.999 for all sub­
stances). Chromatograms of blanks did not show any interfering substances 
at the detection wavelength of 375 nm. Retention times and capacity ratios 
are given in Table I. 
The detection limit of dantrolene and its metabolites was 1 ng, defined as 
three times the noise level. The precision of the determination was measured 
for two different concentrations; the coefficients of variation are given in 
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TABLE I 
RETENTION TIMES OF DANTROLENE AND ITS METABOLITES 
For chromatographic conditions, see text 
Substance Retention 
time (mm) 
Capacity 
ratio (ft ) 
Dantrolene 10 9 3 5 
5 Hydroxydantrolene 7 1 2 0 
F 490 4 1 0 7 
TABLE II 
COEFFICIENTS OF VARIATION 
For description of analytical procedure, see text 
Substance Plasma Urine 
Concentration Coefficient n* Concentration Coefficient 
(mg/l) of variation (mg/l) of variation 
(%) (%) 
Dantrolene 
5 Hydroxydantrolene 
F 490 
0 051 
1 63 
0 066 
2 13 
0 039 
1 24 
3 5 
3 9 
3 1 
4 3 
6 1 
3 9 
6 
5 
6 
5 
4 
5 
0 043 
1 30 
0 055 
1 68 
0 031 
1 07 
7 0 
5 7 
6 0 
6 3 
5 8 
6 3 
6 
6 
6 
6 
6 
6 
π = number of determinations 
TABLE III 
RECOVERIES OF DANTROLENE AND ITS METABOLITES 
For description of analytical procedure, see text 
Substance Recovery* (%) 
Water Plasma Urine 
(extracted) (extracted) 
Dantrolene 
5 Hydroxydantrolene 
F 490 
97 ± 4 
100+ 3 
101 + 4 
99 * 8 
86 ± 2 
8 9 * 4 
103 Í 7 
99 ± 1 
101 t 4 
*Means and standard deviations of three different concentrations (n = 3) dantrolene 3 25, 
0 406, and 0 051 mg/l, 5 hydroxydantrolene 4 20, 0 525, and 0 066 mg/l, F 490 2 68, 
0 335, and 0 042 mg/l 
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Table II. The results of the recovery experiments are mentioned in Table III. 
The standard solutions of all three substances did not show any deteriora­
tion for at least three months when kept at 4° С and when protected from 
light. Upon standing in light, however, F 490 deteriorates extremely quickly. 
On the chromatogram two peaks develop (Fig. 3). After 4 h at room temper­
ature only about 50—60% of the peak heights relative to a freshly prepared 
solution could be measured (Fig. 4). 
freshly 
prepared 
alter ¿.8 h 
standing in light 
Omin 
- ι 1 
0 mm 
Fig. 3. Liquid chromatograms of a solution containing F 490 (1), showing instability upon 
standing in light. 
Ю0· % 
0 1 2 
Fig. 4. Degradation of a solution containing F 490 upon standing in light. 
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Fig. 5. Plasma concentration and renal excretion rate profiles of dantrolene and 5-hydroxy-
dantrolene in a dog after intravenous administration of 1 mg/kg dantrolene sodium. 
Fig. 5 shows the plasma concentration and renal excretion rate profiles 
of dantrolene and 5-hydroxydantrolene in a dog after intravenous admin­
istration of 1 mg/kg body weight dantrolene sodium. No dantrolene is ex­
creted unchanged in dog urine. 
DISCUSSION 
The very low solubility of dantrolene and its metabolites in many solvents, 
including water, and the degradation by light, are complicating factors in the 
analysis. Dantrolene sodium is slightly soluble in water (15 mg/1), but it hydro-
lyzes quickly. The extremely insoluble (less than 1 mg/1) free acid dantrolene 
precipitates. The water solubilities of 5-hydroxydantrolene and F 490 are 
less than 10 mg/1 (Data Sheet, Eaton Laboratories). Protection from light 
during the whole procedure appears to be important, especially for F 490, 
which is very unstable upon standing in light (see Figs. 3 and 4). N,N-dimethyl-
formamide appeared to be a suitable solvent in preparing standard solutions. 
The solutions were stable for at least three months when kept protected from 
light at 4° C. No interference from this solvent was observed in the chromato­
graphic assay. 
Extraction of 1 ml of plasma with 4 ml of the chloroform—1 butanol 
(95:5) mixture yielded good recoveries. For the recovery of dantrolene from 
plasma (see Table III) a higher value than reported by Saxena et al. [26] was 
found; they used 80 ml of a chloroform—butanol (70:30) mixture. 
On the chromatogram, the peaks of parent drug and metabolites were well 
resolved (see Fig. 2). With the reversed-phase method of Hackett and Dusci 
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[27] a relatively poor resolution between dantrolene and 5-hydroxydantrol-
ene was obtained 
Slightly different chromatographic conditions may be needed for measure­
ments in unne samples because of interference by endogenous substances 
with low retention times 
At present only a few pharmacokinetic studies of dantrolene have been 
published Varying values for plasma concentrations and drug metabolite ratios 
have been reported Vallner et al [19] found dantrolene plasma concentra­
tions between 0 03 and 0 2 mg/1, with slightly higher values for the metab 
olites in patients on chronic oral therapy, with daily dosages ranging from 
50 to 200 mg However, Lietman et al [20] and Meyler [23] found plasma 
dantrolene concentrations of between 1 and 2 mg/1 in patients on daily dosages 
of 4—12 mg/kg and 200—400 mg, respectively, the concentration of the 5-
hydroxymetabolite appeared to be only 30—50% that of the parent com 
pound In a preliminary survey of patients on low dosages (0 7—5 mg/kg) we 
found large inter-individual differences in plasma concentrations and drug 
metabolite ratios, with plasma concentrations of 0 2—2 0 mg/1, 0 1—1 0 mg/1, 
and about 0 02 mg/1 for dantrolene, 5-hydroxydantrolene, and F 490, respec 
tively In the dog experiment dantrolene and 5-hydroxydantrolene could be 
detected in plasma up to 3 h after the intravenous dose The amount of 5-
hydroxydantrolene excreted in the unne accounted for less than 1% of the 
dose No dantrolene or F 490 could be detected in the unne 
The reported differences in the concentrations of the drug and of the metab 
olites have stimulated the investigation of the clinical pharmacokinetics of 
dantrolene. The described method provides adequate sensitivity and selectivity 
to make it applicable to pharmacokinetic studies 
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The direct-acting muscle relaxant dantrolene (Fig. 1) is used in patients 
with spasticity and also in humans and animals, including dogs at risk of ma­
lignant hyperthermia [1,2]. Although its efficacy is well established, knowl­
edge concerning the fate of this drug in the body is limited owing to the com­
plicated and extensive metabolism, which is also the case for the structurally 
related nitrofurans [3]. Known metabolic pathways for dantrolene are hy-
droxylation of the hydantoin ring and reduction of the nitro group, which may 
then be acetylated [1]. Many methods have been developed for the quantifi­
cation of dantrolene and its oxidized and reduced metabolites in plasma and 
urine, the latest by Lalande et al. [4], but when these are applied to pharma­
cokinetic studies, the major part of the mass balance is missing. A pilot study 
in the dog showed that less than 1% of the intravenously administered dose 
was excreted in the urine [5] and renal recovery in humans amounted to only 
15% [6]. Other pathways of elimination must exist to explain this incomplete 
recovery. 
ч
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Fig 1 Structures of dantrolene and its metabolite 5-(p-nitrophcnyl)-2 turoicacid (NPEA) 
0378-Ш7/9()/$0.1 50 (О 1990 Elsevier Science Publishers В V 
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Cleavage of the azomethine (-CH = N-) linkage is one pathway in need of 
further investigation. Analogously to nitrofurans [3,7], in vitro acidic hydrol­
ysis at body temperature has resulted in aldehyde formation [8], and the cor­
responding acid, 5-(p-nitrophenyl)-2-furoic acid (NPFA) (Fig. 1), has been 
identified in vivo (Norwich Eaton Pharmaceuticals, product information). This 
paper describes a modification of our previously developed assay for dantro­
lene [5 ], which allows quantification of NPFA in plasma and urine of humans 
and dogs. 
EXPERIMENTAL 
Reagents and chemicals 
All chemicals were of analytical grade. Norwich Eaton Pharmaceuticals 
(Norwich, NY, U.S.A.) kindly supplied NPFA. A stock solution (0.5 mg/ml) 
was prepared in Ν,Ν-dimethylformamide and kept in the dark at 4°C. Phos­
phate buffer (pH 6.8) was 50% (v/v) of dibasic sodium phosphate dihydrate 
solution (11.88 g/1) and 50% (v/v) of monobasic potassium phosphate solu­
tion (9.08 g/1). 
Apparatus and chromatographic conditions 
The HPLC system was similar to that previously described [5]. The mobile 
phase, acetonitrile-phosphate buffer (25:75, v/v for plasma, 20:80, v/v for 
urine), was used at room temperature at a flow-rate of 1.5 ml/min with a CP-
SpherCH column (25 cmX4.6 mm I.D., particle size 8μιη) (Chrompack, Mid­
delburg, The Netherlands). NPFA was detected at 354 nm. 
Procedure 
Plasma. To standard or unknown plasma ( 200 μΐ ) in a small glass centrifuge 
tube, 50 /il of 2 M hydrochloric acid and 1.4 ml of the extraction mixture, chlo-
roform-l-butanol (95:5, v/v) were added. After vortex-mixing for 60 s, the 
tubes were centrifuged at 2000 g for 5 min. An aliquot of the lower layer (1.0 
ml) was then collected and evaporated to dryness in a water-bath (37°C) un­
der nitrogen. The residue was reconstituted with 250 μΐ of the mobile phase 
and subsequently injected into the liquid Chromatograph (50-/il loop). 
Urine. Standard or unknown urine (200 /il) was mixed with 200 /il of the 
mobile phase and directly injected (50 /il). 
Calibration curves were constructed by plotting the concentrations against 
the peak heights. The calibration range was based on the expected concentra­
tions and established in the range 0.1-10 mg/1. 
Recovery experiments 
Samples containing four concentrations of the standard compound in plasma 
in the range 0.1-10 mg/1 were prepared in duplicate and treated as described 
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above. The percentage recovery was determined by comparing the heights of 
the peaks obtained with the heights obtained from standards that were diluted 
with mobile phase to identical concentrations and directly injected. 
Samplet, 
Dantrolene was administered to dogs and human volunteers in different dos­
ages. Dogs also received 5-hydroxydantrolene. Plasma and urine were collected 
and stored in the dark at —20° С until analysis. More details will be published 
elsewhere. 
Dog experiment with the metabolite 
A female Beagle dog with a body weight of 14 kg was anaesthetized with 
pentobarbitone and subsequently given 13 mg of NPFA by constant-rate in­
travenous infusion for 45 min. Serial 2-ml blood samples were collected in 
heparinized tubes at scheduled intervals. Urine samples were collected by means 
of a catheter for the first 7 h, and subsequently spontaneously voided speci­
mens were used. Urinary pH was measured in each sample. 
RESULTS AND DISCUSSION 
Typical chromatograms of NPFA in dog plasma and urine are shown in Figs. 
2 and 3. Neither the chromatograms of the drug-free specimens for the dog ( A ) 
nor those for the human volunteers contained any interfering substances. The 
concentration of NPFA in the spiked samples (B) was0.49mg/l (plasma) and 
0.57 mg/1 (urine). After intravenous administration of 5-hydroxydantrolene 
(3.9 mg/kg) the concentrations of NPFA in the samples shown (C) were 0.86 
mg/1 (plasma) and 0.84 mg/1 (urine). The detection limit of NPFA was ca. 1 
ng, defined as three times the noise level. The retention times (ÍR) were 3.4 
and 7.4 min for plasma and urine, respectively. Calibration graphs showed good 
linearity in the ranges mentioned (r'¿ always greater than 0.99). The precision 
6 о 6 0 6 mm 
Fig. 2 Chromatograms of ( A ) drug-free dog plasma, (B ) dog plasma spiked with 0.49 mg/1 NPFA, 
(C ) dog plasma sample taken after intravenous administration of 5-hydroxydantrolene (3 9 mg/ 
kg) containing 0 86 mg/1 NPFA. Peak 1 = NPFA 
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Fig 3 Chromalograms of (A) drug-free dog urine, (B) dog urine spiked with 0 .")" mg/1 NPFA. 
(0) dog urine sample taken after intravenous administration of 5-hydroxydantrolene Ci 9 mg/ 
kg) containing 0 84 mg/1 NPFA. Peak 1 = NPFA. 
of the determinations in plasma and urine, measured within the same ranges 
at three concentrations in quadruplicate, was within acceptable limits (coef­
ficients of variation always less than 7.6%). The mean ( ±S.D.) recovery for 
plasma was 83 ± 5 % . 
When dantrolene and its reduced and oxidized metabolites were introduced 
into this HPLC system, all compounds could be separated within ca. 30 min. 
Because of band broadening, however, low concentrations escaped detection. 
This implies that for pharmacokinetic purposes the method as such is inade­
quate to determine the five compounds simultaneously. Other refinements, 
such as gradient elution, might favour the sensitivity. 
In a preliminary survey of canine and human urine collected after adminis­
tration of dantrolene and 5-hydroxydantrolene, NPFA was found in low con­
centrations. Total urinary recovery of this metabolite accounted for a few per 
cent of the dose, contributing accordingly to the mass balance of dantrolene in 
humans and dogs. Since in vitro hydrolysis of the azomethine bond results in 
aldehyde formation, urine samples were also screened for the presence of 5- (p-
nitrophenyl) furfural. By increasing the concentration of acetonitrile in the 
mobile phase to 50%, the otherwise unchanged HPLC system could measure 
this compound (kindly supplied by Norwich Eaton Pharmaceuticals) in the 
spiked urine (t
n
 = 6.3 min). However, in neither human nor dog samples was 
the aldehyde detected. 
When the method described for plasma was followed, NPFA was not de­
tected in the human samples. In pilot studies with dantrolene and 5-hydroxy­
dantrolene administered as the parent drug in dogs, NPFA plasma concentra­
tions in excess of the parent drug were measured, indicating that this metabolic 
83 
100 
plasma cone mg/l renai хсг rate ufl/mln 
10 
О 1 
NPFA 
Ini 
X 
13 % 
θ 
t ime (h) 
io 12 
Fig 4 Plasma concentration-time curve and renal excretion rate- time profile of NPFA following 
its intravenous administration (0.9 mg/kg) in a dog. The infusion time (inf.) was 45 mm. 
X = unknown metabolite. 
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Fig 5 Chromatogram of dog urine sample taken after intravenous administration of NPFA (0.9 
mg/kg) containing.') 7 mg/1 NPFA Peaks. 1 = NPFA; 2 = unknown metabolite. 
pathway is important in the dog. The possibility that NPFA was formed in 
vitro following acidification of the plasma samples was ruled out by the absence 
of NPFA in standard solutions treated similarly. 
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The method described was also used in a metabolite kinetic experiment with 
NPFA administered as the parent drug in the dog. Fig. 4 shows the plasma 
concentration-time curve and the renal excretion rate-time profile of NPFA 
after its intravenous administration. The plasma curve shows non-linearity 
for the dose administered, with a terminal half-life of 1.4 h. When administered 
as the parent drug, the major excretory product found in the urine was un­
changed NPFA (58% of the dose). An unknown metabolite (Fig. 5), not pres­
ent in plasma, accounted for a further 13% recovery (calculated as NPFA). 
This unknown metabolite was absent in the samples obtained after dantrolene 
c.q. 5-hydroxydantrolene administration. Total body clearance (D/AUC) and 
apparent renal clearance (A
e
/AUC) of NPFA were 6.2 and 3.6 ml/min, re­
spectively, where D is the dose administered, AUG is the area under the plasma 
concentration-time curve, and A
e
 is the total amount excreted in the urine as 
NPFA. The apparent renal clearance of NPFA was dependent on the pH of 
the urine in the 5-7 range. This dependency may explain the unusual renal 
excretion rate-time course measured during the first 5 h of the experiment. 
In conclusion, we have developed an HPLC method that is applicable to 
pharmacokinetic studies of dantrolene, in particular to metabolite kinetic 
studies in the dog. 
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SECTION III 
PHARMACOKINETICS OF BACLOFEN 

Chapter 7 
COMPARISON OF THE PHARMACOKINETICS OF INTRAVENOUSLY ADMINISTERED 
rac-BACLOFEN AND ITS (-)-(R)- AND (+)-(S)-ENANTIOMERS IN DOGS 
COMPARTSON OF THE PHARMACOKINETICS OF DJTRAVENOUSLY ADMTNISTEREO rac-
BACLOFEN AND ITS (-) (R)-AND ( + )-(5)-ЕМАМТІШЕН5 IN DOGS1 
Wuis F.W., Dirks M.J.M. , Termond E.F.S. , Vree T.B., Van der Kleijn E. 
Department of Clinical Pharmacy, St. Radboud University Hospital, 
Nijmegen, The Netherlands. 
Summary 
Baclofen is a centrally acting muscle relaxant marketed as the 
racemate. Since only the (-)-(R)-enantiomer is pharmacologically 
active, the pharmacokinetics of rac-baclofen and its enantiomers were 
studied individually in the same group of dogs to determine if there 
was any stereospecificity in the drug's kinetics after a single 
intravenous dose. High-pressure liquid chromatography was used to 
determine concentrations in plasma and urine. A major difference was 
found in the urinary recovery of the unchanged drug. Only about 50% of 
the dose of the clinically used racemate appeared as unchanged drug in 
the urine; whereas the active (-)-(R)-isomer was for the most part 
renally excreted (85%). Irrespective of isomeric composition, the renal 
clearance was dependent upon the creatinine clearance. Differences in 
non-renal clearance could not be explained by stereoselective formation 
of the X-hydroxymetabolite. It is concluded that in the dog, the active 
enantiomer is also pharmacokinetically preferred. 
Introduction 
With the development of the centrally acting muscle relaxant baclofen 
(rac-4-amino-3-(p-chlorophenyl)-butanoic acid) in the late 1960s, a 
drug became available that was effective in the treatment of spasticity 
(1). Twenty years later, it is still one of the very few clinically 
used skeletal muscle relaxants for patients with this motor control 
disorder. It has also been shown to be of some value in the treatment 
1Int J Clin Pharm Res 1989; 10: 239-46. 
90 
of trigeminal neuralgia (2). Baclofen is a synthetic derivative of Sf-
aminobutync acid (GABA), a naturally occurring amino acid. With the 
introduction of the p-chlorophenyl substituent into the GABA-molecule, 
a centre of asymmetry is created (Fig. 1). Baclofen is marketed as the 
racemate, but only the (-)-(R)-enantiomer is stereospecifically active 
at so called GABA,,-receptors (3); ( + )-(S)-baclofen has antagonistic 
properties (4). It was found that in treating trigeminal neuralgia rac-
baclofen is five times less efficacious than (-)-(R)-baclofen (5). 
Because of this difference in pharmacological action, it is important 
to elucidate whether there is also a difference between the kinetic 
disposition of (-)-(R)- and (+)-(S)-baclofen in the body. For rac-
baclofen, renal excretion is the major route of elimination both in the 
dog and in man: 80-90% of the radioactivity was recovered in canine and 
human urine following oral or intravenous administration of the 're­
labelled drug (6). In the dog about 55% of the dose was excreted as un­
changed drug; in man it was up to 75%. Less than 10% could be attrib­
uted to a pharmacologically inactive Y-hydroxymetabolite (3-(p-chloro­
phenyl )-4-hydroxy-butanoic acid) (6). Reduced renal function has led to 
high baclofen plasma levels with signs of intoxication (7,8). Other 
pharmacokinetic information is scarce (man) or absent (dog), probably 
due to the lack of suitable analytical procedures (9-11). 
In the laboratory of the Department of Clinical Pharmacy, reversed-
phase high-performance liquid chromatographic (HPLC) methods have been 
developed for the determination of this drug and its metabolite in bio­
logical fluids (12,13). By means of these methods, the pharmacokinetics 
of rac-baclofen, (-) (R)-baclofen, and (+)-(S)-baclofen were compared 
in the same group of dogs. Dogs rather than human volunteers were cho 
sen because no data were available on the toxicity of (+)-(S)-baclofen, 
nor on (-)-(R)-bacloten when given as half of the racemic dose. 
,2C00H 
сн2соон 
H2h' ^ * 
R(-)- baclofen FIGURE 1 
The enantiomers of baclofen 
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Material and methods 
DRUGS 
rac Baclofen, (-)-(R)-baclofen hydrochloride, (+)-(S)-baclofen hydro-
chloride, and 3-(p-chlorophenyl)-4-hydroxy-butanoic acid (sodium salt) 
were kindly supplied by Ciba-Geigy (Basle, Switzerland). All other 
drugs were commercially available: pentobarbital sodium (Narcovet", 
Amerpho, Arnhem, Netherlands), mannitol, and sodium chloride solutions 
for injection (NPBI, Emmer Compascuum, Netherlands). Prior to adminis-
tration, the baclofen dosages were dissolved in 60 ml of normal saline 
solution. 
ANIMAL EXPERIMENTS 
Three male Beagle dogs, weighing 10-17 kg, were used. At the begin-
ning of each experiment the animals were anaesthesized with pentobarbi-
tal sodium (30 mg/kg). Small additional doses of the anaesthetic were 
given during the day to keep the dogs anaesthesized for 7 h. Venous 
catheters were inserted into a foreleg and into the ]ugular vein to 
collect blood for sampling and to administer the drugs. A continuous 
infusion with a solution containing 2% mannitol in normal saline solu-
tion was given to maintain an adequate urine flow. For the collection 
of urine samples, a bladder catheter was introduced. After seven hours 
each dog was placed inside a metabolic cage to collect the spontaneous-
ly voided urine. Thereafter blood samples were taken by veinpuncture. 
After an interval of approximately four weeks, the next experiment 
was performed. Each dog received rac-baclofen (2 mg/kg), (-)-(R)-baclo-
fen (1 mg/kg), and (+)-(S)-baclofen (1 mg/kg) except for dog 1 who died 
before (+)-(S)-baclofen was administered of a cause unrelated to baclo-
fen. The drugs were given by constant rate intravenous infusion for 3 
h; the flow rate was 0.33 ml/min. 
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SAMPLING PROCEDURES 
Blood samples of 2-3 ml were drawn at predetermined intervals for a 
total period of 25 h and collected in hepanmzed tubes. After centnf-
ugation at 1500 g, plasma was stored at -20"C until analysis. Urine was 
collected quantitatively at regular intervals (approximately 30 m m ) 
during the period of anaesthesia. Care was taken to ensure that the 
bladder was empty at the end of each collection period. In the metabol­
ic cages, spontaneously voided urine was collected quantitatively. The 
total urine collection period was 50 h. Samples of 10 ml were stored at 
-20"C until analysis. Urinary pH was measured in each sample. 
ANALYSIS OF PLASMA AND URINE 
Baclofen was measured in plasma and urine by HPLC after denvatiza-
tion with o-phthaldialdehyde followed by fluorimetrie detection, as 
previously described (12). With this method the detection limit in 
plasma is 0.02 mg/1. In a number of urine samples baclofen was deter­
mined with the more rapid direct-ultraviolet method which simultaneous­
ly measures the ^-hydroxymetabolite; the detection limit of both com­
pounds is 4 mg/l (13). Plasma protein binding was measured in a number 
of samples by filtration through EMIT1* free level filters (Syva, Palo 
Alto, USA). No aspecific drug binding to these filters was found. Cre­
atinine was measured throughout each experiment both in plasma and u-
nne by an automated Jaffa method. 
PHARMACOKINETIC ANALYSIS 
Elimination half-lives (tj) were determined by linear regression a-
nalysis of the terminal parts of the log plasma concentration versus 
time curves. For the calculation of the area under the curve (AUC), the 
linear trapezoidal rule with extrapolation to infinity was applied. To­
tal body clearance (CD and apparent volume of distribution (V,) were 
calculated according to CL = D/AUC (D being dose administered), and V^ 
= CL.t4/0.693. The system moment parameter mean residence time (MRT) 
was estimated by MRT = AUMC/AUC - 0.5T, in which AUMC is the area under 
the first moment of the drug concentration versus time curve and Τ the 
infusion time (14). 
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The apparent renal clearances (CLK) were calculated in two ways An 
overall value of CLR was obtained by CL« = ft CL, in which fc is the 
fraction of the dose excreted unchanged into the urine. The mean CL,, 
values with standard deviation were computed from the renal excretion 
rate in each urine sample divided by the plasma concentration at the 
nud-point of the measured time interval allowing for fluctuations in 
the renal clearance within a dog. In the same way, mean values with 
standard deviation of the creatinine clearances (CLt„) were obtained. 
The non-renal clearance (CL,™) was calculated by subtracting the over-
all renal clearance from the total body clearance. 
Data are expressed as mean + s.d. 
Results 
raC-BACLCMEN 
Figure 7a shows the plasma concentration time curve and the renal ex-
cretion rate-time profile of rac-baclofen in a Beagle dog after a sin-
gle intravenous infusion of 2 mg/kg. The half-life in this dog was 3.8 
h, and 53.2% of the dose was excreted unchanged into the urine. Mean 
values of these parameters for the three dogs were 3.7(+0.3) h and 47.7 
(+6.7)%, respectively. No metabolite was found in the urine. The aver-
age plasma protein binding was 35(+ll)%. Values of the pharmacokinetic 
parameters are further presented in Table I. Mean values of the clear-
ance in ml.mm ' were: CL 32.1(+5.7), CL„ 15.5(+3.7), CLC-R 23(+6), and 
C U H 16.71 + 1.6). 
The individual mean values of the renal parameters for each dog are 
listed in Table II. In this table, data of the postinfusion period are 
presented up to the time that a fixed sampling schedule was no longer 
feasible. A linear correlation was observed between the renal clearance 
of rac-baclofen and the creatinine clearance, their values being not 
significantly different (paired t-test). The renal clearance of rac-
baclofen was independent of urine pH and flow. 
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TABLE I 
Pharraacckinetic parameters of baclofen in dcgs after intravenous infusion of 2 mg/kg rac-baclcfen, 1 mg/kg 
M-(R)-baclcfen, and 1 mg/kg < + MS)-baclcfen 
Dcg Exp. Body wt. tè AUC V* MRT fe CL CIH- CLcH** CLNB 
(kg! (h) (mg.h.l-1! (l.kg-1) (h) 
(ml.min-1.kg-1! 
1 rac 11.7 3.9 1C.3 1.C6 4.51 0.498 3.10 1.54 2.5 1.56 
2 rac 10.4 3.4 11.6 0.79 3.83 0.402 2.70 1.09 1.6 1.61 
3 rac 16.0 3.8 16.7 0.66 4.04 0.532 2.00 1.07 1.4 0.94 
mean 3.7 12.9 0.83 4.13 0.477 2.60 1.23 1.8 1.37 
+ s.d. 0.3 3.4 0.20 0.35 0.067 0.56 0.27 0.6 0.38 
1 (-HR) 11.8 4.3 7.60 0.81 5.75 0.875 2.19 1.92 1.6 0.27 
2 (-HR) 10.6 4.1 4.60 1.33 3.86 0.849 3.74 3.17 4.8 С.57 
3 (-HR) 17.3 4.5 7.83 0.80 4.27 0.821 2.04 1.67 2.8 0.36 
mean 4.3 6.68 С.98 4.63 0.848 2.65 2.25 3.1 0.40 
+ s.d. 0.2 1.80 0.31 0.99 0.027 0.94 0.81 1.6 0.15 
2 ( + HS) 10.5 2.6 3.64 1.10 2.87 0.681 4.95 3.37 4.0 1.58 
3 ( + HS) 15.5 2.9 5.72 0.80 3.22 0.419 3.17 1.33 2.3 1.84 
CLR = f
e
.CL; " C L C H = t o t a l mean value. 
( )-(R)-BACLOFEN 
Figure 2b shows the pharmacokinetic profile of (-)-(R)-baclofen in 
the same Beagle dog after a single intravenous infusion of 1 mg/kg. The 
half-life was 4.5 h, and it was for the greater part (82.1%) excreted 
unchanged into the urine. Mean values of these parameters for the three 
dogs were 4.3(+0.2) h and 84.8(+2./)%, respectively. No metabolite was 
found in the urine. The average plasma protein binding was 18(+11)%. 
The pharmacokinetic parameters are further presented in Table I. Mean 
values of the clearances in ml.mm 1 were: CL 33.6(+7.0), CL H 28.4( + 
5.5), CLtI< 39 (±18), and Q ™ , 5.17(+1.68). 
The individual mean values for each dog of CLr>, CL^r,, urine flow, and 
urine pH listed in Table II were obtained in the same way as described 
under rac-baclofen. In all three dogs a linear correlation was found 
between the CL R of (-)-(R)-baclofen and the CU.к. In two dogs the renal 
clearances were not significantly different from the CLC„ (paired t-
test), in one dog the CLR was slightly lower. No correlation between vi­
rine flow or pH and the CL R of (-)-(R)-baclofen was discerned. 
(+)-(S)-BACLOFEN 
The pharmacokinetic profile of (+)-(S)-baclofen in the same Beagle 
dog after a single intravenous infusion of 1 mg/kg is given in Fig. 2c. 
The half-life of (+)-(S) baclofen in this dog was 2.9 h, while only 
41.9% of the dose was found excreted in the urine. In Table I, the same 
parameters for the other dog are presented. As only two dogs remained 
for the experiment with the (+)-(S)-isomer, no mean values are given. 
No metabolite was found in the urine. The average plasma protein bind­
ing was 23(+l2)%. Values for the other pharmacokinetic parameters are 
listed in Table I. 
The renal parameters are summarized in Table II. A linear correlation 
was found between the CL R of (+)-(S)-baclofen and the CL C H. In one dog 
the CUR was slightly lower, in the other dog slightly higher than the 
renal clearance of (+)-(S)-baclofen. Only with urinary flow rates below 
0.2 ml.min 1, did the creatinine clearance as well as the renal clear­
ance of (+)-(S)-baclofen become flow dependent. The CL R of (+)-(S)-
baclofen was independent of pH. 
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PHARMACOKINETIC DlFbbRENCES BETWEEN rac , (-)-(R)-, AND (+)-(S)-BACLO 
FEN 
The fraction of the dose excreted unchanged into the urine was nearly 
twice as large for (-)-(R)-baclofen as for the racemic mixture. The 
non-renal clearance of rac-baclofen was nearly 3 5 times that of the 
(-)-(R)-enantiomer. The half life of ( ) (R)-baclofen was slightly 
longer than that of rac baclofen. As this last parameter is calculated 
from plasma concentration data approaching the detection limit of the 
assay, the relevance of this finding is limited. No other significant 
differences were found between rac-baclofen's and (-)-(R)-baclofen's 
kinetic parameters as listed in Table I. When the pharmacokinetic be­
haviour of {+)-(S)-baclofen and (-)-(R)-baclofen is directly compared, 
the difference in non-renal clearance is the most striking finding. The 
three- to five-fold higher CL N U value of (+)-(S)-baclofen deserves fur 
ther study. 
TABLE II 
Values of the parameters characterizing the renal handling of baclofen 
in dogs calculated from postinfusion data (3.5-7h) 
Dog Experiment CL
n
* СЬ<_к Urine flow Urine pH 
(ml min 1) 
1 rac-baclofen 2 6 + 3 2 8 + 4 0 . 3 9 + 0 . 0 8 8 . 7 + 0 . 3 
? rac-baclofen 1 7 + 1 0 1 5 + 8 0.24 + 0.16 8.8 + 0.1 
3 rac baclofen 1 6 + 9 2 1 + 1 1 0.67 + 0.24 8.9 + 0.2 
1 (-)-(R)-baclOfen 1 4 + 5 15 + 5 0.41 + 0.25 8.2 + 0.3 
2 (-)-(R) baclofen 4 4 + 6 4 5 + 4 0.35 + 0.15 5.4 + 0.2 
3 (-)-(R)-baclofen 3 4 + 7 4 9 + 9 0.81 + 0.38 7.1 + 0.3 
2 (+)-(S)-baclofen 47 +17 40 + 16 0.12 + 0.06 6.0 + 0.5 
3 (+)-(S)-baclofen 2 3 + 5 3 0 + 4 0.23 + 0.08 8.9 + 0.3 
Data are mean +s.d. 
*CLr, = renal excretion rate/plasma concentration. 
98 
Discussion 
In agreement with previous studies (6), about 50% of a dose following 
intravenous administration of rac-baclofen appeared as unchanged drug 
in the urine of dogs. When only the pharmacologically active ( )-(R)-
enantiomer was administered, the drug was for the most part renally ex­
creted unchanged (85%), provided chiral inversion did not occur (19). 
The Y hydroxymetabolite was never detected which does not mean that a 
small percentage (2-10%) could not have been present considering the 
detection limit of the assay (13). Taking into account the earlier men­
tioned study with the '"C-labelled drug in which approximately 90% of 
total activity was renally recovered with less than 10% in the form of 
the /-hydroxymetabolite (6), the mass balance of (-) (R) baclofen is 
almost complete. 
The difference in renal excretion cannot be explained as just differ­
ences in renal clearance. Although the mean overall renal clearance of 
the (-)-(R)-enantiomer was higher than that of the racemate, so was the 
creatinine clearance. When the data of the experiment with (+)-(S) 
baclofen are also considered, it can be seen that the overall renal 
clearances of both enantiomers are practically equal (Table I). No mat­
ter which of the three drugs was administered, the renal clearance was 
always dependent upon and not very different from the creatinine clear­
ance, at least during the postinfusion period while the dog was under 
anaesthesia (Table II). As glomerular filtration is a passive process 
and the differences in unbound baclofen plasma concentrations were 
small, it is not surprising that this dependency is not stereoselec­
tive. Similar renal elimination kinetics have been found for the GABA-
denvative vigabatnn (rac У-vinyl-GABA) : namely, equal renal clear­
ances of the enantiomers with equal dependency upon the creatinine 
clearance, and unequal recovery of unchanged drug m the urine (15, 
16). 
A clear correlation does not exist between the renal clearance and 
the parameters for passive tubular reabsorption, urine pH and urine 
flow, for racemic baclofen or for the separate stereoisomers. Only at 
very low flow rates did the renal clearance (and the creatinine clear­
ance) become flow dependent. It is not known whether active transport 
processes, which are more likely to show enantiomeric differences, play 
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a role in the renal elimination of baclofen. As an organic zwitterion, 
baclofen could be a substrate for the organic anion (inhibited by pro-
benecid) and cation (inhibited by Cimetidine) tubular secretion systems 
(17). As a derivative of an endogenous amino acid baclofen could be ac-
tively reabsorbed in the proximal tubule (18). Stereospecificity m 
renal transport of amino acids does exist; for organic cations it is 
likely; for organic anions it is urúmoun. Preliminary results of exper-
iments with probenecid were not conclusive about the organic anion se-
cretory pathway for baclofen due to large differences in creatinine 
clearance. 
Stereoselective metabolic clearance has been described for a number 
of drugs (19). 3-Blocking agents and non-steroidal anti-inflammatory 
drugs are being investigated more and more frequently in this respect. 
It has been found that oxidation and glucuromdation are among the 
metabolic pathways that can be enantioselective. Stereoselective oxida-
tive desamination was recently reported for primaquine (20). Also for 
the earlier mentioned drug vigabatrin, a marked difference in the non-
renal clearance of its enantiomers could be calculated from the data 
presented (15). 'fhe difference in the non-renal clearance of the enan-
tiomers of baclofen cannot be ascribed to stereoselective oxidative 
desamination resulting in formation of the У-hydroxymetabolite, as 
this metabolite was not found in the urine. Stereoselective glucurom­
dation is also highly unlikely, as no glucuromdes were found with the 
earlier described deglucuromdation procedures (13). The present find­
ings suggest the existence of still unknown stereoselective metabolic 
pathways for baclofen in the dog 
The pharmacologically active (-)-(R) enantiomer of baclofen is also 
kinetically preferred as it is for the most part renally excreted as 
the unchanged drug (21). As enantioselective pathways can be species 
dependent (22), this study should be repeated in man. The first results 
of a very recently published study on enantioselective determination of 
baclofen in human urine did show a R/S ratio in favour of the active i-
somer following administration of the racemate (23). 
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Chapter 8 
PLASMA AND URINARY EXCRETION KINETICS OF ORAL BACLOFEN IN 
HEALTHY SUBJECTS 
PLASMA AND URXNARY EXCRETION KINETICS OF ORALLY А1М1ШSTEREO BACLOFEN 
IN HEALTHY SUBJECTS' 
E.W. Wuis, M.J.M. Dirks, E.F.S. Termond, T.B. Vree, and E. Van der 
Kleijn 
Department of Clinical Pharmacy, St. Radboud University Hospital, 
Nijmegen, The Netherlands 
Summary 
Baclofen, a centrally acting muscle relaxant, is used in the 
treatment of spasticity. Its pharmacokinetics has been derived from 
plasma and urine data in four healthy subjects, whose renal function 
was simultaneously measured. 
After oral administration of a single 40 mg dose, baclofen was mainly 
excreted unchanged by the kidney, 69 (14) %. The half-life, calculated 
from extended least squares modelling (ELSMOS) both of plasma and urine 
data was 6.80 (0.68) h, which is longer than reported in most studies 
based solely on plasma data. 
The renal excretion rate constant had the high mean value of 0.35 
(0.24) h ' , and the apparent renal clearance of baclofen equalled the 
creatinine clearance. Passive tubular reabsorption is relatively 
unimportant, since no dependence was observed on variables urinary flow 
or pH. 
Although active tubular secretion may contribute to its renal 
clearance, as shown by the effect of co-administration of probenecid, 
glomerular filtration appears to be the dominant transport mechanism. 
Key words: baclofen; renal function, healthy subjects, 
pharmacokinetics, probenecid, tubular secretion 
^ur J Clin Pharmacol 1989; 37: 181-4. 
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Baclofen (гас 3-[p-chlorophenyl]-GABA), a centrally acting muscle re 
laxant, is used in the management of patients with spastic disorders 
[1]. In 1972 Faigle and Keberle [2] first described the disposition of 
'"C-baclofen after a single oral dose in man; 80% of the radioactivity 
was recovered in urine, mainly as unchanged drug. In a more recent re­
port, 60% of a dose of baclofen was excreted unchanged by the kidney, 
with a mean overall renal clearance of 100 ml.min 1 [3]. In a study in 
dogs, the renal clearance of baclofen was found to approximate the cre­
atinine clearance [4]. 
The elucidation of the renal elimination mechanism for baclofen is 
important because patients with diminished renal function may develop 
baclofen toxicity, which is manifested by hypothermia, bradycardia, hy 
potension, blurred vision, mental changes, myoclonus, or abnormal EEG 
patterns [5-7]. In elderly patients with lower creatinine clearance duo 
to their age, an unacceptably high level of drowsiness occurred with 
relatively low doses of the drug [8]. Therefore the pharmacokinetics of 
baclofen has been studied, as derived both from plasma and urine data 
in healthy subjects, whose renal function was simultaneously measured. 
Materials and methods 
Tablets containing rac-baclofen 10 mg were obtained commercially 
(Lioresal", Ciba-Geigy). Probenecid was obtained as 500 mg tablets 
(BenemidR, Merck Sharp & Dohme). 
STUDY DESIGN 
The subjects were four healthy Caucasian volunteers (1 male and 3 fe­
males), ranging from 25 to 42 years, and with a mean (SD) body weight 
of 69 (9) kg. They had agreed to participate in the study. The subjects 
did not take any other medication. Each subject received a single oral 
dose of 40 mg baclofen after a standard breakfast. Serial 1-2 ml blood 
samples obtained by fingertip puncture were collected in heparimsed 
tubes at predetermined intervals for a total period of 24 h. Plasma was 
separated by centrifugation (1500 g) and stored at -20oC until ana­
lysed. Urine was collected by spontaneous voiding for 50 h The total 
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volume and pH of each specimen was measured and 10-ml samples were 
stored at -20oC until analysed. 
In two subjects, the experiment was repeated with probenecid 0.5 g to 
a total dose of 3 g as co-medication. 
ANALYSIS OF PLASMA AND URINE 
rac-Baclofen in plasma and urine was measured by HPLC with fluorime-
trie detection [9]. High urinary baclofen concentrations were deter-
mined by the rapid direct-UV method [10]. Plasma protein binding in a 
number of plasma samples was measured by filtration through EMIT Free 
level filters (Syva, Palo Alto CA, USA). No nonspecific binding to the 
filters was found. Plasma probenecid concentrations (Cf,,oft) were deter-
mined by HPLC [11]. Creatinine both in plasma and urine was measured by 
an automated Jaffa method. 
PHARMACOKINETIC AND STATISTICAL ANALYSIS 
Combined plasma and urine data were used for compartmental analysis 
according to the model shown in Fig.l. Curve fitting and calculation of 
the rate constants were done with an extended least squares modelling 
system (ELSMOS), which automatically weights the data [12]. The first 
order rate constants are defined as: k1¿ and kzi are the transfer rate 
constants from the central (1) to the peripheral (2) compartment and 
vice versa, к
л
 is the absorption rate constant, ke and k
r e B are the 
corresponding rate constants for unchanged drug appearing in the urine 
and the remaining processes. The other parameters obtained are the vol­
ume of the central compartment (V
c
/f), the disposition rate constants 
A i and A , , and their corresponding half-lives Й Д І and tj. 
FIGURE 1 
Schematic representation of the 
pharmacokinetic model used to 
calculate the rate constants 
. Kv I 1 "Я ι— 
Tes. 
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Apparent renal clearance (CLK) values were computed from the renal 
excretion rate in each urine sample divided by the plasma concentration 
at the mid-point of the measured interval. Creatinine clearances (CL,,,) 
were similarly obtained. 
Data are expressed as mean (SD). Statistical significance was tested 
by t-tests, paired if appropriate; ρ < 0.05 was taken to indicate sig 
mficance. 
10.00 -, 
1.00 
0.10 
0.01 
cone (mg/l) 
excr rate (mg/h) 
f\ 
* ·» 1 \ 
¡ \ N 
i 4 
ν N 
V 4 * N S V A 4 N ^ \ N. \ ^ Δ 
\ 
1 V л ^ ^ A \ . ^ 1
 V ^ 
\ 4 V ^ X . ЛЧ. ^ ^ 
\ . 
\ . \ * \ . ν » . 
\ ^ * 
^ \ 1 '/2 6.5 h 
10 20 30 40 time 50h 
FIGURE 2 
Plasma concentration-time ( ) and renal excretion rate-time (—) 
curves of baclofen in a healthy subject after a single oral dose of 40 
mg. ELSMOS-computed curves from combined plasma and urine data fitted 
to the model shown in Fig.l. * = measured plasma concentration, Δ = 
'vertical' mid point of the measured renal excretion rate interval 
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Results 
The fitted plasma concentration-time and renal excretion rate-time 
curves of baclofen in a healthy subject after a single oral dose of 40 
mg are shown in Fig.2; the computed half-life in this subject was 6.48 
h. Similar profiles were found in the other subjects. Individual values 
of all the calculated pharmacolunetic parameters are given in Table 1. 
The average plasma protein binding was 31 (11) %. The apparent renal 
clearance of baclofen was high and was found to equal the creatinine 
clearance (p > 0.05). Individual mean values of renal function for each 
subject are listed in Table 2. CLH was independent of urine pH and 
flow. The average recovery of unchanged drug in the urine was 69 (14)%. 
The results of the experiments with probenecid are illustrated in 
Fig.3. In both subjects the apparent renal clearance of baclofen after 
probenecid was significantly lower (p < 0.001) than m its absence (Ta­
ble 2). However, the creatinine clearance was also lower in the expen-
TABLE 1 
Pharmacokinetic parameters of baclofen in healthy subjects derived from 
combined plasma and urine data after a single 40 mg oral dose 
Parameter Subject Mean (SD) 
1 2 3 4 
k 1 7 
κ71 
k
e 
K
r e s 
k„ 
V
c
/f 
A. 
λ -
tis? А г 
tl/p 
(h-M 
(h M 
(h-1) 
(h M 
(h M 
(1) 
(h M 
(h M 
(h) 
(h) 
0.073 
0.118 
0.340 
0.107 
0.618 
27.5 
0.541 
0.097 
1.28 
7.12 
0.194 
0.177 
0.148 
0.154 
0.677 
58.5 
0.581 
0.092 
1.19 
7.56 
0.125 
0.188 
0.222 
0.092 
2.09 
35.0 
0.512 
0.115 
1.35 
6.02 
0.440 
0.171 
0.692 
0.152 
0.339 
14.4 
1.35 
0.107 
0.514 
6.48 
0.208 
0.163 
0.351 
0.126 
0.932 
33.9 
0.745 
0.103 
1.09 
6.80 
(0.162) 
(0.031) 
(0.241) 
(0.031) 
(0.788) 
(18.5) 
(0.403) 
(0.010) 
(0.39) 
(0.68) 
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ments with probenecid. In Subject 3 CL,, was not significantly different 
from CLCI, (p > 0.50) irrespective of the presence or absence of pro­
benecid. In the other subject (4), CL R was significantly lower than 
CL,.!, (p < 0.001) in the presence of probenecid. 
40 
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FIGURE 3 
Relationship between the renal excretion rate and the plasma 
concentration of baclofen m two subjects. The lines represent mean 
CLCR values, with ( — ) and without ( ) probenecid, the markers are 
calculated CL H values of individual samples. Note that in one subject 
(upper) the markedly reduced creatinine clearance in the experiment 
with probenecid may explain the reduction m the renal clearance; in 
the other subject (lower) active tubular secretion appears to 
contribute to glomerular filtration 
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TABLE 2 
Renal handling cf baclofen in healthy subjects 
Subject 
1 
2 
3 
4 
3 
4 
Exp 
b 
b 
b 
b 
b+p 
b+p 
ί-
Ο.756 
0.498 
С.661 
0.832 
0.627 
0.539 
CLB 
133 
147 
142 
170 
101 
90 
(49! 
(18) 
( Ш 
(9) 
(14) 
(17) 
CL C H 
(ml.min-1) 
137 (30) 
150 (16) 
152 (22! 
159 (19) 
99 (12) 
140 (16! 
Urine flew 
1.8 
1.6 
0.8 
C.8 
3.1 
1.6 
(0.4) 
(0.4! 
(0.4) 
(0.2) 
(1.7) 
(0.8) 
Urine pH 
5.3 
5.6 
6.0 
5.4 
7.6 
5.9 
(0.5! 
(0.3) 
(1.1! 
(0.9) 
(0.8) 
(0.7) 
Cprob 
(ing.l-1) 
104 (25) 
69 (18) 
calculated from data beyond 4 h following drug intake, except f
e
; f
e
 = fraction cf dose excreted 
unchanged in urine; b = baclofen, ρ = probenecid. 
Discussion 
The present data confirm earlier studies [2,3,13-15] showing that re­
nal excretion is an important pathway in the elimination of baclofen 
from the human body. The rate of renal excretion was fast and it gov­
erned the elimination process in three of the four subjects studied. In 
Subject 4, who had the highest k,,, the urinary mass balance could be 
considered to be complete as the missing part was expected to be pres­
ent in the faeces. In the other subjects, there must have been further 
pathways of elimination, such as biotransformation to the y-hydroxyme-
tabolite [2], although this substance was not detected. In these sub­
jects incomplete absorption is an unlikely explanation for the smaller 
amount recovered in urine, since almost no difference has been found in 
the urinary recovery of total radioactivity after intravenous or oral 
administration of baclofen [13]. 
The urinary excretion curve clearly shows a final elimination phase, 
which was much more difficult to discern in data obtained solely from 
plasma measurements. This observation may, at least in part, explain 
the earlier reported variation in the half-life of baclofen, since the 
beginning of the final elimination phase happens to coincide with the 
detection limit of the assay in plasma. From the combined plasma and u-
rine data, a longer mean half-life (6.8 h) was calculated than that 
previously calculated just from plasma concentrations (average 2.0 to 
4.4 h depending upon the study) [3,8,16]. Only Krauss [17] reported a 
similar, prolonged half-life of 6.9 h following 20 mg p.о. The mean 
value she calculated for tjД, (0.95 h) also agrees with the value 
found in the present study. The method of computing employed here may 
explain why k^ was found to be only half the value she presented. Since 
primary interest lay in the elimination of baclofen, no attempt was 
made to correct for the delay caused by the inclusion of urine data. 
As observed in the previous experiments in dogs, the apparent renal 
clearance of baclofen was found to be equal to the creatinine clear­
ance. It is anticipated that, like the findings in dogs, the depend­
ence upon the glomerular filtration rate (GFR) will not be stereoselec­
tive, provided that the difference between the unbound plasma concen­
trations of the baclofen enantiomers is just as small. Since none of 
the subjects showed dependence of kinetics on urine flow or pH, it is 
ill 
expected that passive tubular reabsorpLion is a relatively unimportant 
process. Taking into account the fact that the creatinine clearance 
slightly overestimates the GfR in healthy subjects [18], and that ap 
proximately 30% of baclofen is bound to plasma proteins, the intrinsic 
renal clearance of baclofen might be higher than the GFR, suggesting 
active secretion in addition to passive filtration. The reduced renal 
clearance found in the presence of probenecid seems to support this hy­
pothesis, but the differences seen in the creatinine clearance are a 
complicating factor. The influence of probenecid is clearly seen in the 
complete urine mass balance for Subject 4 (Fig.3, lower graph): the re­
nal clearance was reduced, both in comparison to its value without pro­
benecid and relative to the creatinine clearance m the same experi­
ment. In Subject 3, on the other hand, the markedly reduced creatinine 
clearance in the experiment with probenecid may explain the lowered re­
nal clearance of baclofen. Apparently the contribution of filtration to 
the clearance process was of major importance, and masked other poten­
tial secretory pathways in this subject, whose renal excretion alone 
could not totally account for the elimination of baclofen. Incomplete 
administration of probenecid was ruled out by serial measurements of 
its plasma concentration (Table 2) [11]. 
The present study demonstrates that urinary excretion rate data aid 
in understanding the pharmacokinetics of baclofen in man. It was found 
that although the mechanism of urinary excretion may be more complicat 
ed than just glomerular filtration, there is a high correlation between 
the apparent renal clearance of baclofen and the creatinine clearance. 
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Abstract 
The pharmacokinetics of racemic baclofen as determined from plasma 
and urine data in six spastic patients treated with individualized oral 
doses, 30-80 mg daily, are presented. Peak plasma concentrations were 
achieved 1.9 h (+ 0.7) after a dose. The fluctuation in the plasma 
concentration was great, ranging from 188 to 439%. The total body 
clearance averaged 175 ml.mm - 1 (+ 44), plasma protein binding 35% 
(+6). Baclofen was for the greater part excreted unchanged by the 
kidney, 65% (+ 16). Its apparent renal clearance equalled the 
creatinine clearance. The contribution of the renal clearance to the 
total body clearance can explain the previously described toxicity when 
renal impairment is present. The results agree with earlier reports on 
single doses in healthy subjects. 
Key words: Baclofen; Clearance; Patients; Pharmacokinetics 
Introduction 
The gamma-aminobutync acid (GABA) agonist baclofen is a centrally 
acting muscle relaxant, which is used in the treatment of spasticity. 
Once initiated, therapy with this drug is often continued for a pro-
longed period of time. Until now, pharmacokinetic studies with baclo-
fen have mostly dealt with single doses in healthy subjects [1-4]. Mul-
tiple-dose studies in patients are essential in order to obtain pharma-
1Phara Weekbl [Sci] 1990; 12: 71-4. 
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cokinetic information in the same circumstances in which the drug is 
routinely used. In a multiple-dose study in elderly patients receiving 
baclofen in a fixed dosage schedule, the investigation had to be dis-
continued as most patients developed severe drowsiness [5]. In this 
communication we report the results of a pharmacokinetic study of 
baclofen in spastic patients, while they were being treated with indi-
vidualized oral dosages. 
Methods 
PATIENTS 
The subjects were 6 neurological in-patients (4 males and 2 females) 
with spasticity of spinal or cerebral origin. Their mean (+ SD) age and 
body weight were 52 years (+ 6) and 83 kg (+ 13), respectively. None 
was overtly incontinent for urine. Only 1 patient was without any co-
medication; a variety of drugs was taken by the other patients. Full 
details are given in Table 1. The patients were treated with oral race-
mic baclofen (LioresalH tablets, Ciba-Geigy, Arnhem, the Netherlands) 
in doses varying between 30 and 80 mg daily given at 6-h or 8-h inter-
vals (Table 2). The duration of baclofen medication varied among the 
patients, but was such to have caused steady-state in each patient for 
the particular dosage regimen reported. 
SAMPLING PROCEDURE 
Serial 2-3 ml venous blood samples were collected in heparinized 
tubes at predetermined times for the period of a dosage interval. Plas-
ma was separated by centrifugation (1,500 g) and stored at -20°C until 
analysed. Urine was collected on spontaneous voiding in portions equal-
ling the dosage intervals for a period of 3-4 intervals. The total vol-
ume and pH of each urine specimen was measured and 10 ml samples were 
stored at -20°C until analysed. The total number of urine specimens ob-
tained from the 6 patients was 21. 
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TABLE 1 
Characteristics cf the patients 
Patient Age/gender Bcdy weight Clinical diagnosis 
(kg) 
Co-medication 
A 
В 
С 
49/M 
4 7/Τ 
60/M 
107 
82 
80 
52/F 
58/M 
46/M 
71 
77 
80 
spinal cord injury; hack pain 
multiple sclerosis 
multiple sclerosis 
normal pressure hydrocephalus; 
radicular syndrome; lumbago; 
hypothyroidism 
cerebrovascular insufficiency; 
polyneuropathy ; epilepsy; 
dementia 
multiple sclerosis 
lactulose, methenamine mandelate 
vitamines В 
cc-trimcxazcle, phenprcccumcn, 
triamterene, vitamine Bl 
oxazepam, thyroxine sodium 
Phenytoin 
ANALYSIS OF PLASMA AND URINE 
Racemic baclofen in plasma and urine was measured by high pressure 
liquid chromatography (HPLC) with fluorimetrie detection [6]. The mini-
mum detectable concentration was 0.02 mg.l-1. High urinary baclofen 
concentrations were determined, using the rapid direct UV method [7]. 
Plasma protein binding in a number of plasma samples was measured at 
room temperature by filtration through EMIT" Free level filters (Syva, 
Palo Alto, USA). No nonspecific binding to the filters was found. Cre-
atinine both in plasma and urine was measured by an automated Jaffé 
method. 
ANALYSIS OF DATA 
Minimum {Cs^(min>) and maximum (С^
Ч
(
тгііс)) plasma concentrations, and 
the time to reach the maximum (t
ma
^) were obtained from the data at the 
sampling times. The fluctuation in the plasma concentration was ex­
pressed as С„(
т і
„>/С.,
ч ( т і І 1 ) .100%. From the area under the curve dur­
ing a dosage interval τ (AUCssxob which was calculated by the linear 
trapezoidal rule, the average steady-state plasma concentration 
(CS3(aV>) was computed according to Ο^,*,,,, = AUC^^,,-,/!. The total 
body clearance (CL/f) was obtained according to Cl/f = D/AUC 4 4( T > in 
which f is the fraction of the dose systemically available and D the 
dose per dosage interval. Apparent renal clearance (CLR) values were 
computed from the renal excretion rate in each urine sample divided by 
the average steady state plasma concentration. Creatinine clearances 
(CLCR) were similarly obtained. From the total volume of urine collect­
ed, the fraction of systemically available drug excreted unchanged into 
the urine (f
e
) was calculated. The nonrenal clearance (CLrm) was ob­
tained according to CLN,, = (CL/f ) (1-ί
β
). 
Data are expressed as mean (+ SD). Statistical significance was 
tested by the paired t-test; Ρ < 0.05 was taken to indicate signifi­
cance. 
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TABLE 2 
PhannaccKinetic parameters cf baclofen in spastic patients fcllcwing multiple crai doses 
Patient Eaily τ (h) t
m a x
 (h) с
а3(п,аж) .100 <:aala^) f e 
dose % (mg. I-1) 
'-aa (min ) 
Clearance (ml.min - 1) 
CL/f CL H CL«, CL N 
Ά 
В 
С 
D 
E 
F 
Mean 
SD 
40 
40 
во 
30 
60 
75 
6 
б 
6 
8 
8 
e 
3.0 
1.1 
2.0 
2.1 
2.0 
1.1 
1.9 
0.7 
188 
2С9 
354 
220 
256 
439 
0.180 
0.180 
0,336 
0.171 
0,191 
0.220 
0.9С 
0.74 
0.53 
0.46 
0.57 
0.71 
0.65 
0.16 
154 
154 
165 
122 
218 
237 
175 
44 
139 
115 
103 
56 
143 
169 
121 
39 
144 
121 
94 
56 
97 
146 
ПО 
34 
15 
40 
78 
65 
95 
68 
60 
29 
Results 
Figure 1 depicts the plasma baclofen concentration-time curves fol­
lowing multiple oral doses in 6 spastic patients during the dosage in­
terval period. The values obtained for the pharmacokinetic parameters 
are listed in Table 2. Individual mean values are given for the appar­
ent renal clearance of baclofen and for the creatinine clearance. The 
CL H was high and was not significantly different from the CLc-R when all 
renal clearance values from the 6 patients (n = 21) were examined. No 
correlation between urine flow [overall mean value 1.2 ml.min 1 (+ 
0.6)] or pH [overall mean value 6.3 (+ 1.0)] and the CL„ was discerned. 
The average plasma protein binding was ЗЬ% (+6) as determined in 12 
samples from different patients with total baclofen plasma concentra­
tions varying from 0.10 to 0.40 mg.Γ l. 
Discussion 
The pharmacokinetic parameters of baclofen found in this study with 
spastic patients treated with multiple oral doses are in good agreement 
with the results obtained in the earlier mentioned single-dose studies 
in healthy subjects. Only in elderly patients (aged 69-81 years) were 
maximum concentrations after dosing reported at later times [5]. With 
both dosage regimens (q6h and q8h), the fluctuation in the plasma con­
centration was great - ranging from slightly less than 200% to just o-
ver 400% - though consistent with a mean half-life of 7 h as reported 
previously in healthy subjects [3 4]. The half-life was not determined 
in the present study, because this would have implied abrupt withdrawal 
of the drug risking seizures, hallucinations, and dyskinesias [8 9]. 
The clinical relevance of the wide fluctuation in the plasma concen­
tration is not known. Therapeutic concentrations are considered to be 
0.08 to 0.4 mg.l 1 [10], while concentrations of over 0.8 mg.l 1 have 
been associated with toxicity [11 12]. Cerebrospinal fluid levels may 
possibly reflect the concentration at the site of action of this cen­
trally acting muscle relaxant better than plasma [13]. Liquor obtained 
from 3 patients in the present study, however, failed to give detecta-
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ble baclofen concentrations (assayed as plasma), making it unsuitable 
as a sampling medium. 
The apparent renal clearance of baclofen was found to be equal to the 
creatinine clearance. This relationship was established using renal 
clearance values derived from data not solely obtained during the e-
limination phase. The altered bladder function of patients with spas­
ticity (see below) precludes short sampling intervals, while chronic 
dosing further restricts sampling possibilities. However, it can be as­
sumed that, like the findings in healthy subjects in whom ample urine 
sampling during elimination revealed an identical relationship [4], the 
variation in baclofen^ renal clearance is closely related to the vari­
ation in the creatinine clearance. The influence of the renal function 
on the pharmacokinetic pattern of baclofen is most clearly seen in pa­
tients D and F with almost equal nonrenal clearance values (Table 2). 
The difference in total body clearance can be explained completely by 
the difference in creatinine clearance. Thus, the 2.5-fold difference 
in dose is not reflected in the average steady-state plasma concentra-
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FIGURE 1 
Plasma baclofen concentration-time curves following multiple oral doses 
q6h (A) or q8h (B) for the period of the dosage interval in 6 spastic 
patients 
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tions, which were 0.171 and 0.220 mg.l ', respectively. The nearly e-
qual plasma concentration-time curves of patients D and E (Fig. IB) 
with a 2-fold difference in dose, can also be ascribed for the greater 
part to the differences in renal function. These findings may explain 
the earlier reported toxicity of baclofen with normal doses in patients 
with renal impairment [11 14 15], and are in agreement with a case of 
intoxication where a previously effective dose led to unacceptably high 
plasma concentrations after both the creatinine clearance and the renal 
clearance had dropped considerably [unpublished observation]. 
The present study also demonstrates the practical difficulties of u-
rme sampling in spastic patients in whom dysfunction of voiding is 
frequently present [16]. Reduced voluntary control and altered reflex 
activity imply that the short sampling intervals one may need for phar­
macokinetic purposes will often not be feasible, while the volume of a 
portion may be compromised. Very likely there was some inaccuracy in 
the portions collected in patients С and E. When their renal clearance 
values were computed differently (by multiplying f
e
 by CL/f ), the val­
ues were smaller (8/ and 124 ml min 1) though reasonably close to the 
listed values. 
Conclusion 
The results of this baseline study suggest that the pharmacokinetics 
of multiple-dose baclofen in spastic patients will not differ greatly 
from those previously reported after single doses in healthy subjects, 
the renal function being a prominent variable. It remains to be estab­
lished how the separate enantiomers of the clinically used racemic mix­
ture will behave, but it is anticipated that the observed relationship 
between the renal clearance of baclofen and the creatinine clearance 
will not be stereoselective [4 17]. 
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SECTION IV 
PHARMACOKINETICS OF DANTROLENE 

C h a p t e r 10 
WHOLE-BODY AUTORMIOGRAPHY OF г"C-DANTROLENE IN THE MARMOSET 
MONKEY 
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Dantrolene (D) is a skeletal muscle relaxant which impairs muscle 
contraction by interfering with the release of calcium from the sarco­
plasmic reticulum. D is used in the treatment of spasticity and in the 
prevention and treatment of malignant hyperthermia (Ward et al. 1986). 
Despite its presence on the market for nearly twenty years, only lit­
tle is known about its distribution in the body. In man, the apparent 
volume of distribution is approximately 0.5 l.kg ' body weight as cal­
culated from the data presented by Asari et al. (1984). A saliva:plasma 
ratio of 0.05 indicates poor distribution into saliva and may be indic­
ative of high plasma protein binding (unpublished observation). Negli­
gible amounts of unchanged dantrolene have been found in human urine 
and bile. The known metabolites of dantrolene, S-hydroxydantrolene (5-
HD) and acetylated 7-aminodantrolene (ACE-D), have been detected in hu­
man urine; their concentrations in bile were extremely low (Meyler et 
al. 1980; Wuis et al. 1983; Asari et al. 1984). It has been suggested 
that D being a lipophilic compound, may cross the blood-brain barrier 
(Ward et al. 1986). 
In vitro studies with the ^C-labelled drug have demonstrated that D 
binds to the sarcoplasmic reticulum of rabbit skeletal muscle (Dehpour 
et al. 1982). in vivo rat studies have shown that D or one of its me 
tabolites forms a less stable complex with the sarcoplasmic reticulum 
than with the hepatic endoplasmic reticulum (Roy et al. 1980); this is 
an important finding in the light of the drug's liver toxicity in pa­
tients undergoing chronic high dose therapy (Ward et al. 1986). Whole 
body fluorescent studies in mice have revealed that mtraperitoneally 
administered D accumulates mainly in the intestines, liver, and urinary 
bladder, partially in the kidneys, and only slightly in the muscles 
Pharmacol Toxicol 1989; 64: 156-8. 
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(Noulmejade & Maleki 1985). Fluorescence was probably absent in the 
brain, but this was not clearly documented. 
The aim of the present investigation was to clarify the body distri­
bution of D relevant for therapeutic use, i.e. at steady sfate in the 
monkey, a primate, ior this purpose, 1 ЛС-0 (fig. 1) was administered by 
intravenous infusion, and the distribution of radioactivity was studied 
by means of whole-body autoradiography. Prior to the actual distribu­
tion experiment, a preliminary experiment with the unlabelled drug was 
performed to ascertain the pharmacokinetic behaviour of D in the mon­
key. 
1
'
1C-DNa with a specific activity of 32.6 цСі/тд was kindly supplied 
by Norwich Eaton (Norwich NY, U.S Α.). The chemical and radiochemical 
purity were both better than 98% Unlabelled DNa, 5-HD, 7-aminodantro-
lene (AM-D), and АСЕ-D were supplied by the same manufacturer. Insta-
gel" was obtained from Packard, ketamine hydrochloride (Vetalar") from 
Parke Davis, and halothane (Fluothane") from ICI. All other chemicals 
were of analytical grade. Prior to administration, 3.1 mg of (1ЛС) DNa 
was dissolved in 0.4 ml of propylene glycol, 0.25 μΐ of 0.1 M sodium 
hydroxide, and water to a final concentration as mentioned below. 
A male marmoset monkey (Callithnx jacchus) weighing 384 g was given 
1.40 mg of unlabelled DNa by constant rate intravenous infusion for 3 
hr. The infusion fluid contained 0.155 mg/ml of DNa and the infusion 
rate was 3.0 ml/hr. Total sampling time was 5 hr. Λ male marmoset mon­
key weighing 328 g was given 88 μΟι of x',C-DNa by constant rate intra­
venous infusion for 5.2 hr. The infusion fluid contained 0.207 mg/ml of 
DNa corresponding to 6.75 uCi/ml, and the infusion rate was 2.5 ml/hr. 
The animals were anaesthetised with ketamine hydrochloride (40 mg/kg). 
During the experiment, anaesthesia was maintained with halothane. Blood 
samples of 0.8 ml were taken at regular time intervals and collected in 
heparimsed tubes. After centnfugation at 1500 χ g, plasma was kept at 
-20'C until analysis. Urine was collected quantitatively by a bladder 
catheter. All samples were kept protected from light. 
Whole-body autoradiography was carried out according to the Ullberg 
method as described by Van der Kleijn (1969). The animal was instantly 
killed under deepened anaesthesia by submersion into isopentane, cooled 
with solid carbon dioxide to -80°. The whole body was embedded in a 5% 
129 
О г Н и К о ^ Н ^ - І іМН 
FIGURE 1 
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carboxymethylcellulose gel of 0", and again cooled to -80'. By a spe­
cial microtome (PMV 450, Stockholm, Sweden) at a temperature of 20" 
sagittal sections of 30 μιη thickness were made, attached to Scotch 
tape no. 810. After freeze-drying for 48 hr at atmospheric pressure the 
sections were brought onto Structunx D7FW Rontgen film (Agfa-
Gevaert). Exposure took place at -20" for a period of 6 weeks. After 
the films were developed positive prints were made; the white areas 
correspond to the presence of radioactivity. 
Total radioactivity in plasma and urine was determined using a liquid 
scintillation counter. Samples of 0.1 ml were mixed with 11 ml of In-
sLa-geln. Counting was performed with a Packard Tn-Carb Liquid Scin­
tillation Spectrometer Model 3380, using external standardisation. D 
and its metabolites were determined by HPLC based upon an earlier de­
scribed method (Wuis et al. 1982). 
Following the intravenous infusion with unlabelled D, a half-life of 
0.82 hr was found. Total body clearance was 0.77 l.h 1.kg 1 and the ap­
parent volume of distribution 0.91 l.kg ί . As in man, the major metab­
olite appeared to be 5-HD. The mean plasma 5-HD:D ratio was 1.5. Uri­
nary recovery of unchanged D in the 5 hr period was negligible. In this 
period, 6% of the dose administered was excreted as 5-HD, while only 
traces of AM-D and АСЕ-D were detected. With a half-life of less than 1 
hr, steady state conditions are reached after 5 hr of linear infusion. 
In the monkey experiment with 1*C-D, the total radioactivity present 
in plasma after 5 hr, expressed as D, was 5 mg/1. This implies that all 
the observed radioactivity in plasma could be accounted for by D and 
its main metabolite. Total radioactivity recovered in the urine in the 
5 hr was 7%, which corresponds to the percentage recovered as metab­
olites. 
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The autoradiograms of 1',C-D in the marmoset monkey show agreement 
with whole body fluorescent studies in mice (Dehpour et al. 1982); the 
drug has unequal distribution through the body (fig. 2). A high accumu-
lation of radioactivity was observed in the intestines, liver, gall 
bladder, kidneys, and urinary bladder. The presence in the intestines 
could be explained by biliary excretion, which is a major elimination 
pathway for 5-HD in the dog (unpublished observation). As the concen-
trations in human bile are low (Meyler et al. 1980), this pathway is 
WHOLE BODY AUTORADIOGRAPHY IN MARMOSET MONKEY 
'C-dantrolene iv infusion 
FIGURE 2 
Autoradiograms showing the distribution of radioactivity (= white 
areas) after 5 hr of linear infusion of 1"C-dantrolene in a marmoset 
monkey (sagittal sections at two different levels). AG = adrenal gland, 
GB = gall bladder, Ki = kidney. In = intestine, Li = liver. Lu = lung, 
My = myocard. Pa = pancreas, SM = skeletal muscle, Sp = spleen, St = 
stomach, UB = urinary bladder 
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probably less important in man. The high level of radioactivity in the 
liver as compared to that in skeletal muscle agrees with the binding 
studies m the rat (Roy et al. 1980). Presence of radioactivity in the 
kidneys is probably due to metabolites, as the total radioactivity re­
covered in the urine corresponded to the amount excreted as metab­
olites. 
High levels of radioactivity were also found in arterial walls, in 
the lungs, and in the eyes. The radioactivity in the lungs could be due 
to either undissolved D particles or to a local precipitation of the 
drug. Precipitation is a reasonable explanation because in no other 
tissue with dense capillary circulation (liver, spleen, glandular tis­
sue) spots of radioactivity were found. Moreover, pulmonary complica­
tions have been reported to occur in a number of patients following o-
ral D treatment (Petusevsky et al. 1979; Miller & Haas 1984). Pulmonary 
embolism was suspected even though it seemed unlikely in these patients 
based on radiological evidence. It apparently did occur in a patient 
treated with nitrofurantoin, a structural analogue of D with identical 
toxicity on liver and lung (Israel ь Diamond 1962; Faling et al. 1980). 
In the eye, a high level of radioactivity was found in the choroid lay­
er and in the ciliary bodies. This finding as well as relaxation of the 
extraocular muscles, may explain the visual disturbances reported as a 
side effect of D (Dykes 19/5). 
In addition to skeletal muscle, considerable levels of radioactivity 
were found in the myocard, spleen, pancreas, adrenal glands, yellow 
ligaments, and brown fat. Only traces of radioactivity were found in 
the brain. This observation suggests that no significant passage of the 
blood-brain barrier occurs. This holds for the intact D molecule. 
Cleavage of the azomethine bond has been found to occur, at least in 
vitro (Inotsume & NaJcano 1983). From the present experiment no conclu­
sions can be made concerning the presence of the hydantoin moiety of 
the molecule in the brain. The origin of side effects affecting the 
central nervous system such as dizziness, light-headedness, and drowsi­
ness which accompany both acute intravenous and chronic oral adminis 
tration of D (Harrison 1988), remains unanswered. 
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Зшшигу 
Dantrolene, a direct acting muscle relaxant used orally for 
spasticity, has appeared to be effective in the prevention and 
treatment of malignant hyperthermia in man and animals when 
administered intravenously Its pharmacokinetics following intravenous 
administration have been studied in dogs. Concentrations of dantrolene 
and its metabolites in plasma, urine, and bile were determined by 
high-performance liquid chromatography. Recovery of unchanged drug and 
reduced metabolites was negligible; of the hydroxy metabolite 2% was 
found in the urine and about 25% in the bile. The half-life of 5-
hydroxydantrolene was shorter than that of the parent drug as 
demonstrated by administration of the metabolite. The apparent renal 
clearance of 5-hydroxydantro]ene was independent of creatinine 
clearance, urine flow and pH, and appeared to be reduced in the 
presence of probenecid. Bile to plasma ratios of the hydroxy metabolite 
were high with biliary concentrations far exceeding the maximum 
solubility in water. The results of this pilot study indicate that 
hydroxylation is primarily responsible for the excretion of the 
dantrolene molecule from the body. 
1Int J Clin Pharm Res (in press). 
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Introduction 
The direct acting muscle relaxant dantrolene (l-{[5-(p-nitrophenyl)-
furfurylidene] amino)-imidazolidine-2,4-dione) (Fig. 1) has been used 
in the management of patients with spasticity orally for more than 20 
years. Because it interferes with the release of calcium from the sar-
coplasmic reticulum, muscle contraction is impaired. From 1975, intra 
venous dantrolene has been recommended in man and other species in-
cluding the dog for the prevention and treatment of malignant hyper-
thermia, a syndrome which has previously been associated with a high 
mortality rate (1-4). Dantrolene is metabolized by hydroxylation of the 
hydantoin ring and by reduction of the nitro group, which in some spe-
cies is followed by acetylation (5,6). Intermediates of the reduction 
pathway have been associated with hepatic injury (7). Hydroxylated 
dantrolene (Fig. 1) has been reported to contribute to the pharmaco-
logical response (8,9). 
Although its efficacy is now well established, there is little infor-
mation on the disposition of dantrolene or its metabolites. Renal ex-
cretion of unchanged dantrolene was negligible both in a dog and in man 
(10-12). The hydroxy metabolite and the reduced acetylated compound 
have been recovered in human urine; in the dog only 5-
hydroxydantrolene was found. In man, the mean half-life of dantrolene 
was reported to be shorter than that of its hydroxy metabolite (13,14), 
whereas we found in a patient the decay of 5-hydroxydantrolene to 
parallel parent drug 
NO24^H4 : KJUH==N-4^LO 
dantrolene 
5-OH-dantrolene 
FIGURE 1 
Structures of dantrolene 
and its metabolite 
5-hydroxydant rolene 
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loss (15). The purpose of the present pilot study in the dog was to 
investigate, using both plasma and urine data, the pharmacokinetics of 
dantrolene, in particular with respect to its elimination via hydroxyl-
ation. Since the urinary mass balance of intravenously administered 
dantrolene in man and dog is far from complete (11,12), the possibility 
of biliary excretion - a pathway known to exist in the dog for the 
structurally related drug nitrofurantoin (16) - was also investigated. 
Materials and methods 
DRUGS AND FORMULATIONS 
Dantrolene (sodium. 3 HzO), 5-hydroxydantrolene, aminodantrolene, ac-
etylanunodantrolene, amino-5-hydroxydantrolene, and acetylamino-5-hy-
droxydantrolene were kindly supplied by Norwich-Eaton (Norwich, USA). 
The other drugs used were obtained from commercial sources: probenecid 
(Sigma, St. Louis USA), pentobarbital sodium (Narcovet", Amerpho, Arn-
hem, The Netherlands). 
Prior to administration, the dantrolene or 5-hydroxydantrolene dose 
and 4.5 g of mannitol were dissolved in 90 ml of water for injection; 
the pH was adjusted to 9.5 with sodium hydroxide. To make a loading 
dose, probenecid was dissolved in 30 ml of normal saline solution; to 
make a maintenance dose, in 60 ml. The pH of both was adjusted to 9.5 
with sodium hydroxide. 
ANIMAL EXPERIMENTS 
Three beagle dogs, two females (10.7-11.4 kg body weight) and one 
male (14.5 kg) were obtained from the Central Animal Laboratory of the 
University of Nijmegen. The dogs were used several times with a wash-
out period of at least one week between the experiments. At the begin-
ning of each experiment the animals were anaesthetized with pentobarbi-
tal sodium (30 mg.kg 1 ) . Small additional doses of the anaesthetic were 
given as needed to keep the dogs asleep for 7 h. Hydration was main-
tained by continuous intravenous infusion with a solution of 2% manni-
tol in normal saline. After recovery from anaesthesia, the animals were 
housed in metabolic cages enabling collection of spontaneously voided 
urine. 
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Dantrolene or 5-hydroxydantrolene (2.6-3.9 mg.kg-1) was administered 
by constant rate intravenous infusion for 45 m m with a flow rate of 2 
ml.min 1. When a competitive inhibition experiment on active secretion 
was carried out, probenecid was co-administered starting with an intra-
venous loading dose of 15 mg.kg-1 in 15 min (flow rate 2 ml.min-1) and 
followed by a maintenance dose of 2.5 mg.kg-^.h-1 by constant rate in-
fusion (15 ml.h-1) to attain steady-state plasma concentrations between 
50 and 100 mg.l"1 (17). In total eight experiments were carried out 
with the three dogs. 
SAMPLING PROCEDURES 
During the anaesthesia period 2-ml blood samples drawn from a central 
venous catheter were collected in hepannized tubes at predetermined 
intervals. These samples were immediately centri fuged (1500 g) and 
plasma was stored at -20oC pending analysis. Urine was collected 
through a urinary catheter every 30 min. Care was taken that the blad-
der was empty at the end of each collection period. The total volume 
and pH of each specimen were measured and 10-ml samples were stored at 
-20oC pending analysis. In two experiments the animals were also sub-
jected to pen-operative bile drainage. Bile was collected every 30 m m 
and handled as urine. After recovery from anaesthesia, urine collection 
and blood sampling were continued for a total period of 24 h. 
ANALYSIS OF PLASMA, URINE, AND BILE 
Dantrolene, 5-hydroxydantrolene, and acetylaminodantrolene in plasma 
and urine were measured by high performance liquid chromatography 
(HPLC) as described previously (12). When the water content of the mo-
bile phase was slightly increased, aminodantrolene and the reduced hy-
droxylated compounds could be measured simultaneously. Bile samples 
were homogenized by mixing on a vortex, diluted 1:100 with water, and 
directly in3ected. Plasma probenecid concentrations were determined by 
HPLC (18). Creatinine both in plasma and urine was measured throughout 
each experiment by an automated Jaffé method. 
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LIGHT PROTECTION 
During the entire experiment, from the preparation of the infusion 
fluids through to the analysis of the samples, care was taken that all 
solutions and body fluids containing dantrolene or metabolites were 
kept protected from light by wrapping the syringes, tubing, collection 
vessels etc. in aluminum foil. 
PHARMACOKINETIC AND STATISTICAL ANALYSIS 
Elimination half-lives (ti) were determined by linear regression a-
nalysis of the terminal region of the log plasma concentration versus 
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FIGURE 2 
Plasma concentration-time curves and renal excretion rate-time profile 
of dantrolene (D) and its metabolite 5-hydroxydantrolene (ЮН) in dog 
758 after intravenous administration of 2.8 mg.kg-1 of dantrolene 
sodium. The half-lives of both compounds tended to become similar. The 
infusion time was 45 min 
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time curves. Areas under the curve (AUC) were calculated by the linear 
trapezoidal rule with extrapolation to infinity. The total body clear­
ance (CL) and the apparent volume of distribution (V,.) were computed 
according to CL = D/AUC (D being dose administered), and V
z
 = CL.t1/ 
0.693. 
An overall value of the apparent renal clearance (CL
n
) was obtained 
by CL R = Ae"/AUC, in which Ac" is the amount excreted into the urine. 
An overall value of the biliary clearance (CLH) was similarly obtained 
from Ae B (amount excreted into the bile). The mean CU, and CL D values 
with standard deviation were computed using either the renal or the 
biliary excretion rate in each urine or bile specimen, divided by the 
plasma concentration at the mid-point of the measured time interval. 
The mean creatinine clearance values (CLCH) were similarly obtained. 
Data are expressed as mean + s.d. Statistical significance was tested 
by t-tests; Ρ less than 0.05 was taken to indicate significance. 
Results 
DANTROLENE 
The plasma concentration-time curves and the renal excretion rate-
time profile of dantrolene and its metabolite 5-hydroxydantrolene in 
one dog after a single intravenous infusion of 2.8 mg.kg 1 are shown in 
Fig. 2. The half-life of the parent drug in this dog was 1.25 h, while 
the decay of the metabolite tended to parallel parent drug loss. Uri­
nary recovery was low, 2.13% of the dose was excreted as the hydroxy 
metabolite, while recovery of unchanged drug and reduced metabolites 
was negligible. Comparable data were found in the other dogs. Individu­
al values of some pharmacokinetic parameters are given in Table la. In­
dividual mean values of renal function for each dog as calculated from 
post-infusion data are listed in Table II. The apparent renal clearance 
of 5-hydroxydantrolene under the experimental conditions was not 
clearly related to the creatinine clearance, urine pH, or urine flow. 
With very low flow rates below 0.2 ml.min-1 both the creatinine clear­
ance and the renal clearance of the metabolite were reduced. 
In the dog with peri-operative bile drain, no unchanged drug or re­
duced metabolites were detected in the bile samples, but concentrations 
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of 5-hydroxydantrolene were high. Metabolite recovery from bile was a-
bout 21% of the dose; although the utmost care was taJcen, some leakage 
of bile into the duodenum did occur. Individual mean values of biliary 
function for this dog as calculated from post-infusion data are also 
listed in Table 11. The apparent biliary clearance of 5-hydroxydantro-
lene under the experimental conditions was independent of bile flow and 
PH. 
loo =r 
plasma cone (ug/ml), excr rate (ug/min) 
001 
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FIGURE 3 
Plasma concentration-time curve and renal and biliary excretion rate-
time profiles of 5-hydroxydantrolene (DOH) in dog 758 with bile 
fistula after intravenous administration of 3.7 mg.kg-1 of 5-
hydroxydantrolene. The infusion time was 45 min 
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5-HYDROXYDANTROLENE 
The pharmacokinetic parameters of S-hydroxydantrolene when adminis-
tered as parent drug are listed in Table lb. The intrinsic half-life of 
5-hydroxydantrolene was shorter than that of dantrolene. Its urinary 
recovery was low; recovery of reduced metabolites was negligible. Indi-
vidual mean values for the renal function of each dog as calculated 
from post-mfusion data are given in Table II. The CLR was not clearly 
related to CLc-H, urine pH, or urine flow. 
Fig. 3 shows the pharmacokinetic profile of 5-hydroxydantrolene in 
the same dog as depicted in Fig. 2. Biliary recovery of unchanged 5-
hydroxydantrolene in this dog was 27%. Individual mean values for the 
biliary function during the post-mfusion period are also given in Ta-
ble II. The apparent biliary clearance was independent of bile flow and 
PH. 
PROBENECID 
Serial plasma concentration measurements of probenecid led to mean 
levels of over 60 mg.l ' as listed in Table II. After probenecid admin 
istration, the apparent renal clearance of S-hydroxydantrolene de-
creased; when dantrolene was administered as the parent drug, this de-
crease reached statistical significance (p < 0.005). 
Discussion 
The parallel decay of S-hydroxydantrolene to dantrolene loss suggests 
that elimination of the hydroxy metabolite is rate-limited by parent 
drug elimination. That the intrinsic elimination half-life was indeed 
shorter than that of dantrolene, was demonstrated by metabolite admin-
istration. Figure 2 illustrates that too short a sampling time will o-
verestimate the elimination half-life of 5-hydroxydantrolene, when 
present as metabolite. These findings in the dog can explain the earli-
er mentioned observations in man, where limited sampling over a rela-
tively short interval led to the supposedly longer half-lives for the 
metabolite. 
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TABLE la 
Pharaacckinetic parameters of dantrolene (D) and its metabolite 5-hydrcxydantrclene (DOH) in dogs after 
intraveneus infusion of dantrolene sodium 
Dog Body Wt. Dose tà D AUC D V* E V: EGH %B EOH CL D CLH DOH" CLB DCH* 
No. (kg) (mg.kg-1) (h) (mg.h.I"1) (l.kg-1) (ml.min.kg-1) 
758 
576 
207-
10.7 
11.4 
14.5 
2.8 
2.6 
2.7 
1.25 
0.78 
1.21 
2.93 
1.55 
4.63 
1.35 
1.49 
0.79 
2.13 
2.22 
4.25 
12.5 
22.1 
7.52 
0.67 
0.86 
C.65 21 52  3.2 
TABLE lb 
Pharmacokinetic parameters of 5-hydrcxydantrclene (DCH) in dogs after intravenous administration of 5-
hydrcxydantrclene as parent drug 
Dog Body Wt. Dcse t^ DOH AUC DCH V* DOH U' DCH %B DCH CL DOH CLR DOH" CLB DCH* 
No. (kg) (mg.kg-1) (h) (mg.h.l"1) (l.kg-1) 
758 
576 
758* 
11.3 
11.3 
11.3 
2.7 
2.6 
3.9 
0.73 
0.50 
0.69 
2.62 
1.98 
5.62 
1.08 
0.95 
0.69 
1.43 
1.85 
4.04 
(ml.min.kg-1) 
17.1 
21.9 
11.5 
0.25 
0.40 
0.46 3.1 27 
% DCH = percentage of the dose excreted into the urine (U) cr bile (B) as 5-hydrcxydantrclene. 
'with bile drain. 
"calculated from A.tU cr B)/AUC. 
The data from the present study indicate that the smaller apparent 
volume of distribution of the hydroxy metabolite may have caused its 
shorter half-life. The role of the total body clearance is less clear. 
Individual components of this composite parameter will be discussed 
separately. However, from the overall values of the clearances listed 
in Table I, it can be seen that only a minor fraction of the individual 
components is known at present. 
The apparent renal clearance of dantrolene was found to be negligi-
ble. The apparent renal clearance of S-hydroxydantrolene as calculated 
from post-infusion data was at least twice as low as the creatinine 
clearance and was not clearly correlated to the parameters for passive 
tubular reabsorption. The unbound renal clearances could not be calcu-
lated because no data on the extent of binding of dantrolene (or 5-hy-
droxydantrolene) to plasma protein are available. Although dantrolene 
is known to have a high affinity for albumin (19), a property shared 
with the related anionic mtrofurans (20), the bound percentage has not 
yet been established. Ultrafiltration in the present study failed be-
cause of nonspecific binding of unbound drug or metabolite to the fil-
ters. Binding experiments are further complicated by aggregation of un-
bound to bound drug as put forward by Capomacchia and coworkers (21). 
Taking this into account, the unbound renal clearances might be higher, 
even indicating active tubular secretion as demonstrated in the dog for 
nitrofurantoin (22). For S-hydroxydantrolene, the experiments with pro-
benecid seem to support this hypothesis, but the relevance of this 
finding for the dog is limited, since renal excretion of 5-hydroxy-
dantrolene is only a minor pathway of elimination. In man, however, 
where a higher percentage of the dose has been recovered m the urine 
as hydroxy metabolite (11), the possibility of active renal tubular 
transport warrants further investigation. 
In agreement with a previous dog experiment (12), it was found that 
when only urine is taken into account about 98% of the mass balance is 
missing. The absence of the acetylated compound is in agreement with 
the inability of the dog to acetylate aromatic amino groups (23). Its 
precursor aminodantrolene, however, was also not detected, nor was any 
product of the combined metabolic pathways. Further degradation under 
the influence of light (12) was ruled out as all the relevant material 
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TABLE II 
t — < 
£ Henal (R) and biliary (E) handling cf 5-hydrcxydantrclene (DOH) in dcgs after dantrolene and 5-
hydrcxydantrclene admnistraticn (calculated from pcst-infusicn data) 
Dog CLH DOH** CLCB Urine flew Urine pH CLB DCH** Bile flew Eile pH 
No. (ml. min. kg-1! (ші.лііп-1) (ml.min.kg-1) (ml.min-1 ¡ (mg.!-1) 
Dantrolene 
758 0.78+0.36 2.61+0.99 0.46+0.16 8.0+0.6 
576 1.24+0.69 2.76+0.96 0.65+0.28 8.2+0.5 
207- 0.85+0.24 2.38+0.27 С.53+0.47 8.5+C.l 7.52+1.52 0.17+0.09 8.5+C.4 
576 0.23+0.06 3.22+0.44 0.33+0.15 7.6+0.9 6714 
+ probenecid 
5-Hydroxydant rolene 
758 0.48+0.15 3.04+0.67 0.21+0.05 6.9+C.2 
576 0.78+C.52 3.24+1.78 0.43+0.26 5.9+0.2 
758* 1.15+0.28 2.77+0.65 0.35+0.20 8.0+0.1 7.88+1.85 0.12+0.04 8.3+0.1 
576 0.42+0.07 3.27+0.81 0.35+0.21 6.2+0.9 63+1 
+ probenecid 
Cprcb = probenecid plasma ccncentraticn. 
*with bile drain. 
-'calculated from excretion rate/plasma ccncentraticn. 
was protected from light as described above. This implies that other 
pathways must exist for the elimination of dantrolene from the canine 
body. 
Excretion of drugs and their metabolites into bile is a possibility 
for compounds with a relative molecular mass of over 300 who possess 
one or more polar groups (24,25). Unchanged dantrolene (mol. mass 314) 
with its lomsable NH group (pKrt 7 5, Data sheet, Norwich Faton Pharma-
ceuticals) was not excreted into dog bile in quantity. That the intro-
duction of a hydroxyl group as in the case of B-hydroxydantrolene dra-
matically enhanced the extent of biliary excretion, has been described 
earlier for other drugs (24). Rather than an effect on molecular size 
or polarity, it has been proposed that the altered chemical structure 
favours biliary excretion. The high bile to plasma concentration ratios 
that we found for 5-hydroxydantrolene (100-1000) suggest active trans-
port as established for nitrofurantoin in the dog (16). Since animal 
viability upon repeated biliary cannulation is poor, no data on compet-
itive binding experiments with probenecid, which can interfere with 
both renal and biliary transport (25), are as yet provided. Consider-
ing its poor water solubility (< 10 mg.l l , Data sheet, Norwich Faton 
Pharmaceuticals), entrapment by micelles is another likely explanation 
for the high biliary concentrations of S-hydroxydantrolene, which could 
reach values of over 200 mg.!-1 (26). Passive transport would be rela-
tively unimportant as the apparent biliary clearance of this metabolite 
was not dependant upon bile flow and pH in the range investigated. 
The difference in the overall values for the biliary clearance (Table 
I) and the values obtained during elimination (Table II) is partly ex-
plained by the existence of a lag time (Fig. 3), which was not cor-
rected in the data for Table II. A lag time may also explain some of 
the differences found in the earlier mentioned renal clearance values. 
As biliary excretion can be species dependent and the dog is consid-
ered to be a good biliary excréter (24), the results as such cannot be 
transferred to man or other species. In man, negligible quantities of 
drug and metabolite have been discovered in preliminary experiments 
where bile was sampled from post-cholecystectomy patients, when dantro-
lene was given either orally (27) or intravenously (unpublished obser-
vation) . 
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In conclusion, the results of the present study indicate that hydrox-
ylation is an important metabolic pathway for dantrolene in the dog, 
providing a compound with a shorter intrinsic half-life that can be ex­
creted from the body, apparently predominantly via the bile. As about 
70% of the mass balance is still missing following parent or metabolite 
administration, the need of further kinetic studies on metabolites such 
as recently was initiated for azomethine cleavage is obvious (28). 
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Chapter 12 
DANTROLENE PLASMA AND URINE CONCENTRATIONS Ai'TER ORAL 
PRETREATMENT FOR MALIGNANT HYPERTHERMIA: REPORT OF A CASE 
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Departments of Clinical Pharmacy and Anaesthesiology, St Radboud 
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Sunmary 
Dantrolene plasma concentrations and renal clearance calculations in 
a patient undergoing major surgery are reported. The family history was 
positive for malignant hyperthermia. Following oral pretreatment the 
plasma concentrations in this patient were not noticeably different 
from values obtained in a study in awaXe volunteers and which were 
thought to be effective. This is the first report of dantrolene 
measurements made during anaesthesia and in the post-operative period 
Although there is general agreement on the use of intravenous dantro­
lene during malignant hyperthermia (ΜΗ), the mode of administration for 
prophylaxis is still controversial. When administered orally l or 2 
days pre-operatively, dantrolene prophylaxis (1-2 mg kg 1 four times a 
day) has been successful in most cases (1-3). Very recently, both oral 
and intravenous pretreatment failed to protect a 7-year old boy against 
an episode of MH (4). Dantrolene plasma concentrations were not meas­
ured in any of these cases. 
It has been suggested by results obtained in a study using normal 
awake volunteers that blood concentrations of 2.4 mg litre l could be 
effective (5). Dantrolene blood concentrations were measured in a 
patient undergoing major surgery to determine whether concentrations of 
2.4 mg litre 1 can be achieved following oral administration. 
'Eur J Anaesthesiol 1986; 3: 219-23. 
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Case report 
Ά 60-year-old woman (66.5 kg) was admitted for biopsy of the breast. 
Her family history was positive for MH: two cousins had died presumably 
because of MH. Dantrolene was given orally in the 28 h prior to surger-
y. Dantrolene sodium 50 mg was given orally at 08.00, 75 mg at 12.00, 
75 mg at 16.00, and 75 mg at 20.00; an additional dose of 75 mg was ad­
ministered orally at 07.00 on the day of surgery. The total dantrolene 
dose was 350 mg (5.3 mg kg 1 ) . 
Pre-anaesthetic sedation consisted of 10 mg diazepam orally, 5 mg 
dropendol i.m., and 7 mg nicomorphine i.m. Anaesthesia was induced 
with 0.15 mg fentanyl and 450 mg thiopentone i.V., and maintained with 
nitrous oxide 70% in oxygen and intermittent fentanyl (total 0.4 mg 
i.V.). An i.v. bolus injection of 45 pg kg-1 vecuronium was given to 
facilitate endotracheal intubation. A mastectomy was performed follow­
ing a positive biopsy. The course of anaesthesia (4.5 h) and the post­
operative period were uneventful. 
Method 
Blood samples were drawn hourly during anaesthesia and at intervals 
of 3-5 h post-operatively over a total period of 50 h. Urine that had 
been voided spontaneously was collected during the same period. A re­
versed phase high-performance liquid chromatographic method was used to 
determine the concentrations of dantrolene and its metabolites in 
plasma and urine (6). creatinine concentration was also measured in all 
plasma and urine samples. The renal excretion rates and the renal 
clearances were calculated using standard methods (7). Plasma half-
lives were determined by linear regression of the terminal parts of the 
log plasma concentration versus time plots. Peroperatively a muscle bi­
opsy was taken. Susceptibility for MH was tested according to the pro­
tocol of the European Malignant Hyperpyrexia Group (8). 
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Results 
Following oral pretreatment dantrolene plasma concentrations were be-
tween 1.7 and 3.6 mg litre 1 during anaesthesia (Fig. 1). Post-opera-
tively the concentrations declined with a half life of 15 h. For the 
main metabolite, 5-hydroxydantrolene, the same half-life was found. The 
dantrolene sodium 
total dose 
5 3 mg kg ' po 
FIGURE 1 
Plasma concentration-time and renal excretion rate-time profiles of 
dantrolene (D) and its metabolites: 5-hydroxydantrolene (5-OH D) and 
nitro-reduced acetylated dantrolene (F 490), in a patient pretreated 
with divided oral doses of dantrolene sodium. The last oral dose (75 
mg) was given at t = 0. Each horizontal bar represents a urine 
collection interval 
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renal excretion rates of dantrolene and its metabolites were markedly 
depressed on the day of surgery and this led to low renal clearance 
values: 0.04 ml m m ' and 0.4 ml m m 1 for dantrolene and 5-hydroxy 
dantrolene, respectively. Post-operatively renal clearances were ap 
proximately ten times higher in both cases. 
On the day of surgery the creatinine clearance was 45 ml min 1 and 
the urinary flow rate 0.4 ml min L (Fig. 2). Post-operatively, a cre-
atinine clearance of 130 ml ml ^1 was calculated; the urinary flow rate 
was approximately 3 ml m m '. 
Discussion 
The prophylactic dose regimen of dantrolene, for MH, seems to be re-
lated to the pharmacokinetics of the drug. Blood levels which were a-
chiGved with the recommended oral dose regimens in patients who were 
undergoing surgery have not previously been reported (5). Following 
studies in volunteers and in spastic patients, the use of dantrolene 
i.v. has been encouraged because the blood levels were more predictable 
than those recorded following oral doses (5). Dantrolene concentrations 
in a patient undergoing surgery and who was orally pretreated are pre-
sented in this case report. Plasma concentrations are reported here but 
the data are not directly comparable with that presented by Flewellen 
and co-workers in 1983 (5) and who reported whole-blood levels. In hu-
mans whole-blood concentrations have been found to be approximately 1.4 
times greater than the concentrations in plasma (unpublished observa-
tions). If this is taken into account, oral pretreatment led, in the 
case reported here, to accepted effective dantrolene concentrations. 
The half life was also within the range previously reported (5). The 
importance of the dantrolene prophylaxis in this patient remains un-
known. No 'triggering' anaesthetics were given and the responses of the 
muscle biopsy were negative. The latter finding should be interpreted 
with caution as the biopsy was taken after dantrolene pretreatment (9). 
Anaesthesia and surgery may influence the renal excretion of several 
compounds and therefore the urine, drug concentrations and renal func-
tion were measured. The low creatinine clearance and the low urine 
flow, on the day of surgery, may have contributed to the markedly re-
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duced renal clearance of dantrolene and its chief metabolite 5-hydroxy-
dantrolene, when compared with the values found in a group of six nor­
mal volunteers. The mean values for the volunteers were 0.2 ml m m ' 
and 67 ml min 1, respectively (10). 
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FIGURE 2 
Plasma concentration-time an renal excretion rate-time profiles of 
creatinine, and urine flow-time measurements in a patient during 
anaesthesia and in the post-operative period. Each horizontal bar 
represents a urine collection interval. 
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PHARMACOKINETICS AND SPASTICITY 

Chapter 13 
EFFECTS AND PLASMA CONCENTRATIONS OF BACLOFEN AND DANTROLENE IN 
MENTALLY RETARDED PATIENTS WITH CEREBRAL PALSY: A PRELIMINARY 
REPORT 
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Abstract 
Mentally retarded patients with cerebral palsy are often treated with 
antispastic medication without adequate control of the desired outcome. 
We report on a group oí patients that was suspected of having no 
(optimal) clinical benefit. The initial treatment policy for the 12 
patients reported here, was to withdraw their medication (baclofen in 
8, and dantrolene in 4) while monitoring plasma concentration and 
effect. Plasma concentrations were measured by high-performance liquid 
chromatography. Effect was tracked by neurological assessments, and ADL 
performance supported by video recordings. In most cases, minor or 
inconsistent changes in ADL performance were found across the different 
treatment phases. In the neurological examination, most patients with 
major spastic involvement showed a deterioration in overall posture and 
movement rating. These patients had initial plasma concentrations 
between 0.12 and 0.24 mg.l ' of racemic-baclofen, between 0.33 and 
0.44 mg.l ' of dantrolene. The findings of this pilot study suggest 
that such levels may be effective in modifying abnormal motor 
manifestations; no relation to functional response in the everyday-life 
situation was yet found. 
JArch Phys Med Rehabil (submitted) 
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concentrations 
Cerebral palsy is a non-progressive disorder of movement and posture 
due to a defect or lesion of the immature brain (1). The lack of motor 
control in patients with this chronic ailment typically presents as 
spasticity, involuntary movements, and/or incoordination. Most common-
ly, spasticity is the dominant manifestation. In addition to the motor 
deficit, other major disabilities of cerebral palsy are mental retarda-
tion in 50% and seizure disorders m ?5% of the patients (2). Medica-
tions for patients with spastic cerebral palsy often include baclofen 
and/or dantrolene (3,4), while dantrolene has also been given for con-
trol of involuntary movements (5,6). Assessment of the outcome of a 
given therapy is, however, still a major problem. A variety of methods 
has been developed to assist in therapeutic decisions for these pa-
tients (3,6-9), but most are not feasible for severe mental retarda-
tion. 
In our institution for the mentally retarded, 100 patients had disor-
ders of motor control associated with cerebral palsy, a third of whom 
were on long-term antispastic medication. From incidental reports and 
observations we concluded that many patients were suspected of having 
no (optimal) clinical benefit. We have used simple tests and plasma 
concentration measurements to investigate response to antispastic 
treatment in this particular patient population. Drug plasma concen-
trations were included in this pilot study, since this approach has 
previously proved to be successful for regulating drug therapy for epi-
lepsy and other chronic disorders with a hard to evaluate therapeutic 
effect. All patients received a baseline neurological examination to 
document their present status and to set individual treatment goals. We 
report on the outcome for 12 patients who under went a reduction of 
their medication (baclofen in 8 patients, dantrolene in 4) as the ini-
tial treatment policy. 
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Methods 
PATIENTS 
Table I summarises the characteristics of each of the 12 patients (11 
females and 1 male). The female domination reflects a previous admis­
sion policy of our institution. Depending upon the principal handicap, 
a patient was classified either as spastic or dyskinetic, the latter 
presenting as choreo-athetosis, rigidity, dystonia, and/or tremor The 
relatively low body weights are normal for these patients (10). Each 
patient had at least mild mental impairment. Vision and speech deficits 
TABLE 1 
Patient Characteristics 
Patient* Age/Weight Mental re- Vision 
-Motor "f (yr/kg) tardation 
Disorder 
Speech Locomotion 
1-SP 
2-SP 
3-SP 
4-SP 
5-SP 
6-SP 
7-DYS 
8-DYS 
9-SP 
10-SP 
11-SP 
12-SP 
46/39 
37/49 
43/48 
Ь9/58 
29/41 
44/40 
32/40 
44/44 
21/48 
12/38 
13/22 
16/32 
severe 
severe 
severe 
moderate 
profound 
severe 
severe 
moderate 
mild 
mild 
profound 
profound 
good 
good 
good 
good 
dimmi 
good 
good 
good 
dimmi 
shed 
shed 
diminished 
good 
blind 
no 
no 
no 
yes 
no 
no 
yes 
no 
yes 
yes 
no 
no 
walks self 
walks with help 
walks with help 
walks with help 
bed-ridden 
bed-ridden 
chair-bound 
chair-bound 
walks with help 
chair-bound 
chair-bound 
bed-ridden 
*A11 patients are female, except patient 5. 
T S P denotes spasticity is major handicap, and DYS dyskinetic 
involvement. 
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were conunon. All patients were on long-term baclofen and/or dantrolene 
treatment for 5 years or longer. Physiotherapy and drug therapy for ep­
ilepsy and other disorders were continued as needed. Only 1 patient re­
ceived a benzodiazepine drug. 
DRUGS AND PLASMA CONCENTRATIONS 
Baclofen was given as 10-mg tablets (Lioresal", Ciba-Geigy) , which 
contain baclofen in its racemic form. Dantrolene sodium was given as a 
5-mg ml ί suspension (Dantrium", Norwich Eaton); patients treated pre­
viously with 25-mg capsules were changed to identical doses of the sus-
TABLE I 
(continued) 
Orthopaedic Physio- Drug ± Co-medication || 
surgery therapy therapy 
no 
hip, spinal cord 
tendons 
hip, tendons 
no 
tendons 
tendons 
hip 
tendons 
tendons 
tendons 
tendons 
no 
no 
no 
no 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
yes 
В 
В 
В 
В 
В 
в 
в, 
в 
D, 
D, 
D, 
D, 
,а 
,в 
,в 
,Β 
,в 
AED, laxatives 
AED, laxatives 
AED, hormone, laxative, psycho­
active drug 
AED, diuretic, laxatives 
AED, laxatives, vitamin 
AED, hormone, laxatives 
hormones 
anticholinergics, laxatives 
laxative 
AED 
AED, laxatives, mucolytic 
$в denotes baclofen, D dantrolene, and d diazepam. 
(AED denotes antiepileptic drugs. 
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pension. Generally, doses were given 3-timeb daily. Baclofen was with-
drawn at a rate of 5 mg a week as recommended by Terrence and Fromm ior 
patients on long-term treatment (11). Dantrolene dosage was reduced at 
a rate of 15 mg a week. 
Plasma concentrations were measured initially, and when feasible dur-
ing reduction of the medication. Blood was drawn approximately 3 hours 
after the morning dose; plasma was stored at -20°C pending analysis. 
Dantrolene and its metabolite b-hydroxydantrolene and rac baclofen were 
determined by high-performance liquid chromatography as previously de 
scribed (12,13). The total body clearance (CL/f) was calculated from 
the dose per dosage interval divided by the corresponding plasma con-
centration. 
TFSTING OF PATIENTS 
Patients were tested initially, during medication reduction when fea 
sible, and after drug withdrawal. Testing consisted of 3 assessments: 
(1) clinically grading of muscle tone and of posture and movements sta-
tus by a (paediatnc) neurologist; (2) performance of daily living ac-
tivities (ADI,) by an attendant charged with patient supervision; and 
(3) evaluation by 3 observers (consultant physicians) of motor per 
formance recorded by video. 
Muscle tone was graded using a 5-point scale; -2 = considerable de-
crease in tone; -1 = mild decrease in tone; 0 = no increase or decrease 
in tone; +1 = mild increase in tone; and +2 = considerable increase in 
tone. The score was the sum of the score for the neck, trunk, arms, 
hands, legs, and feet divided by 6. When the tone of the extremities 
was not equal on both sides, the average of the scores for the two 
sides was taken. Posture and movements were graded on a 3-point scale. 
Four check lists with 6 items each (neck, trunk, arms, hands, legs, and 
feet) covered posture, spontaneous movement as impaired by abnormal 
tone, spontaneous movement as impaired by abnormal patterns, and con-
trolled movement towards desired object. Left-right differences were 
handled as described above. The percentage of the total score for all 
24 items constituted the measure. The locomotive potential determined 
whether a patient was examined supine, seated, or standing upright. 
166 
The ADL assessments were adapted to the degree of the patient's disa-
bility, and of necessity these were individualised. Several different 
behaviours with regard to motor functioning were included in a check 
list, and graded using a 3 point scale as recommended by Banham (14). 
The percentage of the total score for all the behaviours performed con-
stituted the measure. The attendant most familiar with a particular pa-
tient participated in drawing up a personal check list, which typically 
consisted of 4-8 behaviours related to locomotion (standing, walking 
indoors and outdoors, with aids if needed), arm and hand function (the 
ability to reach for and hold objects, wheelchair use), and/or ease of 
management (while getting dressed, etc.). The same attendant was 
charged with the daily filling in of the check list for that patient 
for discrete treatment periods. Due to the organisation of the insti 
tute, as will be found in other institutes, it could not be avoided 
that this attendant was also acquainted with the patient's medication. 
The results were analysed by visual inspection (15). The bed-ridden pa-
tients and patient 11, who had almost no voluntary control, followed a 
slightly different schedule. Their ease of management or range of pas-
sive motion in the limbs was graded on a 5-point scale, respectively by 
an attendant or physiotherapist. 
Selected aspects of the motor behaviours mentioned above were re-
corded on video-tape when pertinent or applicable. Each behaviour was 
graded separately on a 6-point scale by three observers; their scores 
were averaged. The mean score for the 5-8 behaviours performed by each 
patient constituted the measure. During a particular period, each pa-
tient was recorded only once. The recordings of the different periods 
of a patient were viewed in random order and evaluated in a 'blind' 
manner, i.e. the consultant physicians were unaware which period was 
being shown. The results were analysed on an individual basis; twice 
the standard error of the mean had to be exceeded before the 
qualification improved (or deteriorated) was given. In addition, each 
of the observers was asked to order the recordings from best to least. 
No video recordings were made of those patients with almost no 
voluntary control (see above). 
For all scores, 0 represented the best performance. 
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Muscle Tone Score 
ioli 
Posture and Movements Score 
100-
1 2 3 4 S 6 7 
FIGURE 1 
Muscle tone and Posture and movements scores with and without baclofen 
(patients 1-8) or dantrolene (patients 9-12). The black bars represent 
the score on the initial dose. A thick line on the horizontal axis 
represents a score of 0 
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Results 
OVERALL NEUROLOGICAL EVALUATIONS 
The score for the muscle tone and the posture and movements score of 
each patient with and without drug are shown in figure 1. For the 8 pa­
tients on baclofen (patients 1-8) , no significant difference was ob­
served on each evaluation scale between the period of initial medica­
tion and that of no drug (Wilcoxon signed rank test). When only the 6 
spastic patients on baclofen (patients 1-6) are considered, a signifi­
cant deterioration in the posture and movements score was found; the 
mean (+SD) score increased from 31 (+8) to 40 (+12) (P < 0.05). In the 
same group of 6, the 2 periods could not be distinguished based on mus­
cle tone. For the 4 patients on dantrolene (patients 9-12), the re­
sults followed a similar trend; the number of patients was insufficient 
for a statistical test. 
Table II lists the initial baclofen and dantrolene plasma concentra­
tions and corresponding total body clearances for each patient. 
INDIVIDUAL ADL AND VIDEO EVALUATIONS - CASE REPORTS 
- Patient 1, а 46-уеаг-о1а severely retarded woman with no verbal com­
munication had spastic quadriplegia of unknown etiology. She had de­
veloped flexion contractures, but was independently ambulant. For the 
past 7 years she had been treated with baclofen, 45 mg daily (plasma 
concentration 0.24 mg.l 1 ) . Her epilepsy was held under control with 
Phenytoin 225 mg daily (18 mg.l - 1), and phenobarbitone, 100 mg daily 
(23 mg.l- 1). She also received a bulk laxative and lactulose. The major 
aim for this patient was to maintain her present walking ability. As 
shown in figure 2, the mean ADL score for the drug-free period was 
close to the initial values; on the 20-mg dose, a small deterioration 
in the mean score was found. On the video scale, gait was slightly bet­
ter on low or no drug, but failed to get the qualification improved; 
all three observers ranked the video-tape representing the period of 
initial dosage as being least. Both evaluation methods agreed that her 
locomotive behaviour was not better while on the drug. The low plasma 
concentration (0.04 mg.l M and high clearance value (347 ml.min 1) 
found for the 20-mg dose suggest a deviation from the agreed sampling 
time and/or dosage schedule. Since the onset of baclofen withdrawal her 
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epilepsy has deteriorated. To what extent a temporary reduction in 
Phenytoin dose and level has contributed to this deterioration is not 
clear. The phenobarbitone plasma concentration had not changed. 
Patient 2, a 37-year-old severely retarded woman with no verbal com-
munication had spastic quadnplegia resulting from phenylketonuria. 
Clear dyskmetic involvement was apparent in arms and hands (choreo-
athetosis). She had developed fixed deformities, but could walk inde-
pendently with a little support, for the past 12 years she had been 
treated with baclofen, 45 mg daily (0.15 mg.l l ) . Her epilepsy was held 
TABLE II 
Initial Medications 
Patient Daily dose 
(mg) (mg.kg 1] 
Baclofen 
1 
2 
3 
4 
5 
6 
7 
8 
45 
45 
30 
30 
30 
45 
45 
30 
mean (+SD) 
Dantrolene 
9 75 
10 75 
11 75 
12 90 
mean (+SD) 
1.2 
0.9 
0.6 
0.5 
0. / 
1.1 
1.1 
0.7 
1.6 
2.0 
3.4 
2.8 
Plasma concentration Total body clearance 
(mg.l-1 ) (ml.mm ' ) 
0.24 
0.15 
0.14 
0.19 
0.12 
0.22 
0.22 
0.15 
0.44 
0.33 
0.42 
0.43 
130 
208 
149 
110 
174 
142 
142 
139 
149 (+30) 
93 
124 
98 
115 
107 (+15) 
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under control with valproate 900 mg daily (44 mg.l ' ) . She also re-
ceived bisacodyl and lactulose. The major aim was to maintain her pres-
ent walking ability. As depicted in figure 2, for the period of reduced 
dosage both evaluation methods showed a deterioration in the score. Af-
ter the drug had been totally withdrawn, the deterioration was less se-
vere (ADD or absent (video). Video rank order agreed with the ADL 
findings. Although both evaluation methods showed a similar trend, the 
benefit of baclofen for this patient's locomotive behaviour remained 
unclear. It is noteworthy, that the attendants were of the opinion that 
walking had become much more difficult since the drug usage was termi-
nated and that it remained poor in the weeks that followed. As was seen 
for patient 1, the plasma concentration measured during medication re-
duction while she received 25 mg daily was relatively low (0.06 mq. 
1-'), the clearance high (289 ml.min M . Also, during baclofen with-
drawal 2 major seizures occurred in this patient who had been free of 
major seizures for years. The valproate plasma concentration had not 
changed. 
- Patient 3, a 43-year-old severely retarded woman with no verbal com-
munication had spastic quadnplegia of unknown etiology. Clear dyski-
netic involvement was apparent in left arm (athetosis) and left hand 
(tremor). She had developed minor contractures and could walk when tak-
en by the right hand. For the past 10 years she had been treated with 
baclofen, 30 mg daily (0.14 mg.l 1 ) . Her epilepsy was held under 
control with phenobarbitone 120 mg daily (30 mg.l ' ) . She also received 
halopendol, lynoestrenol, and bisacodyl. The major aim was to maintain 
her present walking ability. As shown in figure ?, on the ADL scale the 
mean score for the drug-free period was close to the initial mean val 
ue. On the video scale, the period of no drug could be distinguished 
from that of initial medication by a deterioration in the score, but 
the difference was small; observer rank order followed that score. 
Whether baclofen was of benefit for her locomotive behaviour remained 
unclear. A remarkable improvement of mood coincided with baclofen with-
drawal that might have affected the ADL rating. In the opinion of the 
attendants trembling of the left hand had decreased, which agreed with 
the findings of the neurological examination. On the 10-mg dose, the 
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FIGURE 2 
ADL (line graphs) and video (histograms) scores for 4 ambulant spastic 
patients (1-4) during baclofen reduction. In each case, the walking 
ability was tested. The mean values for the ADL score in each phase are 
represented by the dashed lines. 
"qualified as deteriorated compared to the other video data reported 
for that patient 
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plasma concentration was high (0.12 m g . ! - 1 ) , the clearance low (Ь8 ml. 
m m -
1 ) . Control of her epilepsy had not deteriorated. 
- Patient 4, a 59-year-old moderately retarded woman with little verbal 
communication had spastic quadriplegia of unknown etiology. Slight dys-
kinetic involvement was apparent in neck and arms. She could walk inde­
pendently with a little support. For the past 6 years she had been 
treated with baclofen, 30 mg daily (0.19 mg.l 4 . Her epilepsy was ac­
ceptable with Phenytoin, 200 mg daily (6 mg.l 1 ) . For mild hypertension 
she was treated with chlorthalidone. She also received lactulose and 
bisacodyl. The major aim was to maintain her present walking ability. 
As shown in figure 2, the mean ADL score for the drug free period was 
similar to the initial mean value; on the 10-mg dose, a deterioration 
in the mean score was found. On the video scale, the period of no drug 
could be distinguished from the two periods while on different doses by 
a deterioration in the score. For two of the three observers, the rank 
order followed the video score. Since the assessments disagreed, the 
benefit of baclofen for this patient's Locomotive behaviour remains un­
clear. It is of note, that the attendants were of the opinion that 
walking had become more difficult since the drug usage was terminated. 
Her epilepsy remained difficult to control; the Phenytoin dose was in­
creased. 
- Patient 5, a 29-year-old profoundly retarded man with no verbal com­
munication and poor vision had spastic quadriplegia resulting from pre­
term birth asphyxia. He was bed-ridden with almost no voluntary move­
ment or control of posture and had fixed deformities. For the past 9 
years he had been treated with baclofen, 30 mg daily (0.12 mg.l T ) . His 
epilepsy was held under control with phenobarbitone 100 mg daily (44 
mg.l 1 ) , valproate 1800 mg daily (67 mg.l" 1), and carbamazepine 600 mg 
daily (4.5 mg.! - 1). He also received ascorbic acid, bisacodyl, and lac­
tulose. The aim was to maintain the present range of passive motion in 
his arms and legs. Reducing the dosage to no drug at all did not induce 
any change in the score for arms and legs as recorded by the physio­
therapist. On a daily dose of 15 mg, a plasma concentration of 0.09 mg. 
I - 1 was measured; the clearance was 116 ml.mm - 1. The findings suggest 
that this patient did not benefit from baclofen in the doses tested. 
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Attendant opinion was that nursing care had become just a little more 
difficult, but that on the whole he was not worse than before. Control 
of his epilepsy had not deteriorated. 
- Patient 6, a 44 year old severely retarded woman with no verbal com­
munication had spastic quadnplegia resulting from perinatal cranial 
trauma. She was bed ridden with almost no voluntary movement or control 
of posture and had fixed deformities. For the past 6 years she had been 
treated with baclofen, 45 mg daily (0.22 mg.l ' ) . Her epilepsy was held 
under control with phenobarbitone 100 mg daily (25 mg.l M . She also 
ADL Score Video Score 
A B C 
FIGURE 3 
ADL (line graphs) and video (histograms) scores for 2 dyskinetic 
patients (7 and 8) during baclofen dosage alteration. In each case, the 
tests included arm function and ease of management. Dashed lines as in 
figure 2. 
"qualified as deteriorated compared to С (patient 7) or A and С 
(patient 8) 
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received ascorbic acid, bisacodyl, lactulose, and lynoestrenol. The aim 
was to maintain the present range of passive motion in her legs and 
arms. As reported for patient 5, for the entire period no change in the 
score was recorded by the physiotherapist. While treated with 30 mg 
baclofen daily, the plasma concentration was 0.18 mg.l л, the clearance 
116 ml.min 1. The findings suggest that this patient did not benefit 
from baclofen. Attendant opinion was that she had 'clinically' im 
proved - i.e., they could do more with her than before and discovered 
more and more activities she liked. Control of her epilepsy had not de­
teriorated. 
- Patient 7, a 32-year old severely retarded woman with little verbal 
communication had dyskinetic quadnplegia of unknown etiology. Her mo­
tor handicap included choreo-athetosis and dystonia; the latter was 
greatly influenced by her emotional status. She was practically chair 
bound and only with a lot of support could she take a few steps. In her 
wheelchair she made attempts to move about independently. For the past 
7 years she had been treated with baclofen, 4Ь mg daily (0.?1 mg.l ' ) . 
She also received diazepam 6 mg daily, and an oral contraceptive. The 
aim was to maintain her present arm and hand function as well as ease 
of management. As shown in figure 3, during the entire period of baclo­
fen reduction, minor changes in the mean ADL score were found, which 
extended to the drug-free period. On the video scale, the period of no 
drug could be distinguished from that of initial medication by an im­
provement in the score; for the 20-mg dose, an intermediate value was 
found. Video rank order varied between the observers. The findings of 
both evaluation methods agreed that this patient did not perform better 
while on baclofen. Variability in the ADL data was considerable but not 
surprising with dystonia as a major handicap. On the 20 mg dose, the 
plasma concentration was low (0.03 mg.l 1) and the clearance high (46? 
ml.mm ' ) . Improvement of mood coincided with baclofen reduction, but 
not as remarkably as for patient 3. 
- Patient 8, a 44-year old moderately retarded woman with no verbal 
communication had dyskinetic quadnplegia of unknown etiology. Her mo­
tor handicap included rigidity, dystonia, and athetosis; spastic in­
volvement was apparent in the legs. She had developed flexion contrac-
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tures and was not ambulant. She could move about independently in an 
electrically-driven wheelchair. For the past 5 years she had been 
treated with baclofen, 30 mg daily (0.15 mg.l ' ) . Alternatively, or-
phenadrine and ipratropium were given against excessive salivation. She 
further received bisacodyl and lactulose. The aim was to maintain her 
present arm function as well as ease of management. Prior to medication 
reduction, the effect of increased dosage was investigated. As shown in 
figure 3, during the entire period of dosage alterations, only small 
changes in the mean ADL score were found. On the video scale, the peri-
od of increased dosage could be distinguished from the period of ini-
tial medication and that of no drug by a deterioration in the score, 
which agreed wtth video rank order. On the 60-mg dose, the plasma con-
centration was 0.31 mg.l ', the clearance 134 ml.mm 1 The findings of 
both evaluation methods agreed that this patient did not perform better 
while on baclofen. Attendant opinion was that operating her wheelchair 
had slightly improved on the high dose but at the expense of hanging 
extremely limply in her chair. As for patient 7, variability in the ADL 
data was considerable but not unexpected. Her bad temper, on and off a 
problem throughout the entire period, made her a difficult patient for 
testing and may have added to the variability. 
- Patient 9, a 21-year-old mildly retarded woman with good language 
function had spastic quadnplegia resulting from prenatal pregnancy 
toxicosis. With support she was ambulant and with an electrically-
driven wheelchair she could move about independently. For the past 6 
years she had been treated with dantrolene, 75 mg daily; the dantrolene 
plasma concentration was 0.44 mg.1-1, the concentration of 5-hydroxy-
dantrolene 0.14 mg.l 1. She also received baclofen, 30 mg daily, which 
was kept unchanged; the baclofen plasma concentration was 0.20 mg.l ', 
Lactulose was the only other drug used. The major aim was to maintain 
her present walking ability. As shown in figure 4, performance on the 
ADL scale was slightly better on low dosage or no drug, which had simi-
lar means. On the video scale, the dantrolene-free period could be dis-
tinguished by a deterioration in the score from the initial medication, 
although the difference was small. For 2 of the 3 observers, the rank 
order followed the video score. On the 23-mg dose, the dantrolene plas-
ma concentration was 0.10 mg.1-1 (CL/f 126 ml.min-1); the concentration 
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of 5-hydroxydantrolene was below 0.02 mg.l ', which is the detection 
limit of the assay. Whether dantrolene was of benefit for her locomo­
tive behaviour remains unclear. After drug withdrawal, dyskinetic in­
volvement became more apparent, notably dystonia in neck and left arm. 
This finding agreed with attendant opinion that the way she operated 
her wheelchair had become more variable. The baclofen plasma concentra­
tion had not changed. 
- Patient 10, a 12-year-old mildly retarded girl with good language 
function and poor vision had spastic quadriplegia resulting from birth 
asphyxia. She was practically chair-bound and only with a lot of sup 
port could she take a few steps. For the past 6 years she had been 
treated with dantrolene, most recently with 75 mg daily; the dantrolene 
plasma concentration was 0.33 mg.l 1, the metabolite concentration 0 08 
mg.l д. She also received baclofen 45 mg daily, which was kept un 
changed; the plasma concentration was 0.31 mg.l - 1. Her epilepsy was 
held under control with carbamazepine 400 mg daily (8.5 mg.l 1 ) . The 
manor aim was to maintain ease of management. As shown in figure 4, on 
the ADL scale performance was best on low dosage or no drug, which had 
almost similar means. On the video scale, the period of initial medica­
tion could not be distinguished from the dantrolene-free period. Video 
rank order varied between the observers. On the 15-mg dose, the dantro 
lene plasma concentration was 0.04 mg.l-1 (CL/f 205 ml.min M ; the con 
centration of the metabolite escaped detection. The findings of both e 
valuation methods agreed that this patient did not perform better while 
on dantrolene. After drug withdrawal, dyskinetic involvement became 
more distinct: dystonia and abnormal movement patterns of a plastic 
rigid type in neck, trunk, arms, and hands. The baclofen plasma concen­
tration had not changed. 
- Patient 11, a 13-year-old profoundly retarded girl with no verbal 
communication had spastic quadriplegia of unknown etiology. Dystonia 
was apparent in the neck. Particularly disabling was the retention of 
primitive responses. She was chair-bound with hardly any voluntary con­
trol and had minor contractures. She had been treated with dantrolene 
for practically her whole life, most recently with 75 mg daily; the 
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FIGURE 4 
ADL (line graphs) and video (histograms) scores for 4 spastic patients 
(9-12) during dantrolene reduction. In patient 9 the walking ability, 
in the other patients ease of management or passive movement was 
tested. Dashed lines as in figure 2. 
'qualified as deteriorated 
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dantrolene plasma concentration was 0.42 mg.l v, the concentration of 
the metabolite 0.13 mg.l '. She also received baclofen, 30 mg daily, 
which was kept unchanged; the plasma concentration was 0.34 mg.l '. The 
major aim was to maintain ease of management. As shown in figure 4, the 
mean ADL score for the dantrolene-free period was similar to the ini­
tial mean value. On the 15 mg dose, a deterioration in the score was 
found. For this dose, the dantrolene plasma concentration was 0.?1 mg. 
1 χ (CL/f 39 ml.min 1 ) ; the metaJbolite concentration escaped detection. 
The findings suggest that the daily care of this patient was not made 
easier while she was on dantrolene. A period of frequent crying coin­
cided with the 15-mg phase that might have affected the rating. In the 
opinion of the attendants, she had become a little more stiff since be­
ing off the drug. The baclofen plasma concentration had not changed. 
- Patient 12, a 16-year-old profoundly retarded blind girl with no ver­
bal communication had spastic quadnplegia of unJcnown etiology. Slight 
dyskinetic involvement was apparent in the face (mouth). She was bed­
ridden with almost no voluntary movement or control of posture and had 
fixed deformities. For the past 5 years she had been treated with 
dantrolene, most recently with 90 mg daily; the dantrolene plasma con­
centration was 0.43 mg.l l, the concentration of the metabolite 0.14 
mg.l *-. She also received baclofen 30 mg daily, which was kept un­
changed; the plasma concentration was 0.15 mg.l T. Her epilepsy was 
held under control with carbamazepine 400 mg daily (8 mg.l ' ) . She fur­
ther received acetylcysteine, bisacodyl, and lactulose. The aim was to 
maintain the present range of passive motion in her arms and legs. As 
shown in figure 4, across the different phases of reduced dosage no 
change in the score as recorded by the physiotherapist was found. On 
the 60-mg dose, the dantrolene plasma concentration was 0.29 mg.l 'l 
(CL/f 113 ml.min l ) , the concentration of 5-hydroxydantrolene 0.11 mg. 
1 1. For the drug-free period, a slight deterioration in the score was 
found. The findings suggest almost no influence of dantrolene on the 
ease of handling this patient. The baclofen plasma concentration had 
not changed. 
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Discussion 
In this pilot study with mentally retarded cerebral palsied patients, 
we measured muscle Lone as the variable related to the pharmacological 
activity of the drugs investigated, baclofen and dantrolene. The in-
crease and decrease in tone seen following withdrawal of either drug 
suggest, however, no influence on this variable. Possible explanations 
are that the normal variation in tone in these patients has masked an 
effect (16) or that the plasma concentrations were too low to exert 
muscle relaxation. Pharmacological activity after prolonged administra-
tion of baclofen in spinal spasticity has previously been described 
with highly varying concentrations that encompassed the values reported 
here (17). In patients with spasticity of different origin, dantrolene 
plasma concentrations of over 0.3 mg.l ' have been associated with mus-
cle relaxation (18,19). 
Posture and movement abnormalities were measured on a simple scale 
that could be used for all patients irrespective of the degree of their 
mental or motor handicap. The results of this test suggest that bacio 
fen and dantrolene did have some effect on the motor manifestations of 
spastic cerebral palsy. The initial 'active' plasma concentrations var-
ied between 0.12 and 0.74 mg.l ' for baclofen, and between 0.33 and 
0.44 mg 1 ' for dantrolene. For a meaningful interpretation of these 
numbers one must realise that the drug taken may either not be a single 
active compound or remain just one active compound. The active hydroxy 
metabolite of dantrolene, which was simultaneously measured in this 
study, was present in concentrations that corresponded to an average 
parent drug/metabolite ratio of 3, which agreed with the Meyler study 
(19). In the case of baclofen, the clinically available dosage form 
contains the racemate - i.e., 50% of the active (-)-(R)-enantiomer and 
50% of the inactive (+)-(S) enantiomer (20), a ratio which may be sub-
jective to change in the body. The assay used in the present study did 
not discriminate between the two. Following a single oral dose in a 
healthy subject, it has been shown that differences in the plasma pro-
files of these isomers were small (21). 
The present study also attempted to document changes in everyday mo-
tor performance of individual patients. Repeated assessments of simple 
daily tasks by a familiar attendant seemed to be the most practical way 
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to measure the effect of medication reduction, supported by incidental 
video recordings for objectiveness. However, changes across the differ-
ent treatment phases were minor, absent, or inconsistent, and did not 
relate to the plasma concentrations in the ranges measured. Whether the 
patients themselves experienced differences in performance, could not 
be tracked in this severely handicapped group. 
Except for a number of samples measured during medication reduction, 
the plasma concentrations did show a good correlation with the dosages 
administered. For baclofen, the mean total body clearance agreed with 
the mean value found for hospitalised spastic patients where multiple 
samples during a dosage interval were available for clearance calcula-
tions (22). This observation also holds for the patients where baclofen 
was present as co-medication. Clearance values for dantrolene, have not 
been previously published. A poor concentration-dose relationship was 
found by Inotsume et al. (23), who measured plasma concentrations fol-
lowing widely varying daily dosages. From the data reported for pa-
tients treated similarly as the cases presented here (19), clearances 
could be derived which agreed with the present values. 
Abrupt withdrawal of baclofen after prolonged treatment has been as-
sociated with hallucinations and seizures (11). Even though baclofen 
was gradually withdrawn in this study, increased incidence of seizures 
occurred in two of the six patients with associated epilepsy. Concomi-
tant reduction in anticonvulsant dosage and level may have played a 
role in patient 1. Baclofen may also have acted as an anticonvulsant in 
the patients 1 and 2, but this aspect of baclofen therapy is still con-
troversial (24). Withdrawal symptoms have not been reported previously 
for dantrolene. In two of the four patients who had their dantrolene 
withdrawn, we observed an increase in dyskinetic involvement. Re-ap-
pearance of pre-existent motor impairment, however, should also be con 
sidered as a possibility, since dantrolene has been reported to be use-
ful in patients with dyskinetic cerebral palsy (5,6). 
In many aspects the present study was a pilot study, m which the 
feasibility of studying concentration-effect relationships of the anti-
spastic drugs baclofen and dantrolene in mentally retarded cerebral 
palsied patients was investigated. Future research efforts should in-
clude both plasma concentrations and pharmacological and clinical vari-
ables repeatedly measured over time under 'single-case research' condi-
181 
tions (15,25), assisted by enantioselective baclofen measurements, and 
extended to cover other dosage regimens. 
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Summary and conclusions 
A clinical question stimulated the pharmacokinetic investigation of 
drugs which are effective in the management of patients with spastici-
ty. Patients suffering from this disorder of motor control may have to 
taJte these drugs daily for extended periods or even for their whole 
life. Physicians in charge of such patients wondered whether plasma 
concentration measurements could guide their prescribing habits for 
spasticity, similar to the practice now common for epilepsy. The neu-
rological disorders resemble each other inasmuch that therapeutic re-
sponse to a given treatment is often hard to evaluate. 
Of the muscle relaxants which have been developed over the years, 
baclofen and dantrolene are established antispastic drugs. Although 
both have been in use since 196/, pharmacokinetic investigations of ei-
ther drug have been limited, which is partly explained by the lack of 
suitable assays. 
The purpose of the present study was to develop chemical analyses for 
the quantitative determination of baclofen and dantrolene, and to apply 
these to study the pharmacokinetics of the drugs. The work is described 
in thirteen articles. 
LITERATURE REVIEW 
In chapter 1 the relevant characteristics of baclofen and dantrolene 
are reviewed, including their place in the treatment of spasticity. 
Both drugs differ completely in their chemical structure and mode of 
action. The GABAn agonist baclofen is a centrally acting muscle relax-
ant. The drug is marketed as the racemate, but the (-)-(R)-enantiomer 
has proved to be the active isomer. Dantrolene, a structural analogue 
of nitrofurantoin, is a directly acting muscle relaxant, which is ex-
tensively metabolised in the body. 
In addition, this chapter deals with several characteristics of the 
spasticity syndrome, because insight into classification systems, meth-
ods of measurement etc. is of importance when one wishes to relate 
plasma concentration to therapeutic response. The meaning of the term 
spasticity is also briefly discussed. The term 'cerebral palsy' is in-
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eluded in the discussion, because it is also referred to as spasticity, 
and is the particular field of clinical investigation described in 
chapter 13. 
ANALYTICAL PROCEDURES 
In chapter ? a high-performance liquid chromatographic (HPLC) method 
for the quantitative determination of baclofen in plasma and urine is 
described. The problem of detecting nanogrammes of a substance with an 
amino acid structure among the abundantly present endogenous amino ac­
ids became Jmorfn as finding ал invisible needle in an invisible hay 
stack Dcrivatization with o-phthaldialdehyde reduced the problem to 
that of the needle in the haystack: the highly fluorescent isoindole 
corresponding to the amino acid (including the ρ chlorophenyl deriva­
tive of У aminobutyric acid, thus baclofen) is synthetised in the pres­
ence of alkylmercapto compounds such as thioglycolic acid. Interfering 
amino acids were efficiently removed by cation exchange extraction 
prior to chromatographic separation. An on column concentration and 
cleaning procedure permitted the injection of the large volumes needed 
to obtain the required sensitivity. Reversed-phase HPLC with fluorime­
trie detection (excitation at 340 nm, emission at 460 nm) completed the 
procedure. With this method, which was demonstrated to be suitable for 
pharmacokinetic purposes, baclofen could be measured in 0.5 ml of plas­
ma or urine with a detection limit of 1-2 ng, a precision better than 
6%, and a recovery greater than 90%. 
Although this method was suitable, a simpler method for high concen­
trations of baclofen in urine was developed which is described in chap­
ter 3. Upon direct injection in a reversed-phase HPLC system with ul­
traviolet detection (220 nm), baclofen can be measured in samples with 
concentrations over 4 mg.l 1 I levels we never encountered in plasma. 
The proposed jf hydroxy metabolite of baclofen, which escapes detection 
in the o-phthaldialdehyde fluorimetrie procedure because it lacks the 
NH7-group required for denvatization, can also be measured with this 
method if present in the same concentrations. 
186 
In chapter 4 the analytical problem that racemic 'fixed-ratio' combi-
nation drugs like baclofen present is tackled. Since the chiral drug 
baclofen is marketed as the racemate, it follows that, to continue the 
metaphor, not one but two needles - one the mirror image of the other -
were concealed in the haystack. Chiral separation was eventually ob-
tained by substituting N-acetyl-L-cysteine, an optically active alkyl-
mercapto compound, for the achiral thioglycolic acid. The o-phthaldial-
dehyde derivatization reaction having thus been modified, the formed 
diastereoisomers could be determined quantitatively, for the present in 
aqueous media. 
In chapter 5 a method for the quantitative determination of dantro-
lene and two of its metabolites in plasma and urine is described. The 
poor solubility of the compounds in water (the metabolites included!) 
and in many other solvents, and the degradation by light are complica-
ting factors in the analysis. Plasma had to be extracted prior to the 
chromatographic separation. A mixture of chloroform-n-butanol (95:5) 
yielded good recoveries for all three compounds. Urine could be direct-
ly injected. With reversed-phase HPLC followed by ultraviolet detection 
(3/5 run), dantrolene, 5-hydroxydantrolene, and nitro-reduced acetylated 
dantrolene (also known as acetylaminodantrolene) could be measured si-
multaneously in a single isocratic run of about 10 min with a detection 
limit of 1 ng, thus providing a method which is suitable for pharmaco-
kinetic studies. 
In chapter 6 a modification of the method is presented which was de-
veloped to determine the metabolite which results from azomethine 
cleavage, notably 5-(p-nitrophenyl)-2-furoic acid. In the extraction 
procedure of chapter 5, this compound appeared to have been discarded 
with the aqueous layer. Acidification prior to extraction, chromatogra-
phic separation with a slightly different mobile phase, and detection 
at a wavelength of 354 nm permitted determination of this cleavage 
product in plasma (and urine). Preliminary pharmacokinetic experiments 
demonstrated that this metabolite is probably not important in man, but 
is in the dog. 
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PHARMACOKINETICS OF DACLOFKN 
Chapter 7. The pharmacokinetics of racemic baclofen and its separate 
enantiomers were studied in dogs. For this part of the study laboratory 
animals were chosen because no data were available on the toxicity of 
the isomers when separately admimsLerod. Because of the resemblance 
between the human and the canine kidney, the dog was chosen. Renal pa-
rameters in pharmacokinetic experiments add information and are indis-
pensable for a drug like baclofen, which has caused signs of intoxica-
tion in patients with renal function impairment. After a single intra-
venous infusion, differences were found in the urinary recovery of the 
compounds. For the active (-(-(Rj-enantiomer, the mass balance was al-
most complete as 8b% was recovered. To eliminate (+) (S)-baclofen, 
more excretion pathways seem to be involved. The findings suggest that 
the active enantiomer is also to be preferred with respect to the 
pharmacokinetic factors. Irrespective of isomeric composition, the ap 
parent renal clearance of baclofen was found to be related to the cre-
atinine clearance. 
Chapter 8 deals with the pharmacokinetics of baclofen in healthy 
subjects after oral administration of the clinically available dosage 
form containing the racemate. Following a single 40 mg dose, baclofen 
was for the greater part excreted unchanged by the kidney within two 
days, on the average, 70% of the dose. The mean half-life, calculated 
from extended least squares modelling (ELSMOS) both of plasma and urine 
data was 7 h, which was longer than reported in most studies based 
solely on plasma data. The apparent renal clearance of baclofen equal-
led the creatinine clearance. Analogous to the findings in the dog, the 
assumption is that this relationship will not be stereoselective. 
Although active tubular secretion may contribute to baclofen's renal 
clearance as shown by the effect of co-administered probenecid, glomer-
ular filtration appears to be the dominant transport mechanism. 
In chapter 9 the pharmacokinetics of baclofen in spastic patients 
treated with individualised oral doses of tablets, containing the ra-
cemate, are presented. Relative to the healthy subjects, sampling op-
portunities were rather limited. The ailment itself made quantitative 
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urine collection a difficult task. The sampling period was also much 
shorter, i.e. a dosage interval (q6h or q8h) for plasma, because drug 
withdrawal was not attempted in view of the risk of adverse reactions 
The fluctuation found in the plasma concentration was considerable, ?00 
to 400%, though consistent with the half-life calculated in chapter 8 
The percentage of the dose excreted unchanged by the kidney was also 
similar to the values found for the healthy volunteers after a single 
dose. In the light of the findings m the previous chapters, the view 
is offered that the observed variation in the apparent renal clearance 
of baclofen is likely to be related to the variation in the creatinine 
clearance. The contribution of the renal clearance to the total body 
clearance can explain the described toxicity when renal function im-
pairment is present. 
PHARMACOKINbTICS OF DANTROLENE 
Chapter 10 describes the distribution of '"C-labelled dantrolene in 
the marmoset monkey as studied by whole-body autoradiography. This lab-
oratory animal was chosen because it is a small primate. At steady 
state following linear infusion, high accumulations of radioactivity 
were found in the kidneys, liver, gall bladder, urinary bladder, and 
intestines, i.e. in organs concerned with the elimination of dantro-
lene. Much lower concentrations were observed in the skeletal muscles, 
the site of dantrolene's action. Only traces of radioactivity were 
present in the brain, suggesting that the intact molecule cannot pass 
the blood-brain barrier. The position of the '"C-label prevented pos-
sible products of azomethine cleavage, notably hydantoin derivatives, 
to be visualised. 
Chapter 11 deals with the pharmacokinetics of dantrolene and its ac-
tive metabolite, 5-hydroxydantrolene, in the dog. To circumvent bioa-
vailability problems, the substances were intravenously administered. 
Because of this approach and the intended sampling of bile, laboratory 
animals were preferred to human volunteers. Despite the intravenous 
route, the mass balance was far from complete. Only the hydroxy com-
pound was recovered in quantity in the urine (2%) and in the bile 
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(25%). Bile Lo plasma ratios of this metabolite were high with biliary 
concentrations far exceeding the maximum solubility in water. The half-
life of 5-hydroxydantrolene was shorter than that of dantrolene as dem-
onstrated by administration of the metabolite. These findings indicate 
that, in the dog, hydroxylation is important in dantrolene excretion 
from the body. 
An example of the pharmacokinetics of dantrolene in man is given in 
chapter 12, where a case report on oral prophylaxis for malignant hy-
perthermia is presented. In addition to dantrolene's use in spasticity, 
it is the drug of choice for this syndrome. Parent drug and hydroxy me-
tabolite both declined with a half-life of l") h, which agrees with the 
findings in the dog. 
PHARMACOKTNETICS AND SPASTICITY 
Chapter 13 describes the results of a pilot study on the effects of 
baclofen and dantrolene in a group of institutionalised patients with 
cerebral palsy. For assessment of the motor handicap tests were devel-
oped, which had to be very simple because of the associated mental re-
tardation. For patients being treated with antispastic drugs and sus-
pected of having no (optimal) clinical benefit, a reduction in medica-
tion was evaluated while monitoring plasma concentration and effect. 
From the cases presented, the feasibility of a study on concentration-
effect relationships in this particular patient population is dis-
cussed. 
CONCLUDING REMARKS 
The investigations carried out and reported in this thesis were done 
in order to obtain insight into the pharmacokinetics of antispastic 
drugs. The assay developed for baclofen was sufficiently sensitive for 
measuring concentrations in plasma and urine following therapeutic 
doses. Because of the high urinary concentrations, a simplified proce-
dure could be used for most urine samples. The first results of the 
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enantioselective analyses should lead to methods which are applicable 
to biological material. The У-hydroxy metabolite of baclofen is 
probably of no importance in man and dog. Our findings were in favour 
of a correlation between the creatinine clearance and the renal clear­
ance of unchanged baclofen, irrespective of isomeric composition. 
Studies with enantioselective assays are required to examine the phar­
macokinetics of baclofen in more detail. 
The assay developed for dantrolene was sufficiently sensitive and 
specific for the quantitative determination of dantrolene and two of 
its metabolites. The method was applicable to plasma, urine, and bile. 
Contrary to the findings in dogs, the drug and its metabolites could 
not be detected in human bile. A product of azomethine cleavage did not 
contribute to the incomplete mass balance of dantrolene in man. Our 
findings are m favour of the concept that hydroxylation diminishes the 
half-life of this drug. Future studies will have to focus upon metab 
olite kinetics. 
The clinical findings indicate how information correlating plasma 
concentration to effect in patients with cerebral palsy might be 
obtained, particularly in coexistent mental retardation. Other anti-
spastic drugs such as tizanidine, which has more recently become 
available, may be similarly tested. Because of the racemic character of 
clinically applied baclofen and the incomplete mass balance of dantro­
lene, it may not come as a surprise that no clear recommendations can 
yet be given on concentration-effect relationships. Λ spin-off of the 
pilot study in the institution concerned is that the prescribing of 
antispastic drugs has remarkably declined. 
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Samenvatting en conclusies 
FARMACOKINEÏIEK VAN ANTISPASTICA 
een studie over baclofen en dantroleen 
Een klinische vraagstelling is de aanleiding geweest tot het hier be-
schreven onderzoek naar de farmacokinetiek van geneesmiddelen die wor-
den toegepast bij de behandeling van patiënten met spasticiteit. Deze 
patiënten, die zich presenteren met stoornissen in de motoriek, moeten 
soms jarenlang (levenslange) dagelijks geneesmiddelen innemen. Artsen 
belast met de zorg voor dergelijke patiënten kwamen met de vraag of het 
meten van geneesmiddelconcentraties m plasma hun voorschrijfpatroon 
bij dit ziektebeeld zou kunnen beïnvloeden. Met deze aanpak hadden ze 
goede ervaringen opgedaan bij het behandelen van patiënten met epilep-
sie, een neurologische aandoening die in zoverre vergelijkbaar is met 
spasticiteit, dat het effect van een bepaalde therapie eveneens vaak 
moeilijk is te beoordelen. 
Van de verschillende spierverslappers die in de loop der jaren zijn 
ontwikkeld, hebben baclofen en dantroleen zich een plaats verworven bij 
de behandeling van spasticiteit. In navolging van de Angelsaksische li-
teratuur zijn spierverslappers met dit toepassingsgebied hier antispas-
tica genoemd. Hoewel baclofen en dantroleen al vanaf 1967 worden ge-
bruikt, zijn farmacokinetische gegevens nog maar spaarzaam beschikbaar, 
hetgeen deels kan worden verklaard door het ontbreken van geschikte be-
palingsmethoden. Dit leidde tot het formuleren van de volgende doel-
stellingen: het ontwikkelen van chemische analyses voor de kwantitatie-
ve bepaling van baclofen en dantroleen, en het bestuderen van de farma-
cokinetiek van beide antispastica middels deze analyses. Het onderhavi-
ge werk is een bundeling van dertien artikelen over dit onderwerp. 
LITERATUUROVERZICHT 
In hoofdstuk 1 wordt een literatuuroverzicht gegeven van enige ken-
merkende eigenschappen van baclofen en dantroleen, met inbegrip van hun 
plaats bij de behandeling van spasticiteit. Beide middelen zijn volko-
men van elkaar verschillend qua chemische structuur en werkingswijze. 
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De GABAH-agonist baclofen is een centraal-werkend spierrelaxans, dat in 
de handel is als racemisch mengsel, maar waarvan slechts een enantio-
meer, de (-)-(R)-isomeer, verantwoordelijk is voor de werking. Dantro-
leen, een verbinding die structuurovereenkomst vertoont met nitrofuran-
toine, is een direet-werkende spierverslapper die sterk onderhevig is 
aan metabole afbraak. 
Dit hoofdstuk behandelt verder een aantal kenmerken van het syndroom 
spasticiteit, omdat enig inzicht in classificatiesystemen, meetmethoden 
e.d. van belang is als men verbanden wil gaan leggen tussen plasmacon-
centraties en therapeutisch effect. Er wordt tevens kort ingegaan op 
wat allemaal onder de tamelijk verwarrende term spasticiteit wordt ver-
staan. Zo wordt het ziektebeeld infantiele encefalopathie, dat in de 
Angelsaksische literatuur bekend staat als 'cerebral palsy', ook met de 
term spasticiteit aangeduid. Het in hoofdstuk 13 beschreven klinische 
onderzoek heeft betrekking op patiënten met deze specifieke aandoening. 
ANALYTISCHE BEPALINGSMETHODEN 
In hoofdstuk 2 wordt een methode voor de kwantitatieve bepaling van 
baclofen in plasma en urine met behulp van hoge-drukvloeistofchromato-
grafie (HPLC) beschreven. Het probleem om nanogrammen van een stof met 
een aminozuurachtige structuur aan te tonen temidden van de overvloedig 
aanwezige endogene aminozuren, is te vergelijken met het zoeken naar 
een onzichtbare speld in een onzichtbare hooiberg. Denvatisering met 
o-ftaaldialdehyde bracht het probleem terug tot dat van de bekende 
speld in de hooiberg: in aanwezigheid van alkylmercaptoverbindingen d n 
dit geval thioglycolzuur) worden aminozuren, met inbegrip van het p-
chloorfenyldenvaat van У-aminoboterzuur, te weten baclofen, omgezet 
in sterk fluorescerende isoindolen. Extractie via een kationuitwisse-
lingsprocedure voorafgaande aan chromatografische scheiding bleek in­
terfererende aminozuren effectief te kunnen verwijderen. Met behulp van 
een concentratiekolom werd een verdere concentratie en opschoning van 
de monsters verkregen. De relatief grote volumina die zo konden worden 
opgebracht, droegen bij aan de vereiste gevoeligheid. 'Reversed-phase' 
HPLC met fluorimetrische detectie (excitatie bij 340 nm, emissie bij 
460 nm) completeerde de analysegang. Met deze methode was het mogelijk 
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om uitgaande van 0,5 ml monster baclofen in plasma of urine te bepalen 
met een detectielimiet van 1-2 nq, oen nauwkeurigheid van tenminste 6% 
en een opbrengst van ruim 90%, hetgeen geschikt bleek te zijn voor 
farmacokinetische doeleinden. 
Alhoewel geschikt, werd daarnaast een minder bewerkelijke methode 
voor het bepalen van hoge concentraties baclofen in urine ontwikkeld 
(hoofdstuk 3). Via directe injectie in een reversed-phase HPLC-systeem 
met ultraviolet-detectie (220 ran) was het mogelijk monsters met baclo-
fenconcentraties van meer dan 4 mg.l ' te meten. Dergelijk hoge waarden 
werden nooit aangetroffen in plasma. Een mogelijke metaboliet van 
baclofen, 3-(p-chloorfenyl)-4-hydroxyboterzuur, die men mist bij de 
derivdtisenngsreactie met o-ftaaldialdehyde wegens afwezigheid van de 
hiervoor benodigde NH¿-groep, kan ook met deze methode worden gemeten, 
mits aanwezig in even hoge concentraties. 
In hoofdstuk 4 wordt de analytische problematiek die men met chirale 
geneesmiddelen zoals baclofen in huis haalt, aangepakt. Aangezien de 
handelsvorm van baclofen, zoals eerder opgemerkt, het racemische meng-
sel bevat, waren er kennelijk niet een maar twee spelden verborgen in 
de hooiberg, zijnde elkaar's spiegelbeeld. Chirale scheiding werd uit 
eindelijk verkregen door het achirale thioglycolzuur te vervangen door 
de optisch actieve alkylmercaptoverbinding N-acetyl-L-cysteine. Met 
deze modificatie van de o-ftaaldialdehyde-derivatiseringsreactie konden 
de gevormde diastereoisomeren kwantitatief, vooralsnog in waterig 
milieu, worden bepaald. 
In hoofdstuk 5 wordt een methode voor de kwantitatieve bepaling van 
dantroleen en twee van zijn metabolieten in plasma en urine beschreven. 
Complicerende factoren bij de analyse vormden de uitermate slechte 
oplosbaarheid van deze verbindingen in water (ook de metabolieten!) en 
vele andere oplosmiddelen, alsmede de ontleding onder invloed van 
licht. Plasma werd geëxtraheerd met een mengsel van chloroform-n-buta-
nol (95:5), waarmee een goede opbrengst voor alle drie de verbindingen 
werd verkregen; urine behoefde geen verdere voorbewerking. Met behulp 
van reversed-phase HPLC gevolgd door ultraviolet-detectie (375 nm) was 
het mogelijk dantroleen, 5-hydroxydantroleen en acetylaminodantroleen 
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in een enkele isocratische analysegang van ongeveer 10 min te analyse-
ren met een detectielimiet van 1 ng, hetgeen de methode geschikt maakte 
voor farmacokinetische studies. 
Een modificatie van deze methode is opgenomen in hoofdstuk 6. Met de 
bovenbeschreven exLractieprocedure bleek namelijk de metaboliet die na 
verbreking van de azomethinebinding in het dantroleenmolecuul ontstaat, 
het 5-(p-nitrofenyl)-2-furaanzuur, met de waterige laag te zijn verdwe-
nen. Extractie na aanzuring en enkele kleine aanpassingen van mobiele 
fase en golflengte (354 nm) maakten het mogelijk ook deze verbinding in 
plasma (en urine) te bepalen. Uit de eerste resultaten van farmacokine-
tisch onderzoek blijkt dat deze metaboliet vermoedelijk niet van belang 
is bij de mens, maar wel bij de hond. 
FARMACOKINETIEK VAN BACLOFEN 
Hoofdstuk 7. De farmacokinetiek van racemisch baclofen en van elk 
enantiomeer afzonderlijk werd bestudeerd bij de hond. Tot een onderzoek 
met proefdieren werd besloten, omdat toxiciteitsgegevens over de sepa-
raat toegediende isomeren ontbraken. De keuze voor de hond werd mede 
ingegeven door de overeenkomst in nier tussen mens en hond. Het betrek-
ken van renale parameters bij farmacokinetische experimenten verschaft 
veel extra informatie en is onontbeerlijk voor een geneesmiddel als ba-
clofen, waarvan bekend is dat verschijnselen van intoxicatie kunnen op-
treden bij verminderde nierfunctie. Na een eenmalige intraveneuze infu-
sie werden onder meer verschillen geconstateerd in de hoeveelheid re-
naal uitgescheiden stof. Voor de actieve (-)-(R)-enantiomeer was de 
massabalans bijna compleet met een recovery van 85%. Voor het verwij-
deren van (+)-(S)-baclofen schijnen verschillende eliminatieroutes ver-
antwoordelijk te zijn. De bevindingen suggereren dat werkzaamheid en 
een gunstig farmacokinetisch profiel in het geval van baclofen samen-
gaan. De samenhang die werd gevonden tussen de schijnbare renale kla-
ring van baclofen en de creatinineklaring, bleek onafhankelijk te zijn 
van de isomere samenstelling van de toegediende verbindingen. 
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Hoofdstuk 8 handelt over de farmacokinetiek van baclofen bij gezonde 
proefpersonen na orale inname van de in de handel zijnde doseervorm, 
dwz. tabletten met het racemaat Na een eenmalige dosis van 40 mg werd 
binnen twee dagen gemiddeld 70% van de toegediende hoeveelheid onver-
anderd teruggevonden in de urine. De halfwaardetijd die werd berekend 
uit het gecombineerd fitten van plasma- en urinegegevens met behulp van 
'extended least squares modelling· (ELSMOS), bedroeg gemiddeld 7 uur. 
Dit is langer dan gerapporteerd in de meeste andere onderzoeken die 
zich alleen op plasmagegevens baseerden. De schijnbare renale klaring 
van baclofen was gelijk aan de creatinineklaring. Gezien de bevindingen 
bij de hond kan men veronderstellen dat dit verband niet stereoselec-
tief zal zijn. Hoewel actieve tabulaire uitscheiding een bijdrage kan 
leveren aan de renale klaring, zoals werd aangetoond met het toedienen 
van probenecide, is het aannemelijk dat glomerulaire filtratie een 
overheersende rol speelt bij het transport van baclofen via de nier. 
De farmacokinetiek van baclofen bij spastische patiënten die met in-
dividuele onderhoudsdoses in de vorm van tabletten met het racemaat 
werden behandeld, is het onderwerp van hoofdstuk 9. Vergeleken met de 
bovenbeschreven gezonde vrijwilligers was monstername maar zeer beperkt 
mogelijk. De aandoening zelf was ervoor verantwoordelijk dat het kwan-
titatief verzamelen van urine moeizaam verliep. De totale periode van 
monstername was ook beduidend korter, nl. een dosenngsinterval (6 of 8 
uur) in het geval van plasma, omdat in verband met de kans op onttrek-
kingsverschijnselen stoppen met de therapie niet verantwoord werd ge 
acht. De aanzienlijke fluctuatie die in de plasmaconcentratie werd ge-
vonden, 200 tot 400%, paste goed bij de halfwaardetijd zoals berekend 
in hoofdstuk 8. Het percentage van de dosis dat onveranderd in de urine 
werd aangetroffen, was eveneens niet afwijkend van de waarden na eenma-
lige toediening aan proefpersonen. Op grond van de bevindingen in de 
beide vorige hoofdstakken wordt de variatie in de schijnbare renale 
klaring van baclofen met de variatie in de creatinineklaring in verband 
gebracht. De bijdrage die de renale klaring levert aan de plasmakla-
ring, kan een verklaring vormen voor de beschreven toxiciteit bij 
patiënten met verminderde nierfunctie. 
196 
FARMACOKINETIEK VAN DANTROLEEN 
Hoofdstuk 10 beschrijft de verdeling van '"C-gemerkt dantroleen bij 
de marmosetaap zoals bestudeerd met behulp van macroautoradiografie. 
Dit proefdier werd gekozen omdat het een kleine primaat is Na lineaire 
infusie tot 'steady-state' werd onder meer een sterke ophoping van ra-
dioactiviteit gevonden in de nier, lever, galblaas, unneblaas en dar-
men, dwz. in organen die in verband kunnen worden gebracht met de eli-
minatie van dantroleen. Op de plaats van werking, de skeletspieren, 
werden veel lagere concentraties aangetroffen. Slechts sporen radioac-
tiviteit waren aanwezig in de hersenen, hetgeen suggereert dat het in-
tacte molecuul de bloed-hersenbarnère niet kan passeren. Door de po-
sitie van het '"C-label konden eventuele ontledingsprodukten ten ge-
volge van het verbreken van de azomethinebinding, met name afgeleiden 
van hydantoine, niet worden waargenomen. 
Hoofdstuk 11. De farmacokinetiek van dantroleen en 5-hydroxydantro-
leen, een actieve metaboliet, werd bestudeerd bij de hond. Om mogelijke 
problemen van biologische beschikbaarheid te vermijden, werden de ver-
bindingen intraveneus toegediend. Vanwege deze benadering werd de voor-
voorkeur gegeven aan proefdieren, hetgeen tevens een goede mogelijk-
heid bood om uitscheiding via de gal te onderzoeken. Ondanks de intra-
veneuze toediening werd een verre van volledige massabalans gevonden. 
Alleen de hydroxyverbinding werd in redelijke hoeveelheden teruggevon-
den in de urine (2%) en in de gal (25%). Vergeleken met plasma waren 
de concentraties van 5-hydroxydantroleen in de gal zeer hoog, waarbij 
de maximale wateroplosbaarheid ver werd overschreden. Door het toedie-
nen van de metaboliet als moederverbinding kon worden aangetoond, dat 
met hydroxylering de halfwaardetijd afneemt. Uit deze bevindingen mag 
worden afgeleid, dat hydroxylering een belangrijke rol speelt bij het 
verwijderen van dantroleen uit het lichaam van de hond. 
Hoofdstuk l?. De farmacokinetiek van dantroleen bij de mens wordt be-
schreven aan de hand van een geval van profylactisch gebruik bij ma-
ligne hyperthermie. Behalve spasticiteit is het syndroom maligne hyper-
thermie het indicatiegebied voor dantroleen geworden. Na orale voorbe-
handeling waren de halfwaardetijden van moederverbinding en hydroxyme-
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taboliet beide 15 uur, hetgeen in overeenstemming is te brengen met de 
bevindingen bij de hond. 
FARMACOKINETIEK EN SPASTICITEIT 
Hoofdstuk 13 beschrijft een verkennende studie naar de effecten van 
baclofen en dantroleen bi] een groep patiënten met cerebral palsy, die 
waren gehuisvest in een zwakzinnigemnstituut. Voor het registreren van 
het motorisch functioneren werden evaluatiemethoden ontwikkeld, die 
zeer eenvoudig moesten zijn vanwege de eveneens aanwezige geestelijke 
handicap. Bij patiënten die met antispastica werden behandeld en bij 
wie het vermoeden bestond dat de huidige therapie niet (optimaal) ef-
fectief was, werd de medicatie verminderd onder controle van plasmacon-
centratie en effect. Aan de hand van de gepresenteerde casussen wordt 
de haalbaarheid van een studie naar concentratie-effect relaties bij 
dergelijke patiënten aangegeven. 
SLOTOPMERKINGEN 
Het in dit proefschrift beschreven onderzoek werd uitgevoerd om 
inzicht te verkrijgen in de farmacokinetiek van antispastica. De voor 
baclofen ontwikkelde analysemethode bleek voldoende gevoelig te zijn 
voor het kwantitatief meten van plasma- en urineconcentraties na 
therapeutische doses. Een sterk vereenvoudigde procedure kon worden 
gebruikt voor de hoge concentraties die meestal in de urine werden 
aangetroffen. De methode die werd ontwikkeld voor het meten van de 
afzonderlijke enantiomeren van baclofen, zal in de toekomst toepasbaar 
moeten worden gemaakt voor biologisch materiaal. Voor de Y-hydroxyme-
taboliet van baclofen lijkt geen rol van betekenis te zijn weggelegd 
bij mens en hond. Er werden aanwijzingen gevonden voor een lineair 
verband tussen de creatinineklaring en de renale klaring van onveran-
derd baclofen, ongeacht de isomere samenstelling. Gedetailleerd onder-
zoek met enantioselectieve analysemethodes is noodzakelijk voor het 
verder in kaart brengen van de farmacokinetiek van baclofen. 
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De voor dantroleen ontwikkelde analysemethode bleek voldoende gevoe-
lig en specifiek te zijn voor het kwantitatief meten van onveranderd 
dantroleen en twee van zijn metabolieten. Hiermee konden concentraties 
in plasma, urine en gal worden gemeten. In tegenstelling tot de bevin-
dingen bij de hond werden bij de mens echter geen meetbare concentra-
ties in de gal aangetroffen. Een metaboliet die na verbreking van de 
azomethinebinding kan worden gevormd, bleek ook niet bij te dragen aan 
de verre van volledige massabalans van dit geneesmiddel bij de mens. Er 
werden aanwijzingen gevonden dat door hydroxylenng van dantroleen de 
halfwaardotijd wordt bekort. Toekomstig onderzoek zal zich moeten 
toespitsen op het metabolisme van dit geneesmiddel. 
De klinische bevindingen geven aan hoe men te werk kan gaan bij 
onderzoek naar het verband tussen plasmaconcentratie en effect bij 
patiënten met cerebral palsy, met name bij een eveneens aanwezige 
geestelijke handicap. Andere antispastica, zoals het meer recent be-
schikbaar gekomen tizanidine, kunnen in principe ook met een derge-
lijke proefopret worden geëvalueerd. Ge¿ien het racemisch karakter van 
klinisch toegepast baclofen en de nog verre van volledige massabalans 
van dantroleen is het niet verwonderlijk dat vooralsnog geen duidelijke 
uitspraken kunnen worden gedaan over concentratie-effect relaties. Een 
bijkomend gevolg van de verkennende klinische studie is geweest, dat 
men in het instituut waar dit onderzoek plaatsvond, minder antispastica 
is gaan gebruiken. 
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STELLINGEN 
1. Aangezien de aanduiding R of S ter onderscheiding van de enantiome-
ren van een verbinding uitsluitend wordt toegekend op grond van 
afspraken betreffende de prioriteit van de substituenten aan het 
chirale centrum, kan men er niet van uitgaan dat een bepaalde 
configuratie van een geneesmiddel een metaboliet met dezelfde 
aanduiding oplevert. 
2. Het verdient aanbeveling om, in analogie met het Angelsaksische 
taalgebruik, geneesmiddelen die bij de behandeling van spasticiteit 
worden gebruikt antispastica te noemen. 
- dit proefschrift 
3. Resorptieverschillen vormen niet de enige verklaring voor de iarma-
cokinetische verschillen tussen de enantiomeren van baclofen. 
- Krauss D, Dissertation, Frankfurt, 1988 
- dit proefschrift 
4. De verre van volledige massabalans van dantroleen valt niet te 
verklaren uit de algemeen aanvaarde slechte resorptie. 
5. Het Geneesmiddelvergoedingssysteem dat de Staatssecretaris van WVC 
wil invoeren zal niet noemenswaardig bijdragen aan een beheersing 
van de kosten van het gebruik van antispastica. 
- brief dd 13 november 1990 aan de Voorzitter van de 
Tweede Kamer der Staten-Generaal 
6. Homeopathische middelen werken niet maar helpen soms wel, antispas-
tica werken wel maar helpen soms niet. 
7. Het is opmerkelijk dat bij de ziekenhuisopname van patiënten niet 
standaard het lichaamsgewicht wordt gemeten. 
8. Bij knoflook-overgevoeligheid is 'buiten de deur eten' steeds weer 
een hachelijk avontuur, dat al begint bij het (gratis) voorafje. 
9. Wie glasafval per fiets vervoert, is een milieuvriendelijke optimist 
gezien de onvermijdelijke scherven in de onmiddellijke omgeving van 
glasbakken. 
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